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The tumor suppressor p53 plays a cardinal role in genomic stability and cancer prevention, and 
hence, realizing new cancer therapeutics lie in dissecting the multitude of complex, yet intricate, 
cellular networks involving p53. Because inactivating mutations in p53 are a direct cause of 50% 
of all human cancers, reactivating mutant p53 has long been an attractive approach towards 
possible cancer treatments. Drug development following this rationale can stem from high-
throughput small molecule screens or rational design of peptides or small molecules, but to date 
these attempts have been confounded by either low specificity and high toxicity, or by the 
flexible structure of p53. In this current study, we were able to select 7 p53 activating peptides 
(pap) for 3 of the hotspot mutants by exploiting the In-Vitro Compartmentalization selection 
platform to provide a functional high-throughput peptide screen. Additionally, a sensitive, non-
radioactive, real-time PCR based p53-DNA binding assay was developed with the purpose of 
validating these peptides. The DNA binding assay could accurately measure binding between 
different IVT synthesized p53 variants and nano-molar concentrations of DNA response 
elements (REs). An extrapolation of the utility was further demonstrated in measuring drug 
induced activation in sequence-specific DNA binding, and multiplexing of at least 4 different REs 
in a single binding experiment. Data from the DNA-binding assay, together with other in-vitro 
assays, indicate that the paps interact directly with mutant p53 and reactivate sequence-specific 
DNA binding. Some paps also show mutant specificity, strong binding preference for certain REs, 
and markedly higher reactivation compared to compounds previously described. Interestingly, 
one of the peptides (pap-MPH), had sequence homology to the RING domain for p53’s natural 
binding partner, Mdm2, and could reactivate p53 G245S-FL mutant’s DNA binding to p21 and 
PUMA-BS2 REs. Our results also somewhat support a long debated notion that p53 can have one 
or more intermediately folded states, and that structural rigidity in the DNA binding domain may 
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not translate into higher target gene transactivation potential, rather a degree of induced fit 
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 Since its initial discovery more than 30 years ago [1,2], p53 has been through several 
mistaken identities before being recognized as a bona-fide tumor suppressor. After 50 000 
published journal articles, numerous questions have been answered but a lot more have 
arisen in a bid to fully understand this protein. To date, p53 has been described to have an 
extremely diverse repertoire of biological functions, including roles in embryogenesis, the 
induction of senescence and aging [3], the regulation of metabolic pathways [4], the innate 
and adaptive immune system [4,5], as well as its role in the prevention of tumorigenesis. 
Of the biological functions described, p53’s tumor suppressive role has received the most 
attention scientifically, due largely to its mode of discovery, and is consequently the most 
well characterized. Termed ‘The Guardian of the Genome’ [6], p53 acts as a central 
checkpoint and sits at the core of a complex wiring of cellular networks to prevent the 
propagation of genomic aberrations and instability [7,8]. It responds to a multitude of stress 
stimuli (genotoxic insults, oncogene activation, spindle deformities, hypoxia, glucose 
starvation and several others [5,8,9]) by facilitating cellular outcomes which include; DNA 
repair, reversible cell cycle arrest, irreversible apoptosis, senescence or autophagy (Figure 
1.1). A heterogeneity in p53 dependent response is often observed and is influenced by cell 
type, nature of stress stimuli, and genetic background amongst other factors [10,11].  
1.1 p53 function in cells 
1.1.1 Transcriptional activity and DNA binding 
 Transcriptional regulation is p53’s most well understood mechanism of affecting 
cellular outcome. P53’s basal level is normally kept low by its transcriptional target and 
natural E3 ligase Mdm2, which poly-ubiquitinates and targets p53 for proteasome 
degradation (Figure 1.1). Following cellular stress signals, p53 undergoes post-translational  









modifications from upstream mediators (for example, ATR and ATM can phosphorylate p53 
directly or through their respective substrate kinases CHK1 and CHK2 [12,13,14,15]), and 
two critical events occur. Firstly, p53 protein level is stabilized through the attenuation of 
the p53-Mdm2 feedback loop from (i) Mdm2 modifications culminating in the destabilization 
of Mdm2 protein levels (eg. Mdm2 phosphorylation by ATM results in dissociation in HAUSP 
and increase ubiquitin mediated degradation[16]), and (ii) phosphorylation of critical p53 N-
terminal serine and threonine residues leading to a disruption in Mdm2 binding [17]. 
Secondly, the protein is further ‘activated’ through numerous different modifications 
(phosphorylation, acetylation, sumolation and neddylation) on other residues (Figure 1.2), 
acting as a chemical code and priming p53 for binding to different DNA recognition 
sequences and actuating different responses (Figure 1.1). However, the observation that a 
fairly normal p53 response can be elicited despite critical serine and threonine residues 
mutation [8], and that phosphorylation of Ser392 allows p53 to be transcriptionally active 
without protein level stabilization [17], suggests that both events are mutually crucial but 
not essential. 
P53 regulates hundreds of genes in the human genome [18,19] by recognizing DNA response 
elements (REs), and binding as a dimer of dimers [20] (with each p53 monomer interfacing 
with a 5-bp quarter site [21]) to either up-regulate, or repress transcription. Although 
conventionally defined as 2 decamer half-sites (RRRCW WGYYY, where R is a adenine or 
guanine, W is a purine, and Y is a pyrimidine [22])separated by a variable spacer sequence 
(0-13 bp), the p53 DNA recognition element has been shown to be very degenerate [23]. 
Some non-canonical sites include the pig3 microsatelite response element (TGYCC)n[24], the 
triplet pair element at the aqp3 locus [25], and the “head-to-tail” configuration of the mdrI 
site [26].  
  











More recently, a study aimed at profiling the DNA elements behind the 
transactivation/transrepression selectivity of p53 (through analyzing over 160 REs) re-
defined the p53 consensus, and highlighted the importance of the core CWWG motif within 
each half-site decamer. Accordingly, substitution of the dinucleotide core (WW) alone was 
sufficient in reversing the mode of transcriptional regulation [27]. This result strongly implies 
that different p53 conformations are selected or induced by the precise DNA binding 
interaction which in turn effects p53’s binding to co-factors or repressors. Once bound, p53 
dependent recruitment of histone acetyltransferases (HATs) such as p300/CBP[28,29] and 
pCAF[30], histone methyltransferases (HMTs)[31], and other cofactors coordinate the 
modification and remodeling of nearby chromatin structure, allowing further assembly of 
the transcriptional machinery(TAFs, RNAPII, EFs )[32] (Figure 1.1).  P53 response elements 
are usually located proximal to the transcriptional start site (TSS), and follow a general rule 
of decreased transactivation potential the further apart they are [19]. Because binding of a 
p53 tetramer to its full DNA recognition site exerts steric pressures and contorts the DNA 
[33], REs with d(CATG) sequences spanning the junction of 2 pentamer quarter-sites (eg. the 
p21 3’ site)  have also been associated with increased DNA flexibility, and consequently, 
higher binding affinity [34]. Additionally, the highly basic carboxyl-terminal domain (Ctd) of 
p53 is known to interact non-specifically to supercoiled DNA [35,36], suggesting a linear 
diffusion ‘scanning’ mechanism along genomic DNA that is postulated to facilitate sequence-
specific DNA binding [37,38]. 
Amid the plethora of events that influence p53’s propensity to select target promoters are 
cis-acting elements (post-translational modifications and p53-protein interactions) that 
ultimately translate into structural confinements, locking p53 in a conformation best-suited 
for a particular RE site. This is illustrated by structural data where p53 tetramers adopt 
different conformations when bound to different consensus half-sites [39]. Also, a 
thermodynamically favorable His→Asn mutation at amino acid residue 115 has also been 




described to induce a conformational change. The result is an increase in p21 transactivation 
and G1 growth-arrest, but incompetence in evoking DNA-damaged induced apoptosis [40]. 
Consensus sequence disparity within response elements also affect interaction affinity 
intrinsically [41] with dissociation constants (KD) to p53 core-dimers ranging from low nM 
affinity in strong promoters like Gadd45, p21, and PCNA to low μM affinities in weaker 
promoters such as PUMA-BS1 and P2XM sites [21,34]. 
1.1.2 Transcriptional independent activities and function 
P53 also play a crucial role in maintaining genomic integrity through mediating the 5 
major DNA repair pathways in eukaryotes (mispatch repair, nucleotide excision repair, base 
excision repair, non-homologous end joining and homogolous recombination [42]) in both 
transcription dependent, and independent pathways. For example, wild-type p53 binds to 
helicases XPB and XPD, which are subunits of the transcription factor TFIIH complex and help 
mediate the process of nucleotide excision repair [43]. P53 is also known to stimulate the 
basepair excision pathway through complexing with apurinic endonuclease-I (APE/REF1), 
DNA polymerase β and 8-oxoguanine glycosylase (OGG1). For this purpose, the structural 
integrity of both the core and terminal domains are indispensible [44]. Cytoplasmic p53 has 
also been shown to translocate to the mitochondria following stress signals, and interacting 
with pro- and antiapoptotic members of the Bcl-2 family of proteins, eventually leading to 
the release of cytochrome c and the actuation of apoptosis [45,46]. 
1.2 P53 structure and domain organization 
In its native folded state, full-length p53 is a 43 kDa protein, consisting of multiple 
tertiary domains bearing hallmark features symbolic of typical transcription factors (TF) 
(Figure 1.2); (i) an intrinsically unstuctured N-terminal transactivation domain (TAD, residues 
1 – 92) [47] (ii) a proline rich domain (residues 65 – 101), (iii) a highly ordered core DNA 




binding domain (residues 101 – 292), (iv) an oligomerization domain (residues 326 – 356), 
and (v) an unstructured C-terminal basic region (residues 364 – 393), also known as the 
regulatory domain [48]. 
1.2.1 N-terminal transactivation domain 
P53’s transactivation domain is cardinal to its ability in transcriptionally regulating 
target genes. It spans residues 1 – 92 of the p53 protein and is further divided into 2 
subdomains (TAD1 and TAD2) (Figure 1.2). It’s responsible for recruiting transcriptional 
cofactors (p300/CBP) and facilitating the assembly of the basal transcriptional machinery 
through direct protein interactions. The inherent lack of structural order in transcriptional 
activation domains is characteristic of many transcription factors, like p53, and underscores 
a manner in which binding partner promiscuity and diversity is achieved [49]. Each of p53’s 
TAD subdomains are known to adopt a nascent secondary structures when bound to partner 
proteins [50,51]. TAD1 (residues 18 – 25) can assume an amphipathic α-helical structure 
upon binding to the Taz2 domain of p300 [52], Mdm2 [53] and MdmX [54]. A similar 
phenomenon is also observed when TAD2 binds to replication protein A [55]. These short 
recognition motifs undergo ephemeral, disorder-to-order conformational adaptations when 
bound to interaction partners, allowing variability in partner selection.  
The amino-terminal domain of p53 also contains multiple sites that can be post-
translationally modified to influence cellular outcome. For example, phosphorylation of 
Ser46 by protein kinases (HIPK2,  p38 and DYRK2) after DNA damage leads to selective 
transactivation of proapoptotic targets (PUMA, Noxa, p53AIP1), driving the cell towards 
apoptosis instead of p21 dependent growth arrest [56,57,58]. Additionally, phosphorylation 
of residues Ser15, Thr18, and Ser20 is critical in disrupting Mdm2-p53 interaction and 
stabilizing p53 cellular levels [17]. Apart from transactivation of target genes, p53’s N-
terminal domain may also be involved in core folding and thermal stabilization [59,60].  




1.2.2 DNA binding core domain 
Uncovering full-length p53’s structure is vital in determining how the core DNA 
binding domain binds target recognition sequences at the molecular level, and in further 
discerning the functional context of each of its domains. However, owing to its highly flexible 
N- and C-termini and its relatively low Tm (melting temperature), this has eluded structural 
biologists for a long time [47,61]. Additionally, its size, places p53 at the threshold 
boundaries and excludes the use of other techniques such as conventional NMR (nuclear 
magnetic resonance) studies and cryo-electron microscopy [50]. The first crystal data solved 
was of p53’s core domain bound to DNA as a monomer, and provided significant insight into 
residues and motifs critical in sequence specific DNA binding. P53’s primary DNA interfacial 
region within the core domain consisted of a loop-sheet-helix (LSH) motif presented by a 
sandwich of 2 anti-parallel β-sheets, and 2 large loops held together by a tetrahedrally 
coordinated zinc atom [62]. Interaction between the core and sequence specific DNA 
comprises 3 main modalities: (i) side chain projections from residues Lys120 (L1 loop), 
Cys277 and Arg280 (immediately preceding and within α-helix respectively) form critical 
contacts with the major groove (2nd, 3rd purine, and cytosine bases respectively, of the first 
quarter-site), (ii) Arg248 of the L3 loop contacting and reaching into the minor groove 
(comprised of AT rich region spanning 2 tandem pentamer quarter-sites), and (iii) extensive 
non-consensus interaction with the DNA phosphate backbone conferred by residues Ser241 
(L3 loop), Ala276 and Arg273 (LSH motif) (Figure 1.3 – 1.4). Two additional phosphate 
contacts from core residues Lys120 and Arg280 are also made several bases away [62] 
(Figure 1.4). More recently, structural modeling of polymerized full-length p53 binding DNA 
inferred from data using NMR, small-angle x-ray scattering and electron microscopy, 
suggests a model in which free, unbound p53 dimers adopt a dynamic, open conformation in 
solution with its core domain accessible to target DNA [47,63]. Once bound, the p53 
tetramer wraps around the DNA double helix with each monomer contacting a 5-bp quarter  














site, and forms a more compact structure, binding ~100 times stronger than its monomeric 
form [64]. In this form, the proline rich domain (residues 64 – 92) stiffens, adopting a poly-
proline II structure and projects the TAD away from the core p53-DNA complex to interact 
with transcription co-activators [65]. Tetramerization of p53 is also essential for the 
modification of certain residues critical to its function as a transcription factor [66,67]. 
1.2.3 Oligomerization domain 
 The oligomerization domain (OD) of p53 is required for the formation of p53 
tetramers which are crucial for the transactivation of target genes, and p53-mediated 
growth arrest [68]. The structure of the OD was solved using X-ray crystallography and NMR 
spectroscopy [69,70]. Each monomer subunit contains a β-sheet, turn, α-helix motif, and 
comes together as a dimer of dimers to form a symmetrical tetramer.  
1.2.4 C-terminal regulatory domain 
Similar to the N-terminal domain, p53’s C-terminal domain (Ctd) is intrinsically 
disordered. Interestingly, this basic Ctd is absent in other homologs of the p53 gene family 
[37] and its function has been subjected to much debate. The carboxyl terminal domain 
contains many sites for post-translational modifications including acetylation, neddylation, 
methylation, ubiquitination at a cluster of 6 lysine residues 370, 372, 373, 381, 382 and 386, 
[71,72] and phosphorylation of serine and threonine residues [52]. Like the TAD, the 
inherently disordered Ctd provides a basis for interaction promiscuity to protein binding 
partners, and can also undergo disorder-to-order transitions, adopting various secondary 
structures depending on the situation. A change in structural adaptation between an α-helix 
or β-stand is observed in the region of residues 376 – 387 when the binding partner switches 
between S100B [73] or sir2 protein deacetylase [74]. Initially, p53’s Ctd was postulated to 
play an allosteric auto-inhibitory role to DNA binding of the core domain following 




observations of increased binding to sequence specific target REs when deleted, acetylated, 
or in the presence of antibodies specific to the carboxyl terminal domain (Pab421 and 
Bp5310.1) [75,76]. This phenomenon, however, is often observed only in ‘latent’ p53 
(bacterially expressed p53) and in binding to short oligonucleotide target sequences [77] in 
in-vitro environments. Carboxy-terminally truncated p53 also has impaired binding 
capabilities to target REs in-vivo when expressed at physiological levels [38] and to 
chromatinized DNA templates in-vitro [77]. Taken together, allosteric inhibition by the Ctd 
could be a conditional in-vitro phenomenon. Additionally, p53’s C-terminal domain has also 
been described to augment p53-transactivation independent DNA repair by acting as ‘DNA 
damage biosensor’ capable of interacting with various conformations of DNA including 
single-stranded DNA [78], Holliday junctions and cruciform structures [23,79], and damaged 
DNA [80,81]. 
1.3 P53 in human cancer 
Given p53’s biological significance in monitoring genomic integrity within a vast and 
complex, yet fine-tuned network, it’s easily conceivable that disruptions in pathways 
involving p53 often lead to tumorigenesis. Such disruptions may include localization of p53 
away from the nucleus and abnormal activation of its negative regulators; Mdm2 gene 
duplication, deletion or epigenetic silencing of the p14ARF (cellular antagonist of Mdm2) 
gene, or activation of HPV viral onco-protein E6 [9,82]. High levels of NF-κB have also been 
reported to suppress wild-type p53-dependent growth arrest and apoptosis (despite proper 
p53 stabilization, activation and localization), especially in renal cell carcinoma [83,84]. 
The most frequent disruption leading to cancer development is the inactivation of p53, 
illustrated through several observations. Animal models demonstrate the spontaneity of 
tumorigenesis in the absence of p53: knockout mice models generated without the p53 gene 
develop tumors at very young ages [85]. In humans, patients harboring familial mutations in 




the p53 allele belong to a rare autosomal dominant genetic condition, the Li-Fraumeni 
syndrome, and are predisposed to a variety of tumor development with almost complete 
penetrance [5,86]. However, the loss of p53 function most frequently occurs through 
random somatic mutations in the TP53 gene (p53 encoding gene), resulting in more than 50% 
of all human tumors harboring inactivating mutations [7,87]. Notably, a loss of 
heterozygosity usually occurs in both somatic and germline p53 mutations during 
tumorigenesis, inactivating the remaining wild-type allele [88]. Characterizing the frequency 
of such TP53 mutation across different cancer types is important in cancer prognosis, 
treatment and epidemiological studies. The heterogeneity of p53 function in tumorigenesis 
is evident in the widely discrepant incidences of TP53 mutation across different cancer types, 
ranging from ~10% in hematological malignancies to above 50% in ovarian, colorectal and 
head and neck cancers [89,90,91]. Additionally, the presence of mutant p53 protein is often 
associated with poor cancer treatment prognosis, due to multiple drug resistance and poor 
response to conventional radio- and chemotherapy [92]. 
1.4 Inactivating mutations in TP53 
Unlike other tumor suppressor genes which generally undergo deletion mutations 
during carcinogenesis [88,93], approximately 75% of inactivating mutations in TP53 occur 
due to single base pair missense substitutions, resulting in the synthesis of a stable full-
length mutant protein with defective wild-type gene transactivation functions. Other genetic 
alterations includes frameshift insertions and deletions (9%), nonsense mutations (7%) and 
silent mutations (5%), and occur at much lower frequencies [94]. Furthermore, critical amino 
acid mutations arising from nucleotide substitutions at highly mutable CpG dinucleotides 
account for 30% of all missense mutations [95]. Missense mutations of the TP53 gene have 
been detected throughout the coding region but tend to cluster within the DNA binding core 
domain of the protein (>95%), with 6 specific residues being identified as mutational  









‘hotspots’ in human cancer (R175, G245, R248, G249, R273 and R282)[94,96] (Figure 1.5). 
This phenomenon underscores the importance of target-specific DNA binding in actuating 
p53 dependent transcriptional activation, with particular emphasis placed on the 6 critical 
residues.  
1.4.1 Classification of p53 mutations and hotspot mutants 
P53 mutants can be broadly classified into 2 categories, structural or contact 
mutants depending on their mode of inactivation. Additionally, structural mutants can be 
further subtyped as ‘local’ or ‘global’ based on the extent of structural perturbation. Each of 
the hotspot residues corresponds to residues either directly involved in the DNA binding 
interface or is implicated in wild-type structural integrity. Four of the structural mutations 
manifest predominantly by one specific substitution (R175H, G245S, R249S and R282W), 
whereas the remaining contact mutations have 2 each (R248Q, R248W, R273H and R273C: 
with the more frequent substitution indicated in bold) [97] (Figure 1.5 – table).  
1.4.2 p53 DNA contact mutants 
Mutations at Arg273 and Arg248 belong to the DNA contact class of mutants; the 
mutations abrogate sequence specific DNA binding functions but have little effect on the 
overall folding of p53 protein. Arg248 within the L3 loop make critical contacts with DNA by 
directly inserting into the minor groove of DNA (Figure 1.3 – 1.4). Arg273 (loop-sheet helix 
motif) makes contacts with the DNA phosphate backbone and is also involved in an 
extended network of interactions, including salt bridge contacts involving Asp281 and 
Arg280 (which makes major groove contacts) [62] (Figure 1.3 – 1.4). Both R273H and R248Q 
mutants are able to activate transcription from a GAL4 binding site when fused to the DNA 
binding domain of GAL4, suggesting a defect only in DNA binding [98]. Unlike structural 
mutants, R273H mutant p53 was also not found to associate with heat shock protein hsp70 




[99], is negative for the PAb240 epitope (a linear epitope only exposed in unfolded p53 
[100]), and Pab1620 epitope positive (a native epitope present only in the folded state) 
[101,102]; further indicating a native folded state. Furthermore, fluorescence-based studies 
of purified p53 core protein at equilibrium using mutants harboring either a R273H or R248Q 
mutation show these to be mostly folded at 37oC (98% and 86% of wild-type, respectively), 
and have no residual binding to p53 specific REs at 20oC [97]. 
1.4.3 P53 local structural mutants 
Both G245S and R249S belong to the class of local structural mutants; Gly245 
(facilitates a tight turn within L3 loop) and Arg249 (forms H-bonds with Gly245 and Met246 
within the L3 loop, and salt bridge with Glu171 in L2 loop) [62] are involved in presenting the 
L3 loop to contacting DNA (Figure 1.3) and maintaining structural integrity of the DNA 
binding region, and are consequently implicated both in DNA binding as well as structural 
distortions in the immediate region.  
1.4.4 P53 global structural mutants 
Substitutions at Arg175 and Arg282 cause global denaturation of the protein. 
Equilibrium studies of the mutant core domain reveal that only ~30% are in their native form 
compared to wild-type [97]. Arg175 is buried away within a polar region surrounded by the 
L2 and L3 loops and is involved in interactions bridging the two loops. Substitution at Arg175 
may also disrupt zinc coordination as it immediately precedes the zinc ligand Cys176 [62] 
(Figure 1.3). Coordination of zinc is extremely vital in the structural fidelity of p53’s core, 
evident as the protein unfolds when in the presence of metal chelating agents [103]. 
Additionally, the R175H mutant does not transactivate when fused to GAL4 [98], has a 
PAb240+/PAb1620- profile, and was immuno-precipitated from hsp70 ex-vivo [99]; evidence 
that R175H is inactivated through substantial structural denaturation. Arg282 lies in H2 




region of the DNA-binding helix which is packed between the surfaces of two β-strands (S2 
and S2’), and makes extensive contacts within the core domain; including van-der-Waals 
contacts with Phe134, Thr125 and Ser127 within the β-hairpin, as well as H-bonds with 
Tyr126, Glu286, Ser127 and Thr118 [62]. Substitution of Arg282 to a tryptophan residue 
leads to a severe disruption of structure due to its large side chain [97]. Unlike its gene 
family homologs, p53 has evolved to be thermodynamically brittle at the physiological 
temperature (the Tm of p53’s core domain is close to 20
oC lower then p63 [104]). This 
reaffirms the notion of how a slight architectural defect can tip the structural threshold 
towards denaturation and irreversible aggregation [105]. 
1.5 Mutant p53 gain-of-functions (GOF) 
While mutant p53’s loss-of-function contributes to cancer predisposition and 
progression, animal models and cell culture work indicate that p53 mutants have gain-of-
function (GOF) traits that exacerbate tumorigenesis. This important revelation came after 
critical observations that the often aberrant high levels of mutant p53 (mp53) accumulation 
in cancer cells [106,107] are not detected in either the normal tissues of mutant p53 knock-
in mice [108,109] or in Li-Fraumeni patients [88]. Compelling genetic evidence for the gain of 
function hypothesis came from the finding that tumors that arose in p53 mutant mice were 
more aggressive and invasive then the tumors that arose in p53 null mice [108,109].  This 
has further prompted the notion that a selective pressure must exist in transformed cells 
keeping mp53 levels high, possibly due to tumor promoting GOF attributes [88,110]. Mutant 
p53 GOF commonly involves protein-protein interactions with natural partners of p53’s wild-
type form, but with either debilitating or antagonistic outcomes [88].  
  




1.5.1 Mutant p53 GOF through dominant negative effects 
The most immediate GOF effect conferred by mp53 is the dominant negative effect 
on wild-type p53; attenuation in transcriptional activation and target gene binding is 
detected when wild-type p53 is co-translated with mutant proteins [111,112]. Interestingly, 
the heterogeneity in potency and mode of inactivation across different types of mutants 
suggest a complex mechanism extending beyond simply sequestering functional wild-type 
monomers, and may involve intermolecular cross-talk between monomers [113]. Similarly, 
this dominant negative effect is seen also in p53 dependent transcriptional repression, 
particularly through structural mutants in the inflammatory pathway, and may be a severe 
contributing factor to tumorigenesis in chronic inflammation [88].  
1.5.2 Mutant p53 GOF via transcription factor interactions 
Another GOF mechanism is the ability of mp53, primarily those with elevated 
PAb240 epitopes, to interact with particular isoforms of p63 and p73 [114,115], thereby 
mitigating their roles in cancer suppression [116]. Moreover, p73-dependent sensitization of 
cancer cells to chemotherapeutic agents can be abrogated by presence of mp53 [117]. 
Studies extended to mouse models have similarly demonstrated the pernicious affects of 
losing either the p63 or p73 allele in tumorigenesis [118], as well as mp53’s GOF inactivation 
of these [109]. In addition to the p63 and p73 homologs, mp53 also interacts with other 
proteins to promote cancer progression. The R248W and R273H mutants can bind the 
nuclease Mre-11 and cripple the ataxia-telangiecstasia mutated (ATM) response to DNA 
double-stranded breaks [119]. Finally, mp53 has been postulated to directly bind to and 
transactivate genes through either recognizing yet unknown DNA binding consensus 
sequences, or by hijacking bona-fide transcription factors to regulate target genes [120]. 
Indeed, global gene expression profiling indicates that mp53 modulates a large and diverse 
subset of target genes [121,122], and in-vivo chromatin immuno-precipitation (ChIP) assays 




reveal that mp53 are physically recruited to promoter regions of these genes [123,124]. As a 
DNA consensus recognition sequence that unifies mp53 transcription GOF has yet to be 
uncovered, a theorized mechanism of binding is the selective association to DNA structural 
motifs, induced by repetitive sequence elements with a propensity to form non-B 
conformations[125]. Association of p53 mutants with other TFs often alter or attenuate their 
transcriptional abilities. Interestingly, many of mp53’s binding partners also bind wild-type 
p53 physiologically, but often with antagonistic outcomes. For example, wild-type p53 binds 
to proto-oncoprotein Ets-1 to inhibit its transactivation, whereas physical interaction 
between mutant p53s (V143A, R175H, D281G, R248Q, R273H) and Ets-1 potentiates Ets-1 
dependent transcription [126]. The transcription factor vitamin D3 receptor (VDR) is another 
natural binding partner of p53, but with varying outcome depending on the state of p53. 
Whilst vitamin D induces cell death in a p53 wild-type background, the R175H mutant has 
been shown to localize to VDR response elements through VDR interaction, leading to 
nuclear accumulation, transcriptional activity and cell survival (protection from etoposide 
induced cell death)[127]. Mutants R273H and R175H were recently also shown to interact 
with NF-Y (a natural binding transcription factor) resulting in the recruitment of antagonistic 
epigenetic modifiers from wild-type p53 binding, and consequently, mp53/NF-Y dependent 
target gene activation and DNA synthesis[128]. Mutant p53 has also been reported to 
influence the p63 transcriptome, leading to an increase in metastasis and invasiveness. 
Accordingly, mutant p53 (R175H and R273H) blocks p63-dependent transactivation by 
complexing with the ∆Np63α isoform [129] and effecting receptor recycling, and also 
possibly through R-SMAD (receptor regulated-SMAD protein) in a TGFβ1 dependent manner, 
eventually leading to the down-regulation of p63 target genes like CCNG2 and SHARP1, 
which are postulated to be involved in suppressing metastasis [130]. 
  




1.6 Developing cancer treatment by augmenting wild-type p53 activity 
Cellular transformation is a multi-step process that requires the occurrence of 
several events, often involving impairment in the p53 network. Several genetic models 
demonstrate the efficacy of restoring wild-type p53 activity in controlling and inhibiting 
cancer growth without undesirable cytotoxicity [131,132,133,134], underscoring the 
importance of wild-type p53 activity in cancer treatment. P53 gene therapy is an exciting 
treatment strategy that has capitalized on this observation. The adenovirus-based vector 
(Advexin, Gendicine) is able to invade tumor cells, delivering a functional copy of the p53 
gene and is currently in extended clinical trials in the Unites States [135,136]. Another 
noteworthy approach is cyclotherapy, and involves a combinatorial drugging tactic that 
leverages on the fundamental differences in cellular responses between cancer and normal 
cells. Accordingly, normal cells are first driven into a state of reversible p53-dependent 
growth arrest using a non-genotoxic drug (eg. Nutlin, a cis-imidazoline analog that disrupts 
p53-Mdm2 binding by mimicking three residues contact from the induced α-helix in the p53 
Ntd) [137], this not only protects them, but also sensitizes cancer cells to subsequent 
treatment using mitotic inhibitors that targets proliferating cells specifically. Such inhibitors 
include VX-680, an inhibitor of aurora kinase (a protein kinase that regulates mitosis by 
controlling chromatid segregation), [138] or PLK1 (protein kinase involved in G2/M cell cycle 
transition) inhibitor BI-2536 [139]. 
In 50% of human cancers where p53 status is wild-type, the focus lies in capitalizing on this 
factor. The present availability of compound libraries and selection techniques has 
potentiated the ease and efficacy of high-throughput screening (HTS) in elucidating small 
molecule activators of p53. Two approaches frequently employed are either a biochemical 
screen using purified proteins (also known as reverse chemical genetics) or cell-based assays 
in which a particular phenotype is selected for (or forward chemical genetics)(reviewed in 




[140]). Several notable achievements in this area include using small molecules to either 
augment p53 activity (through stabilization or activation) or trigger a p53-dependent 
response [141,142], and priming cancer cells to respond favorably to anti-cancer drugs. 
Hdm2 (an E3 ligase) is both a transcriptional target, as well as cellular antagonist of p53 (by 
poly-ubiquitinating p53 and targeting it for proteasome degradation). A very well explored 
strategy is the stabilization of p53 through derailment of the p53-Mdm2 negative feedback 
loop, usually through competitive inhibition. This includes development of (i) compounds 
Nutlin[143], RITA[144] and MI-219[145], each binding with high affinity to either Mdm2 or 
p53 at the site of interaction, (ii) peptides engineered to mimic the α-helical Ntd of p53 that 
inserts into the hydrophobic cleft on the surface of Mdm2 [146,147], and (iii) small 
molecules that inhibit E3-ligase activity of Mdm2 [148]. Other methods that activate wild-
type p53 include the Tenovin family of compounds that inhibit p53 deacetylation by sirtuins 
[149] and mycophenolic acid, a compound which enhances the interaction between Mdm2 
and ribosomal proteins L5 and L11 [150]. In another study, the synergistic use of older 
classes of anti-tumor compounds, specifically actinomycin-D (a genotoxic drug) and 
leptomycin-B (a compound that inhibits nuclear export) was shown to efficiently stabilize 
and activate wild-type p53 activity in three HPV integrated cervical carcinoma cell lines 
(HeLa,  SiHa and CasKi), inducing an apoptotic phenotype [151]. Curaxins belong to a new 
class of compounds, recently reported to augment p53-dependent cell death through the 
concomitant activation of p53 (through casein-kinase II activation) and inhibition of NF-κB, 
by targeting the FACT (facilitates chromatin transcription) complex [152]. A summary of 
cancer treatment strategies that target the p53 pathway is shown in Figure 1.6. 
1.7 Targeting mutant p53 GOF 
In 50% of human cancer where p53 is mutated, 2 schools of approach exist around 
tackling mutant p53 protein; deactivating its GOF or reactivating its LOF (loss of function). 




The field of neutralizing mp53’s oncogenic gain-of-function(s) is in its budding phase as we 
are just beginning to unpick the workings behind this phenomenon mechanistically. Also, 
whilst full-length p53’s unsolved structure poses a universal challenge to developing 
therapeutics, developing small molecules to target specific mutants or specific interactions 
involving mutants presents an even bigger obstacle. 
A very recent impetus aimed towards treatment of cancer lies in the impediment of 
molecular interaction derived from mutant p53’s gain-of-function. A key advantage in taking 
this approach is that it is conceivably easier to disrupt mp53’s undesired interactions than to 
restore its wild-type functions.  
RETRA is a small molecule derived from a compound library screen for p53-dependent 
transcriptional activity in a human epidermal cancer cell line bearing the R273H mutant. 
RETRA was able to induce an increase in p53 transcription activity in cell lines carrying 
endogenous R273H mutations when using both an ectopic reporter cassette as well as 
endogenous p53 target genes (CDKN1A and BBC3). RETRA was also able to delay the onset 
and severity of tumor formation in nude mice. Cell culture characterization revealed that the 
observed phenotype was a mutant p53 (but not wild-type) and p73 (but not p63) dependent 
event, and the authors hypothesized that RETRA is disrupting mutant p53 GOF by interfering 
with mp53/p73 interaction and releasing p73 to induce certain p53-regulated genes [153]. 
Another example is SIMP5 and SIMP6; two peptides selected from a library derived from the 
DNA binding domain of human p73, targeted at sensitizing SKBR3 breast cancer cells 
(carrying endogenous R175H p53 mutation) to the effects of cisplatin and adriamycin. 
Accordingly, SIMP5 and 6 were able to specifically target and disassemble p53-R175H/p73 
mutant complexes, leading to an increase in p73-dependent transcription and expression of 
target proteins (Bax, p21, p53AIP1 and killer/DR5)[154]. In a separate study, a selection was 
configured explicitly to derive peptide aptamers that bind p53-R175H tightly. Using a yeast- 









2-hybrid screen, a library of randomized 15 amino-acid peptide constricted by a thioredoxin-
A scaffold was generated (prey) and sampled against the p53-R175H core domain (bait). The 
authors demonstrated that the peptide aptamers (PAs) isolated were able to decrease 
transactivation of 2 known mutant p53 gene targets (c-myc and EGR-1), however, it is 
unclear if this is p53 dependent. The PAs were also able to induce apoptosis (demonstrated 
by an increase in annexin V and PARP expression) in cancer cells bearing endogenous R175H 
and R273H mutant p53[155]. Strangely, while the observed apoptotic phenotype required 
the presence of mutant p53 (apoptosis was ablated when mp53 was knocked-down), EMSA 
results revealed that the PAs did not restore wild-type sequence specific DNA binding to the 
mutants, suggesting a mechanism more complex than merely targeting and obliterating 
mp53’s GOF. The area of developing cancer treatment based on targeting mutant p53’s gain-
of-function is in its early phase and will undoubtedly require further study to be clinically 
viable. 
1.8 Reactivating mutant p53 
Restoring wild-type transcriptional activity to p53 mutants has been a daunting task, 
but several lines of thought have advocated its feasibility. Firstly, more than 75% of p53’s 
mutations are missense point mutations and ~95% of these lie in the core domain. This 
indicates the presence of full-length proteins with defects in a single, possibly druggable 
region. Additionally, mutants of the β-sandwich region (eg. V143A) are often 
transcriptionally active at lower permissive temperatures [96], and slightly distorted mutants 
like G245S, R248Q and R249S have only localized changes and potentially similar overall 
tertiary folds to wild-type [156]. Both observations imply a potential for mutant p53 
reactivation. Secondly, owing to constitutive oncogenic stress stimuli and the absence of an 
active p53-Mdm2 feedback loop, mutant p53 accumulates at high levels and in activated 
states from persistent post-translational modifications; two prerequisite events required for 




p53-dependent activity[156]. Furthermore, the concept of reinstating transcriptional activity 
and sequence-specific DNA binding to mutant p53 was proven attainable through second 
site suppressor (SSS) mutations, when several hotspot mutant phenotypes were shown to 
be rescuable.  A mutagenesis screen of mutants containing random second site mutations 
revealed that the H178Y mutation can rescue the G245S phenotype even though both 
mutations are inactive when expressed alone. When compared to wild-type levels, 
transactivation was restored partially for p21, Mdm2, Bax and Gadd45, and fully for 14-3-3σ 
response elements [157].  
Interestingly, a similar phenotype is observed also when p53 proteins harboring either the 
G245S or H178Y mutation were co-expressed in p53-null Saos-2 osteosarcoma cells [157], 
implying substantial intermolecular cross-talks between monomeric subunits capable of re-
establishing wild-type conformation to defective monomers. In another study, the H115N 
SSS mutation was able to reverse the R248Q mutant phenotype, restoring structural 
integrity and sequence-specific DNA binding [158].  
1.9 Reactivation of mutant p53 using peptides 
1.9.1 p53 C-terminal peptide 
Hupp and colleagues reported that wild-type full-length p53’s latent state can be 
activated in-vitro, neutralizing the auto-inhibitory carboxyl-terminal domain either through 
its removal, treatment with specific antibodies, or phosphorylation of C-terminal residues 
[75,159]. Soon after, the same group reported that a peptide sequence, derived from c-
terminal residues 369 – 383, was capable of activating p53’s latency in sequence specific 
DNA binding (shown via electrophoretic mobility shift assay, EMSA). The lack of activity from 
other peptides with varying sequences derived from the same region indicated a highly 
specific interaction. This peptide-dependent activation can be further enhanced if p53-Ctd 




was first phosphorylated or exposed to DnaK interaction [160]. Several years later, another 
group took this peptide sequence, shortened it (residues 361 – 382) (Figure 1.7), and 
demonstrated its functionality in reactivating mutant p53 in cells. Accordingly,  the C-
terminal peptide (p53-ctp or peptide 46) (fused to a Drosophila Antennapedia protein 
transduction domain, PTD), was able to induce p53-dependent growth arrest in Saos-2 cells 
stably expressing p53-R273H under a tetracycline-repressible-promoter [161]. Furthermore, 
TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) staining indicated 
that the PTD-fused c-terminal peptide was able to induce apoptosis in several cell lines with 
varying status of endogenous p53; Ew36 (wt-p53), BL41 (R248Q) and SW480 
(R273H/P309S)[161]. More recently, a retro-inverso version of this peptide was synthesized 
(using D-isomers amino acid residues) fused to the TAT PTD (derived from HIV Tat protein), 
and when administered to tumor bearing immuno-deficient mice [inoculated with either 
TA3/St (wt-p53) or Namalwa (R248Q) cancer cells], was shown to increase the survivability 
as a direct result of tumor growth inhibition [162] (Table 1.1). Despite the positive results 
demonstrating the p53-activating potential of the c-terminal peptide, the presence of a 
direct interaction between p53-ctp and p53’s DNA binding core has not been proven 
unequivocally [163]. Using the scintillation proximity assay, one study revealed that p53-ctp 
does not associate directly with the p53 core domain (unlike CDB3 nonapeptide) [164]. 
However, a study measuring  binding between p53-ctp and deletion mutants of p53 
demonstrated that a direct interaction does exist, but requires the presence of both the p53 
C-terminal (residues 363 – 393) and proline-rich (residues 80 – 94) domains [165]. A more 
skeptical interpretation came from the observation that only lysine residues within the p53-
ctp (demonstrated through an alanine scan [160]) are critical in its activation of p53. This 
may underscore the importance of ionic interactions and fuel a hypothesis that the very 
positively charged p53-ctp interacts non-specifically and aggregates DNA, hence contributing 
to both sequence-specific and non-specific DNA binding, resulting in a chemical artefact 




masquerading as a positive phenotype [163]. Notably, poly-lysine peptides have been known 
to activate sequence specific DNA binding of latent p53 and other transcription factors in-
vitro through this mechanism [166]. This may also explain p53’s observed interaction with 
the c-terminal peptide [167]. Existing in-vitro, ex-vivo and in-vivo data demonstrate p53-
ctp’s reactivating potential on wild-type p53 and mutants R273H and R248Q only, there is no 
explanation to this apparent selectivity or data showing reactivation of other mutants. 
Whilst p53-ctp’s activity has been shown to be p53-dependent, it will be interesting to test if 
the in-vivo tumor suppressive phenotype is a result of restoring mp53 transactivity or an 
inhibition of its oncogenic GOF. Interestingly, similar to the C-terminal, p53’s proline-rich 
domain was also described to confer DNA binding latency to full-length protein, a phenotype 
which can also be ablated using synthetic peptides derived from the same domain (residues 
80 – 94) [165]. The feasibility of using polyproline peptides to reactivate mutant p53, was 
however, not actively pursued. 
1.9.2 CDB3 nonapeptide 
CDB3 is another example of a peptide re-activator of mutant p53 derived through 
rational design. CDB3 (Figure 1.7) emerged as a lead compound in a NMR screen for tight 
binders when several synthetic peptides with overlapping sequences, based on the co-
crystal structure of p53 core domain bound to 53BP2 (a natural p53 binding protein that 
potentiates p53-dependent transcriptional activity and apoptosis [168]), were designed 
[169]. The authors then discovered that labeling CDB3 at the N-terminal with fluorescein (FL-
CDB3) increased the binding affinity to p53, giving a KD of ~0.5 μM. FL-CDB3 bound p53 at 
the periphery of the DNA binding region in the core domain (competes for sequence specific 
DNA binding) and was able to modestly increase the apparent Tm of wild-type and R249S 
core domain by 1.5oC and 1.0oC, respectively [169]. In a separate study, levels of both p53 
and p53 target proteins (p21 and Mdm2) were up-regulated in mutant p53 cancer cells 




(H1299-R175H and Saos2-R273H under a tetracycline inducible promoter) when treated 
with FL-CDB3, and in a p53-dependent manner [170]. Immunoprecipitating cell extracts, the 
authors also showed that FL-CDB3 treatment induced a decreased PAb240, and increased 
PAb1620 epitope phenotype in both p53 mutants [170]. CDB3 was also shown in a separate 
study using SPA (Scintillation Proximity Assay) to bind directly to the core domain, and can 
be displaced by consensus oligo-nucleotide [164]. FL-CDB3 dependent increase in p21 levels 
was, however, not accompanied by a growth arrest phenotype, although apoptosis was 
mildly induced (19% increase in sub-G1 DNA content) in mutant p53 cells (but not wild-type 
or p53-null cells) [170] (Table 1.1). The authors postulated a ‘chaperone’ model for CDB3 
activity; in a 2-state equilibrium where p53 exists as ‘folded’ or ‘unfolded’, CDB3 binds to 
native p53 and shifts the equilibrium towards the ‘folded’ direction. At this point, an obvious 
conundrum is that a ‘chaperone’ strategy would expectedly, in theory, only rescue p53 
mutants carrying structural defects (i.e. G245S or R248Q) or DNA binding defects due to 
structural distortions (i.e. temperature sensitive phenotypes from mutations affecting the β-
sandwich; V143A and I195T), and not a native DNA contact mutant seen in this study (R273H 
mutant is also not in dynamic equilibrium [171]). Using heteronuclear single quantum 
coherence NMR, a more in-depth structural characterization of FL-CDB3 binding R249S 
mutant was achieved. Accordingly, the R249S mutant exists in a dynamic equilibrium of 
several distinct states of native and native-like conformations. Binding of FL-CDB3 at the 
DNA interface region causes chemical shifts at a distal region distorted by the mutation, 
restoring wild-type structure. Notably, while FL-CDB3 bound in a similar fashion to both 
wild-type p53 and R273H mutant, it did not induce chemical shifts in areas detected in the 
R249S mutant [171]. This further supports the idea that the R273H mutant should not be 
rescued by CDB3 peptide.  
The ‘chaperone’ strategy seen here will probably only work well in a narrow subset of 
mutants – those that are in dynamic equilibrium consisting of several native-like states. Also, 




it may be more ideal to rationally design a chaperone that binds away from the DNA 
interface region, which is difficult considering the scarcity of structural data. 
1.10 mutant p53 reactivation using small molecule compounds 
1.10.1 CP-31398 
Compared to peptide based re-activators, small molecules capable of rescuing mp53 
phenotype have been reported more prolifically. One of the earliest compounds discovered, 
through RCG, was CP-31398 (Figure 1.7). CP-31398 belonged to a group of lead compounds 
which, was although initially selected to enhance wild-type p53 thermal stability (via the 
retention of PAb1620 epitope when the DNA-binding core domain was heated in the 
presence of a synthetic compound library), was shown to stabilize certain mutant proteins 
further [172]. The selected compounds that stabilized mp53 share a common feature in 
which a hydrophobic (R1) and positively ionizable (R2) group is separated by a specific linker. 
Although the precise mechanism is unknown, an interesting observation, that changing the 
linker length or the polarity at the R2 group makes compounds inactive, suggests a 
mechanism whereby compounds are making specific bivalent contacts in spatially sensitive 
orientations [172]. CP-31398 stabilizes the PAb1620 epitope in V173A and R273H mutants 
in-vitro and up-regulates p21 levels in p53 null cancer cell lines (Saos-2) over-expressing 
V173A and R249S p53 mutants. Also, treatment of CP-31398 in nude mice inoculated with 
either A375.S2 melanoma (endogenous 249 mutation) or DLD-1 colon carcinoma 
(endogenous 241 mutation) cells resulted in a tumor suppression, contrary to vehicle-only 
treated control mice [172]. The precise mechanism of CP-31398 is unknown and 
discrepancies in reports have shrouded the topic even more. For instance, one group 
reported a decrease in sequence-specific DNA binding when wild-type and mutant p53 (from 
endogenous cell lysate) was incubated with CP-31398 [173], while another reported a 
restoration of the same function to bacterial purified R273H mutant [174]. The latter result 




also contradicts a separate observation that CP-31398 induces PAb1620, but only in newly 
synthesized protein (shown in cyclohexamide treated cell culture)[172,173]. Furthermore, 
CP-31398 was also reported to induce PUMA [175] and p21 [176] expression in a p53 
independent manner. Data from a more recent study indicated that CP-31398 was able to 
inhibit p53 ubiquitination mediated by Mdm2, but not HPV-E6 [164].  
1.10.2 PRIMA-1 
PRIMA-1 (Figure 1.7) was identified through a low-molecular-weight compound 
screen for an induction of growth arrest in Saos2 cells stably transfected with tetracycline 
regulated p53-R273H mutant. It has since reached phase I of clinical trials as well as sparked 
much interest in its mode of activity. Initial in-vitro studies revealed that PRIMA-1 can 
thermally stabilize (increase PAb1620 and reduce PAb240 epitopes) purified wild-type and 
R175H p53, and endogenous R175H mutant from cell lysate [177]. EMSA also showed 
restoration of sequence specific DNA binding to PRIMA-1 treated cancer cells carrying 
various endogenous mp53 (Table 1.1). A more recent study has shed light on its precise 
molecular activity, accordingly, PRIMA-1 metabolizes spontaneously in-vivo into the effector 
molecule, methylene quinuclidinone (MQ), attacking and forming adducts with thiol groups 
of amino acid exposed in unfolded mutant p53, and thus stabilizing the protein [178]. 
PRIMA-1 can also induce apoptosis in various cancer cells carrying endogenous p53 
mutations, and in a mutant but not wild-type p53 dependent manner. Additionally, PRIMA-1 
induced apoptosis often involved an up-regulation of pro-apoptotic gene targets including 
NOXA, Bax and PUMA [178,179], and is dependent on the mitochondrial intrinsic pathway 
[180]. In vivo study show that a twice daily intra-tumor dosing of PRIMA-1 in nude mice 
transfected with Saos2-R273H cancer cells, resulted in significant tumor shrinkage [177]. The 
success of PRIMA-1 as a re-activator of mutant p53 has prompted further screens and 
structural characterizations of its analogs[181]. PRIMA-1MET is the methylated analog of 




PRIMA-1 and was described to be more active and specific for mutant p53 then its 
predecessor [182,183].  
1.10.3 MIRA-1 
MIRA-1 (and its active analogs MIRA-2 and -3) (Figure 1.7) was identified by the 
same group and screening process as PRIMA-1, and was reported to induce growth 
suppression to several tumor cell lines carrying tetracycline regulated mutant p53 (R175H 
and R273H) in a p53-dependent manner [184]. While, all the compounds were reported to 
protect purified GST-fused wild-type p53 from the lost of PAb1620 epitope, reports of 
induced cellular phenotypes varied between analogs. Accordingly, only MIRA-1 treatment 
was shown to elicit an increase in sub-G1 cells (Saos2-R273H) and p21 levels (H1299-R175H). 
MIRA-3, on the other hand, was reported to stabilize PUMA protein levels, and shrink xeno-
grafted tumor in nude mice [184]. Most notably, although many of the reported drug 
induced phenotypes were shown to be p53 dependent, p53 independent cytotoxicity was 
observed in several instances at a 15 μM working concentration. Similarly, an increase of 
drug dosage from 1mg/kg – 5mg/kg resulted in acute toxicity in the mice (Table 1.1).  
1.10.4 STIMA-1 
A similar screen, using tetracycline regulated R273H mutant p53 against a 
compound library of CP-31398 derivatives, identified STIMA-1 (Figure 1.7) as yet another 
mutant p53 reactivator. Using similar assays to PRIMA-1 and MIRA compound validation, the 
authors reported that STIMA-1 restored growth suppressive functions to p53 mutants, 
R273H and R175H in a p53-dependent manner [175]. Treatment of STIMA-1 was also 
accompanied by increased expression of p21, PUMA and Bax proteins, and caspase 
activation in H1299 cells (p53 null human lung carcinoma) in a p53-depdent fashion [175] 
(Table 1.1). The authors also provide evidence and postulate that compounds MIRA-1, 




STIMA-1 and CP-31398 behave as Michael acceptors (where their common double bond 
allows them to participate in nucleophillic reactions), alkylating thiol groups on cysteine 
residues in the p53 mutant protein, which somehow stabilizes the native fold of the protein 
[175]. 
1.10.5 SCH529074 
SCH529074 (Figure 1.7) is a small molecule compound selected from a chemical 
library screen for cognate DNA binding to purified p53-R273H core domain using an 
oligonucleotide coated bead-based binding assay [164]. The characterization of SCH529074 
was relatively comprehensive, and compared several functional activities against other 
known mutant activators (CDB3, p53-ctp, PRIMA-1 and CP-31398). In this study, SCH529074 
was shown to interact directly with p53 (wild-type and R273H mutant) DNA binding core 
domain (at a site similar to CDB3), and could restore DNA binding to cognate sequence in 
R273H core domain [164]. SCH529074 treatment in several endogenous mp53 cancer cell 
lines also increased protein and transcript levels of target genes (Bax, p21 and PUMA) in a 
p53-dependent manner. Furthermore, orally administered SCH529074 resulted in tumor 
shrinkage in nude mice subcutaneously xeno-grafted with DLD-1 human colorectal 
carcinoma cells (S241F) [164] (Table 1.1). Interestingly, SCH529074 could also specifically 
block Mdm2-mediated poly-ubiquitination of p53 [164]. 
1.10.6 Phikan 083 
Phikan083 (PK083) (Figure 1.7) belongs to the carbazole class of small molecules that 
was identified to specifically target and structurally stabilized the core domain of the p53 
Y220C mutant. The identification of PK083 was an extension from an earlier structural study, 
where the authors crystallized several hotspot mutations, each in a super-stable variant of 
the p53 core domain (termed quad-mutant, QM) [185] and examined the extent of 




destabilization caused by each mutation. The crystallographic study revealed that the Y220C 
mutation, caused by a mutation located at the distal end of the β-sandwich, resulted in the 
loss of hydrophobic interactions and suboptimal packing of the core. More importantly, the 
mutation creates a solvent accessible surface cavity away from the DNA binding interface of 
the core, and while it destabilizes the protein, the overall core domain remains intact [186]. 
Realization of the potential druggability of the Y220C cleft led to the development of an in-
silico screen against a massive virtual library of >24.8 million conformers. The authors 
included elements of structure-based modeling, crystal structure based ligand docking and 
manual selection in their screening algorithm and derived the compound PK083. Differential 
scanning calorimetry (DSC) showed that the Tm of p53QM-Y220C core domain was raised by 
~2oC with 2.5 mM of PK083 with an approximate KD of 140 ± 73 μM [187] (Table 1.1). The co-
crystal structure of PK083 and p53QM-Y220C core domain was also solved, and revealed 
that the planar carbazole ring is largely buried within the cleft and sandwiched between the 
hydrophobic side chains of Pro222 and Pro223 on one side, and Val147 and Pro151 on the 
other [187]. The authors then went on to use fragment-based ligand screens and molecular 
dynamics simulations to identify compounds that could potentially bind the Y220C 
mutational cleft. Through co-crystallizing p53QM-Y220C core domain with several of the 
lead compounds, they further characterized and established a framework of understanding 
key interactions and molecular docking at the Y220C mutational cleft [188]. Although there 
are no published reports showing activity of these compounds in cells or animal models, it 
exemplified the feasibility of designing small molecules that could target and stabilize 
specific p53 mutants. 
1.10.7 RITA 
 RITA, a compound previously described to activate wildtype p53 (by binding p53’s 
Ntd and disrupting p53-Mdm2 interaction [144]), was recently described to also display 




mutant p53 reactivating properties [189]. In this study, RITA treatment was reported to 
suppress cell growth in a panel of human cancer cells carrying different p53 mutations (Table 
1.1) (although drug-induced growth arrest in the same cells without p53 were not studied), 
and induced apoptosis in HCT116 cells in a mutant p53 dependent manner. Notably, the 
kinetics of RITA-induced cell death ranged from 6 hours to 7 days in different cells, 
suggesting either a heavy dependence on the presence of unknown co-factors, or possible 
p53-independent cytotoxicity. Apoptotic phenotype in several cell lines (A431, MDA-MB231 
and SKBR-3) could also be abated through concomitant treatment of pifithrin-α (inhibitor of 
p53 transcription activity) and pifithrin-μ (inhibitor of p53 transcription-independent pro-
apoptotic functions), suggesting p53 transcription-dependent and –independent activation. 
A RITA-dependent increase in mRNA levels of several p53 downstream targets (p21, Noxa, 
PUMA and GADD45) was also described (between 2 -4 fold increase), but was inconsistent 
across different cell lines. 
1.10.8 Other compounds 
Finally, there are also sporadic reports of less novel compounds that seem to have 
restorative functions to mutant p53. Ellipticine is an alkaloid compound with a known anti-
neoplastic function based mainly on formation of DNA adducts through intercalation, and 
topoisomerase II inhibition [190]. Shi and colleagues noted, in a drug sensitivity analysis 
against a panel consisting of 60 human tumor cell lines, that a group of ellipticine derivatives 
displayed preferential potency in cells with mutant p53 backgrounds [191]. In another study, 
a derivative (9-hydroxyellipticine) compound was able to restore wild-type p53 activity in 
several cancer cell lines carrying endogenous p53 mutations (SW480, SKBR3 and MKN1), 
inducing growth arrest and apoptosis [192]. Subsequently, a more detailed characterization 
showed that ellipticine induced the transcription of p53 reporter gene in Saos2 (p53 null) 
cells only when mp53 (R175H, R248W, R249S, R273H and D281G) was present [193]. An 




increase in levels of p21 and Mdm2 (C33A-R273C and T47D-L194F) and PAb1620 epitope 
(DLD1-S241F) were also seen in ellipticine treated endogenous mp53 cell lines. In-vivo 
models, however, only showed an increase in Mdm2 levels in tumors derived from nude 
mice subcutaneously inoculated with endogenous mp53 cancer cells. Also, no direct 
interaction between compound or p53 was revealed or implied in the data. In fact, presence 
of ellipticine failed to elicit PAb1620 retention when purified p53 protein was heated, 
contrary to the effects of CP-31398 which was used as a positive control [193]. More 
recently, a separate study showed an increase in nuclear p53 localization and a concomitant 
increase in p53 transcriptional activity in HCT116 (wildtype p53+/+) cells that was p53 and 
ellipticine co-dependent [194].  
Amifostine (WR2721) is an anti-mutagenic compound used clinically to control the 
deleterious side effects of chemo- and radiotherapy [195]. In two separate studies, WR2721 
(and its active metabolite WR1065 (Figure 1.7)) was shown to stabilize and activate 
endogenous wild-type p53 in MCF7 (human breast adenocarcinoma) cells [196], as well as 
restore transcriptional activity to several mutants (yeast-2-hybrid assay) [197]. A later study 
also showed that WR1065 could induce PAb1620 epitope, and p21 expression to 
endogenous V272M mutants in TE-1 (esophageal squamous cell carcinoma) cells [198]. Of 
note, WR1065 is actively degraded, and as such, requires either a high working 
concentration (2-4 mM) or the presence of aminoguanidine (4 mM) to exhibit appreciable 
activity (Table 1.1).  
Osmolytes such as glycerol has also been shown to sensitize mutant p53 cells to the effects 
of heat and γ-irradiation insults, possibly acting as a chaperone molecule to reduce thermal 
instability, and induce apoptosis [199,200].  
  


























1.11 Limitations of current approaches in identifying reactivating molecules 
 From many of the examples highlighted above, the work of developing chemical 
compounds to target and specifically restore wild-type p53-dependent response faces many 
challenges. Drug related cytotoxicity and undesired non-specific effects are especially big 
hurdles. Small molecules have low target specificity and can cause DNA damage or p53-
independent toxicity (eg. MIRA-1) (Table 1.1). This limits the pool of candidate compounds 
as those with high IC50 or KD values become unsuitable as low activity cannot be 
compensated by increasing dosage. The primary method of using FCG has resulted in 
successful identification of new compounds due to the large chemical libraries and high-
throughput methods of screening. However, it often implies that the precise mechanism of 
drug activity is unknown (eg. STIMA-1, WR1065, Ellipticine, CP-31398, MIRA) (Table 1.1) 
leading to difficulties in characterizing the compound, or enhancing drug activity. In addition, 
many of the reported compounds have also not been described to interact directly with p53. 
Peptide-based therapy, on the other hand offers many advantages, like low cytotoxicity and 
high target specificity that chemical compounds cannot. Additionally, the short half-life 
attributed to peptides in cells can now be addressed using several tactics, namely the use of 
peptide aptamers, stapled peptides, or D-isomers amino acids. However, the field of peptide 
therapy in the context of p53 has dwindled due to several implementation limitations. The 
conceptualization of peptide sequences often begins through rational approaches (for 
example, structural elucidation from p53 complexes or in-silico modeling using solved 
mutant structures) which become difficult considering p53’s unsolved full-length structure. 
This is further compounded by diversity in the structure and characteristic of each p53 
mutant, and tissue specific response in different cancers.  
An attractive solution will therefore be to combine the strengths of each approach and 
identify peptides in a forward genetic screen. 




1.12  Scope of thesis 
 The aim of thesis is to identify and validate peptide sequences (from a random 
peptide library of 20-mers) capable of reinstating sequence-specific DNA binding to 
physiologically relevant p53 response elements in hotspot p53 mutants. This is achieved by 
using a selection technique (In Vitro Compartmentalization) in a methodology that 
encompass key elements of (a) high-throughput screening (b) random generation of peptide 
sequences, and (c) little to no limitations on mp53-peptide mode/site of interaction. 
Additionally, a sensitive real-time PCR-based high-throughput assay that measures p53-DNA 
binding was also developed for the purpose of validating peptide sequences identified from 
the IVC selection. This assay will also be used to compare the relative reactivation potential 
of several published and unpublished reactivating compounds with the selected peptides.




2  General materials and methods 
 Unless otherwise stated, all chemical reagents used were of analytical grade and 
were used without further purification. Most chemicals were obtained commercially from 
Sigma-Aldrich (Singapore). H2SO4, HCl and DMSO solutions were obtained from Merck 
Chemicals (Singapore). HyClone® molecular grade water (Thermo Scientific, Singapore) was 
used in for molecular procedures and for DNA storage. SYBR® Green I nucleic acid stain was 
obtained from Molecular ProbesTM (Invitrogen, USA). Phosphate Buffered Saline (PBS), LB 
media, and LB-agar were prepared and supplied by the Biopolis Shared Facilities (Singapore). 
2.1  Chemicals, reagents and other materials 
2.1.1  Buffers and solutions 
Buffers Recipe 
p53 binding buffer 1 20 mM Hepes( pH 7.3), 1 mM MgCl2, 0.1% (v/v) NP-40, 10 mM NaCl, 500 μM 
ZnCl2, 2 mM DTT 
p53 binding buffer 2 25 mM NaPi (pH 7.2), 150 mM NaCl, 4 mM DTT 
6X p53 binding buffer 2 150mM NaPi (pH 7.2), 600 mM NaCl, 24 mM DTT 
6X DNA loading dye Sterile H2O, 0.5 g (w/v) bromophenol blue, 15% (v/v) glycerol (autoclaved), 15X 
Sybr green I (Molecular Probes, Invitrogen) 
DNA standards Sterile H2O, 6X DNA loading dye (1:6 dilution), 100 ng/μL 1kb+ DNA ladder 
(Invitrogen) 
Wash buffer 1 (WB1) Phosphate buffered saline, 0.1% (w/v) BSA 
Wash buffer 2 (WB2) Phosphate buffered saline, 0.1% (w/v) BSA, 0.1% (v/v) Tween-20 
Antibody coating buffer 0.1M CO3 /HCO3 (pH 9.0 – 9.5) 
Coomassie blue protein 
stain 




10% (v/v) acetic acid, 40% (v/v) methanol, 50% (v/v) dH2O 
Plate layering buffer 2% (w/v) BSA, 300 mM KCl, 0.1% (v/v) Tween-20 
Table 2.1 – List of common buffers and solutions 
2.1.2  Antibodies 
 Antibodies used in this thesis for purposes of western blotting, ELISAs and other in 
vitro techniques are listed in the table 2.2. P53 and p21 antibodies were kindly given by Dr 




Borivoj Vojtesek (Masaryk Memorial Cancer Institute, Brno, Czech Republic). AC-15 was 
purchased from Abcam®. 




MM IgG2A 20SDLWKL25 [201] 
1801 MM IgG1 46SPDDIEQWFT55 [48] 
Bp53 10.1 MM IgG2A 371SKKGQSTSRH380 [202] 
Pab 240 MM IgG1 213RHSVV217 [101] 
Pab 1620 MM IgG2A Native Protein. 145LWVDSTPPPGTRV157 and 
201LRVEYLDDRNTF212 [203] 
CM1 RPS Polyclonal pan, but mainly in N- and C-terminals [48] 
118 p21 MM IgG1 - 
AC-15 β-action MM - - 
Table 2.2 – List of antibodies used. MM = mouse monoclonal, RPS = rabbit polyclonal sera. 
2.1.3  DNA oligonucleotide sequences 
Oligo reference DNA sequence (5’ → 3’) 
RANLIB2 AAT ACG ACT CAC TAT AGG GAG AGG AGG TAT ATA CAT G (60 Ns) TAG AGG AAG 
AAG ACT GGG CAT GTC TGG GCA 
RL2-pUMA2-F2 CGC GCC TGC AAG TCC TGA CTT GTC CGC GGT AAT ACG ACT CAC TAT AGG GAG 
AGG AGG TAT ATA CAT G 
RL2-p21-2R TGC CCA GAC ATG CCC AGT CTT CTT CCT CTA 
PET-F2 CAT CGG TGA TGT CGG CGA T 
PET-RC CGG ATA TAG TTC CTC CTT TCA GCA 
RF2 GAC TCA CTA TAG GGA GAG GAG GTA TAT ACA TG 
rPETr GCG TCC CAT TCG CCA ATC CG TGC CCA GAC ATG CCC AGT CTT CTT CCT CTA 
PetRevWalt GCG TCC CAT TCG CCA ATC CG 
Table 2.3 – Oligonucleotides for construction of random peptide DNA library (Ranlib) 
Oligo reference DNA sequence (5’ → 3’) 
RL2-T7-F1 GCG GTA AAC GAC TCA CTA TAG 
SPN-R1 CTC TAC TAT AAA TGT TGC TAA ACT G 
MPH-R1 CCT CTA AAC TAT GCG TTT GTA AC 
VRH-R1 TCT AAT GGT CGG TCC AAC CC 
RLQ-R1 CTA CGG GCA GTG ACC GAT A 
ILN-R1 CCT CTA CCT AGT GAA GAA AGT G 
TALID-R1 CTC TAT GAC ATT CGA GGA TAA CC 
Table 2.4 – Oligonucleotides for amplifying peptide cDNA 
  




Oligo reference DNA sequence (5’ → 3’) 
p21-TOP TAG AGG AAG AAG ACT GGG CAT GTC TGG GCA 
p21-BOT TGC CCA GAC ATG CCC AGT CTT CTT CCT CTA 
PUMA-TOP CGC GCC TGC AAG TCC TGA CTT GTC CGC GGC 
PUMA-BOT GCC GCG GAC AAG TCA GGA CTT GCA GGC GCG 
Scram-TOP GTC GTT CTG ATC CAG GTG ATG TAG TCG ACG 
Scram-BOT CGT CGA CTA CAT CAC CTG GAT CAG AAC GAC 
PUMA2-PET-F2 CGC GCC TGC AAG TCC TGA CTT GTC CGC GGC CAT CGG TGA TGT CGG CGA T 
RGC-PET-F2 CAC ATG CCT TGC CTG GAC TTG CCT CAT CGG TGA TGT CGG CGA T 
P21-PET-F2 TAG AGG AAG AAG ACT GGG CAT GTC TGG GCA CAT CGG TGA TGT CGG CGA T 
P2XM-PET-F2 CTT GGG AAC AAG GGC ATG AGC TTG TCT GGG CTC ATC GGT GAT GTC GGC GAT 
WPET-R1 TAA TTT CGC GGG ATC GAG ATC T 
Table 2.5 – Oligonucleotides for generating DNA response elements 
Oligo reference DNA sequence (5’ → 3’) 
QC-Y220C-Top CAT AGT GTG GTG GTG CCC TGT GAG CCG CCT GAG TTG GC 
QC-Y220C-Bot GCC AAC CTC AGG CGG CTC ACA GGG CAC CAC CAC ACT ATG 
QC-R175H-Top CAC ATG ACG GAG GTT GTG AGG CAC TGC CCC ACC ATG AGC GCT GC 
QC-R175H-Bot GCA GCG CTC ATG GTG GGG GCA GTG CCT CAC AAC CTC CGT CAT GTG 
QC-R273H-Top ACG GAA CAG CTT TGA GGT GCA TGT TTG TGC CTG TCC TGG GA 
QC-R273H-Bot TCC CAG GAC AGG CAC AAA CAT GCA CCT CAA AGC TGT TCC GT 
QC-G245S-Top GTA ACA GTT CCT GCA TGG GCA GCA TGA ACC GGA GGC CCA TC 
QC-G245S-Bot GAT GGG CCT CCG GTT CAT GCT GCC CAT GCA GGA ACT GTT AC 
QC-R248Q-Top CTG CAT GGG CGG CAT GAA CCA GAG GCC CAT CCT CAC CAT CA 
QC-R248Q-Bot TGA TGG TGA GGA TGG GCC TCT GGT TCA TGC CGC CCA TGC AG 
Table 2.6 – Oligonucleotides for site-directed mutagenesis 
Oligo reference DNA sequence (5’ → 3’) 
Pet-F3 (Test_1F) ATA GGC GCC AGC AAC CGC ACC TG 
Test_2F CTT CCA CTT TTT CCC GCG TTT TC 
Test_3F CTC CTT TCG CTT TCT TCC CTT CCT T 
WPET-R1 TAA TTT CGC GGG ATC GAG ATC T 
WPET-R2 CTC GAT CCC GCG AAA TTA ATA CGA C 
WPET-R3 CCG AAT TAA TTC CGA TAT CCA TGG 
Walt_Pet_R2_correct GTC GTA TTA ATT TCG CGG GAT CGA G 
PumaBS2_short_F CGC GCC TGC AAG TCC TGA CTT G 
P21_short_F TAG AGG AAG AAG ACT GGG CAT GTC TG 
RGC_short_F CAC ATG CCT TGC CTG GAC TTG CC 
P2XM_short_F CTT GGG AAC AAG GGC ATG AGC TTG T 
Table 2.7 – Real-time PCR primers 
Oligo reference DNA sequence (5’ → 3’) 
P2inTRX-F ATG ATG CCA CAC TTA ATG GCA TGT CCG TGC AAA ATG ATC GCC CCG 
P2inTRX-R ACA TGC CAT TAA GTG TGG CAT CAT ACC GCA CCA CTC TGC CCA GAA 
Nano-F  
Nano-R  
T7-F GAA ATA ATA CGA CTC ACT ATA GG 
PelB-R CTA GGC CAT CGC CGG CT 
Table 2.8 – Oligonucleotides for generating expression constructs. 
  




Oligo reference DNA sequence (5’ → 3’) 
M13-F GTA AAA CGA CGG CCA GT 
M13-R CAG GAA ACA GCT ATG AC 
∆22-F TGA GGA TCC GAA TTC GAG CTC 
∆22-R GGA CTT CAG GTG GCT GGA GT 
Table 2.9 – Other oligonucleotides 
2.1.4  DNA plasmid vectors 
 pET-22b(+) plasmids carrying p53 cDNA were used mainly as vectors for gene 
manipulation and templates in generating PCR fragment templates for IVT protein 
expression. 
pET-22b(+)-p53wt-FL      cDNA sequence encoding full-length human p53 was cloned into the 
pET22b(+) vector between the Nde I and Nco I restriction sites, under a strong phage T7 
promoter. This vector acted as the parental plasmid from which downstream modifications 
to the p53 gene were generated and cloned. Full-length p53 mutants were synthesized using 
this plasmid through the QuikChange site-directed mutagenesis kit (Section 2.2.4). This 
vector was made by Dr Farid Ghadessy (p53lab, Astar, Singapore). 
pET-22b(+)-p53wt-∆22      cDNA sequence carrying the p53 gene with a 22-residue C-
terminal truncation (p53wt-∆22) was cloned using the pET-22b(+)-p53wt-FL vector via PCR 
(Table 2.8, Section 2.1.3). All other p53-∆22 mutant encoding plasmids were synthesized, 
using this plasmid as template, through QuikChange site-directed mutagenesis (Section 
2.2.4).  
pET-22b(+)-Nanop53wt-FL/pET-22(+)-Nanop53wt-∆22      Using PCR, a 9-mer streptavidin-
affinity tag (DVEAWLGAR) was appended to the N-terminal of the p53 gene for plasmids 
pET-22b(+)-p53wt-FL and pET-22b(+)-p53wt-∆22. Like above, subsequent p53 mutant 
encoding vectors were created via mutagenesis using the QuikChange kit (Section 2.2.4). 
Mammalian expression vectors listed below were primarily used in cell culture work 
described in Chapter 8. 




pcDNA3(+)-p53wt-FL      This vector carries a full-length wild-type p53 cDNA sequence under 
a human cytomegalovirus immediately-early (CMV) promoter, and allowed transient and 
efficient p53 protein expression in mammalian cells. QuikChange site-directed mutagenesis 
(Section 2.2.4) was performed using this plasmid to generate p53-G245S mutant expressing 
vector. This vector was provided by Dr Sergio Menendez (Institute of Molecular and Cell 
Biology, Singapore). 
pcDNA3(+)-TrxA      cDNA sequence encoding the bacterial protein Thioredoxin A (Trx-A) was 
cloned into the pcDNA3(+) vector between the BamH I and Xho I restriction sites. Gene 
sequences encoding variants of Pap-MPH were subsequently inserted into the Trx-A active 
site using PCR, resulting in expression constructs pcDNA3(+)-Trx-MPHs,  pcDNA3(+)-Trx-
MPHo and pcDNA3(+)-Trx-MPHScram  (Section 8.3.4). The Thioredoxin-A expressing 
parental vector was constructed by Dr See Hai Yun (p53lab, Astar, Singapore). 
pCMV-hmdm2      The human Mdm2 cDNA sequence was cloned into this vector and under 
the influence of a CMV promoter. This vector was provided by Dr Suzanne Camus (Institute 
of Molecular and Cell Biology, Singapore). 
pBlueScript SK(-)      For optimal transfection efficiency, this plasmid was used as a dummy 
vector for normalizing total DNA transfected into H1299 cells. The vector is ~3kbp in size, 
and carries minimal DNA elements, including a T7 phage promoter, a multiple cloning site, 
and an ampicillin resistance cassette.   
pRGC-∆fos-lacZ      This was used as a reporter vector for p53 activity in cells. It has two 
ribosomal gene cluster (RGC) p53 binding sites in tandem, and is proximal to the minimal c-
fos promoter, upstream of the lacZ reporter gene, which encodes β-galactosidase. This 
vector was provided by Dr Farid Ghadessy (p53lab, Astar, Singapore). 




pCMV-Luc      For cell based β-galactosidase reporter assay, the pCMV-Luc was used as an 
internal control for normalizing transfection efficiency. It carries the luciferase gene under 
the control of a CMV promoter. This vector was provided by Dr Farid Ghadessy (p53lab, 
Astar, Singapore). 
2.1.5  Synthetic peptides 
 Synthetic peptides used in this study were all commercially obtained from 
Mimotopes Pte Ltd (Australia), and were purified via High Performance Liquid 
Chromatography (HPLC). Peptides used for in vitro assays had a minimum purity of 80%, 
whereas peptides utilized in cell culture experiments were synthesized with a minimum 
purity of 90%. A list of synthesized peptides can be found in Table 2.10. 

























Table 2.10 – List of synthetic peptides 
  




2.2  Methods in DNA manipulation and gene sub-cloning 
2.2.1  Polymerase chain reaction 
 DNA amplification via PCR was typically performed by creating a mastermix, 
proportionally scaled up as required, containing the necessary ingredients from the 
BIOTAGTM DNA polymerase PCR kit (Bioline, UK) as indicated in Table 2.11. dNTP mix was 
obtained from Vivantis Technologies (Singapore), and oligonucleotide primers were 
commercially synthesized by 1st BASE (Singapore). 
Reagent Volume (μL) 
10X NH4 reaction buffer 3.0 
Forward primer (10 μM) 1.5 
Reverse primer (10 μM) 1.5 
dNTP mix (2 mM) 3.0 
MgCl2 solution (50 mM) 0.9 
Tag polymerase (5 units/μL) 0.2 
DNA template as needed 
nuclease-free H2O as needed 
Total 30 
Table 2.11 – PCR mastermix recipe 
PCR thermal cycling procedures were performed using a Peltier Thermal Cycler (DNA Engine 
DYADTM, Bio-Rad, USA) following PCR protocols listed in table 4. 
Protocol No. PCR cycling program 
1 (Hotstart) – 
Random library 
synthesis 
1 → 95oC – 2 mins 
2 → 95oC – 1 sec 
3 → 55oC – 20 secs 
4 → 72oC – 30 secs 
Repeat 2→4, 25 cycles 
5 → 16oC - ∞ 
2 – colony PCR 1 → 95oC – 10 mins 
2 → 95oC – 5 sec 
3 → 55oC – 30 secs 
4 → 72oC –  20 secs 
Repeat 2→4, 30 cycles 
5 → 16oC - ∞ 
3 – p53 cDNA 1 → 95oC – 1 mins 
2 → 95oC – 5 sec 
3 → 60oC – 30 secs 
4 → 72oC – 90 secs 
Repeat 2→4, 30 cycles 
5 → 16oC - ∞ 




4 – library rescue 1 → 95oC – 2 mins 
2 → 95oC – 1 sec 
3 → 55oC (unless otherwise stated) – 20 
secs 
4 → 72oC –  30 secs 
Repeat 2→4, 25 cycles 
5 → 16oC - ∞ 
5 – PCR fragment 
response 
elements 
1 → 95oC – 1 mins 
2 → 95oC – 5 sec 
3 → 60oC – 30 secs 
4 → 72oC – 15 secs 
Repeat 2→4, 30 cycles 
5 → 16oC - ∞ 
6 – DNA 
sequencing 
1 → 95oC – 1 mins 
2 → 95oC – 10 sec 
3 → 55oC – 5 secs 
4 → 60oC –  4 mins 
Repeat 2→4, 29 cycles 
5 → 4oC - ∞ 
Table 2.12 – List of PCR thermal cycling protocols 
2.2.2  Synthesis of double-stranded DNA duplexes  
 10 μM DNA duplex stocks (20 – 25-mers) were generated by making a mixture 
containing 10 μM of the respective sense (either with or without 5’ biotin modification) and 
anti-sense oligonucleotides in 100 mM NaCl, 10 mM Tris-Cl (pH 8.0) and 1 mM EDTA. The 
mixture is then heated to 95oC for 5 minutes and cooled slowly to room temperature, 
allowing the oligonucleotides to anneal. A list of the oligonucleotides used for this can be 
found in Section 2.1.3. 
2.2.3  TOPO TA cloning 
 For the purpose of DNA sequence analysis and other downstream sub-cloning 
procedures, PCR amplified DNA libraries/products are cloned using the TOPO TA cloning kit 
(Invitrogen) following manufacturer’s protocol. Briefly, PCR amplified DNA fragments are 
inserted into the pCR®2.1-TOPO® vector through base-pairing between PCR 3’ 
deoxyadenosine (A) and vector 3’ deoxythymidine (T) overhangs. Cloned vectors were 
transformed into chemically competent E.coli (Top10 strain, Invitrogen) cells and cultured 
overnight in LB-amp growth media. Subsequent sequence analysis of DNA inserts were 




performed using miniprep purified plasmid DNA (Section 2.2.8), or PCR products from 
bacterial colony PCR (Section 2.2.6). 
2.2.4  Generating mutant p53 cDNA using Site-directed mutagenesis  
 Mutant p53 vector constructs were generated by mutagenizing the pET22b-p53wt 
parental plasmid vector using QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene), 
following manufacturer’s protocol. A list of oligonucleotides for this purpose can be found in 
Section 2.1.3. Following PCR reaction, parental plasmid is digested by Dpn I restriction 
endonuclease, and mutant plasmids were transformed and propagated in XL1-Blue 
Supercompetent cells, before being isolated via miniprep (see Section 2.2.8), and verified 
through DNA sequencing (see Section 2.2.5).  
2.2.5  DNA sequencing analysis 
Purified DNA plasmids or PCR products were sequence analyzed via BigDye 
terminator cycle sequencing using a Peltier Thermal Cycler (DNA Engine DYADTM, Bio-Rad, 
USA) and PCR protocol-6 (Section 2.2.1). Each sequencing reaction typically contained 3pmol 
of sequencing primer, 8 μL of BigDye premix, DNA template (relative amount used shown in 
table 2.13), and nuclease-free H2O made up to 20 μL. A list of oligonucleotides used for 
sequencing can be found in Section 2.1.3. 
DNA Template Quantity (ng) 
PCR product: 
100 – 200 bp 
200 – 500 bp 
500 – 1000 bp 
1000 – 2000 bp 
 
 
1 – 3 
3 – 10 
5 – 20 
10 – 40 
 
Plasmid DNA: 
3000 – 5000 bp 
 
100 – 150 
Table 2.13 – Amount of DNA template used for cycle sequencing 




Completed cycling reactions were submitted to the DNA Sequencing Facility (IMCB, 
Singapore) for clean-up and sequencing. Resultant chromatograms were analyzed using 
either Chromas (version 1.45) or SeqMan (DNASTAR Lasergene 8). 
2.2.6  Bacterial colony PCR 
 Direct PCR amplification using lysed bacterial colonies provided a cost-effective and 
quick way to check for inserts, as well as sequences. Using a fine pipette tip, bacterial 
colonies are first spotted onto an ampicillin agar plate (preserving clones for downstream 
manipulation), before being transferred into a PCR tube containing PCR reaction mix 
(described in Section 2.2.1), and amplified following PCR protocol-2. PCR products are either 
visualized via agarose gel electrophoresis (Section 2.2.8), or DNA sequence analysed (Section 
2.2.5). 
2.2.7  PCR synthesis of IVT expression constructs 
 P53 expression constructs were generally synthesized by PCR amplification using 
primers Pet-F2 and Pet-RC (PCR protocol 3, Table 2.12) and the appropriate plasmid vector 
as DNA template (either pET-22b(+)-p53wt-FL, or pET-22b(+)-p53wt-∆22, or pET-22b(+)-
Nanop53wt-FL, or pET-22(+)-Nanop53wt-∆22). Pel-B leader sequence expression construct 
was PCR synthesized using primers T7-F and PelB-R, and pET-22b(+) empty vector as DNA 
template. PCR expression constructs were all column purified, diluted to 30 ng/μL (using 10 
mM Tris-Cl, pH 8.0), aliquoted and stored at -20oC. 
2.2.8  Separation and visualization of DNA fragments using agarose gel electrophoresis 
 PCR products were size separated via agarose gel electrophoresis (CertifiedTM 
Molecular Biology Agarose, Bio-Rad) in a 0.5X electrolyte solution (10X Tris/Borate/EDTA 
buffer, pH 8.3, 1st BASE), stained using SYBR green I and visualized using the ChemiDoc XRS 
detection system (Bio-Rad). 




2.2.9   DNA purification, measurement and storage 
 Plasmid DNA were isolated and purified from transformed bacterial culture using the 
NucleoSpin® Plasmid kit (Macherey-Nagel, Germany) following manufacturer’s instructions. 
PCR products are either column purified using the QIAGEN® PCR Purification kit, or gel 
separated, extracted and gel-purified using the QIAquick® Gel Extraction kit (both following 
manufacturer’s protocol). DNA samples were measured using the Nanodrop 8000 
Spectrophotometer (Thermo Scientific). Unless otherwise specified, PCR DNA reagents used 
for IVT expression and DNA binding experiments were all aliquoted and stored at -20oC in 10 
mM Tris-Cl (pH 8.0). 
2.3  Other general methods 
2.3.1  ELISA-based methods  
 A variation of ELISA-based methods are described in this thesis and involve different 
plate matrices, surface coated proteins, as well as methodologies in capturing target protein 
complexes. While distinctive steps pertaining to each method are described in their 
respective chapters, steps involving secondary detection antibody leading to substrate 
development of calorimetric readout are described below. 
After the incubation in which target complexes are captured on the plate, the 
solution is discarded, and wells are washed three times in WB1, and three times in WB2. 
Wells were then incubated with 50 μL of HRP-conjugate [either polyclonal antibody 
(DakoCytomation) PO161 (rabbit anti-mouse) and PO217 (swine anti-rabbit), or a 
streptavidin conjugate (Thermo Scientific) at 1:1000 and 1:4000 dilution, respectively (1% 
BSA/PBS)] for 10 minutes at room temperature. The wells are then washed a final time (3x 
WB1 followed by 3x WB2), and developed using the TMB peroxidase EIA substrate kit (Bio-
Rad) following manufacturer’s protocol. After 1 – 2 minutes, the calorimetric reaction is 




stopped by adding 50 μL of 1M H2SO4, and measured on the SpectraMax Plus 384 microplate 
reader (Molecular Devices, USA) at a wavelength of 450 nm. 
2.3.2  Immobilizing antibodies on 96-well polystyrene plates via adsorption 
 Antibodies were diluted to an appropriate concentration, typically to give 0.5 μg per 
well (unless otherwise specified), in antibody coating buffer (Section 2.1.1), of which 50 μL is 
added per well for overnight incubation in a humidifying chamber. The following day, the 
buffer is discarded and the wells are rinsed twice in WB1, twice in WB2, and blocked in 3% 
BSA/PBS for 3 hours at room temperature. After which, the blocking solution is discarded, 
and the wells are washed again as above before being used. 
2.3.3  Western blotting 
 IVT or whole cell lysate were diluted in 1X NuPAGE® LDS sample buffer (Invitrogen) 
with 100 mM DTT, boiled for 10 minutes, and separated on a NuPAGE® 10% Bis-Tris Gel 
(Invitrogen) in 1X NuPAGE® MOPS SDS Running Buffer (Invitrogen) at 150 volts for 1.5 hours. 
Protein bands were then transferred onto a nitrocellulose membrane using the iBlotTM Dry 
Blotting System (Invitrogen) following manufacturer’s instructions, blocked in 5% (w/v) non-
fat milk (in 0.1% Tween-20/PBS buffer), and probed with the relevant primary antibodies 
(Section 2.1.2). Protein bands were then detected using the relevant enzyme conjugated 
secondary antibodies (either the ECLTM Anti-mouse IgG, HRP-linked whole antibody from 
Amersham, or PO217 from Invitrogen) and developed using the Immun-StarTM WesternCTM 
kit (Bio-Rad) following manufacturer’s protocol. Images were captured using the Fujifilm LAS 
4000 Luminescent image analyzer. Unless otherwise specified, Precision Plus ProteinTM 
WesternCTM protein standard was used and was visualized via the Precision Streptactin-HRP 
conjugate (Bio-Rad). 
  




2.3.4  Protein expression using IVT systems 
 Two in vitro transcription/translation systems were used for the work described in 
this thesis. The EcoProTM T7 System (Novagen®, USA) was used in the IVC selection scheme 
(Chapter 3) and in the final configuration of the p53-DNA binding assay (Chapter 7). The 
PURE-SYSTEM (Cosmo Bio, Japan) was used in experiments pertaining primarily to 
optimization and assay developmental aspect of this thesis (Chapter 4 – 6).  Both IVT 
extracts were constituted following manufacturer’s specifications and, unless otherwise 
specified, were typically incubated at 30oC for 2 hours for protein translation. Typically, for 
p53 protein expression, 30 ng of p53 cDNA template (PCR amplified followed by column 
purification) were used per 10 μL IVT reaction, unless otherwise stated. 5% (v/v) DMSO was 
added to all IVT reactions after Chapter 4 as a measure to increase protein yield.




3   Selection of mutant p53 reactivating compound using In Vitro 
Compartmentalization 
3.1  Introduction 
In-vitro-compartmentalization (IVC) is an in-vitro, completely cell free, high-
throughput selection platform made up of a heterogenous system of two immiscible liquid 
phases. The system is comprised of numerous water-in-oil emulsified aqueous 
compartments, typically 1 – 100 μM in diameter, in which a certain phenotype is selected for. 
A typical selection scheme is engineered to limit the distribution of the gene library, such 
that a compartment contains a gene or less on average. Natural selection is the cardinal 
mechanism behind evolution and functions because gene products and the genes 
responsible are co-compartmentalized. The activity of a particular protein or RNA product (in 
a cell or organism) directly determines the chance of survival and replication of the gene 
encoding it, but has no effects on other genes in other cells/organism [204]. Each IVC 
compartment mimics a cell or uni-cellular organism in this aspect. A biochemical or 
enzymatic reaction occurs within the aqueous phase of each discrete microdroplet such that 
the critical association (either covalent or non-covalent) of physically linking the genotype 
with phenotype is established. Once the linkage is created, information pertaining to 
positive selectants can be retrieved by breaking the emulsion and probing for a property 
specific to a positive selection event, and later enriched by repeating the selection.  
  





Target molecule class Selected property Selection scheme 
DNA methyltransferase 
[205] 
Altered non-canonical recognition 
sequence. 
Protection, of non-canonical sequence (AGCC) that 
were selectively methylated, against restriction digest. 
Restriction endonuclease 
[206] 
DNA endonuclease activity. Incorporation of biotin moiety (via DNA polymerase) 
onto endonuclease gene sequences that are selectively 
cut. 
Ribozyme[207] Altered chemical activity. Utilizing antibodies raised against the transitional 
chemical product of a desired reaction. 
DNA polymerase [208] Enhanced thermal stability and 
resistance to inhibitor, heparin. 
Bacterial cells carrying specific polymerase gene 
variants were compartmentalized, lysed and selected 
based on PCR phenotype via cognate polymerase. 
Ribozyme [209] trans-acting RNA ligase activity Ribozyme gene and unligated substrate are 
immobilized on beads and encapsulated, FACS is 
subsequently used to select for beads carrying a 
fluorescent tag which can only hybridized with a 
ligated product. 
Phosphotriesterase [210] Increased catalytic speed Finished product selection using product-specific 
antibody from a pool of gene variants and substrate 
coated beads.  
Transcription factor [211] Altered specificity to various DNA 
recognition elements 
Antibody recognition and isolation of transcription 
factor bound gene. 
Table 3.1 – Directed evolution of enzymes using In Vitro Compartmentalization 
 
Since the initial development of proof-of-concept, in which the wild-type HaeIII 
methyltransferase gene was selected from a 107 – fold excess of genes encoding inactive 
enzyme [212], the IVC selection technique has been employed successfully in the directed 
evolution of different classes of molecules for various altered biochemical properties (Table 
3.1). Notably, IVC selections are relatively high-throughput (a typical 1 mL emulsion contains 
approximately 1010 compartments) and when compared to its display-based predecessors 
like phage- and ribosome-centred technologies, is capable of more versatile selections. 
Progressively smarter and more innovative adaptations are being employed (eg. caged 
biotinylated substrate which is released on UV-irradiating the emulsion [210,213], or the 
sequential compartmentalization and PCR of bacterial cells in emulsion [208]) in IVC 
schemes and are often paired with other powerful techniques like PCR and FACS 
[209,214,215].  
In the current study, An IVC approach has been adopted to select functional peptides that 
can selectively restore sequence-specific DNA binding to several p53 ‘hotspot’ mutants 




(Figure 1.5). The aqueous phase of this selection was comprised of a mixture of (i) an in-vitro 
bacterial IVT cocktail containing the necessary ingredients to transcribe and translate 
polypeptides, (ii) a randomized peptide cDNA library and (iii) p53 genes carrying a specific 
mutation. The mixture is re-constituted in mineral oil such that each compartment contains 
less than 1 peptide-encoding gene on average. The peptide cDNA library was engineered to 
carry DNA elements (T7 promoter and ribosome binding site) required for transcription 
initiation under a prokaryotic system upstream of a 60 base pair randomized reading frame, 
and is additionally flanked by a PUMA-BS2 p53 response element (RE) on the 5’ end, and a 
p21 3’ site RE on the 3’ end [21](Figure 3.2). The selection scheme functioned such that only 
peptide genes belonging to a positive event will be isolated and subsequently enriched in 
further rounds of selection. In a positive selection event (Figure 3.1 right bubble), a peptide 
gene enclosed in a specific droplet codes for a functional peptide that binds to, and causes 
the mp53 to bind to either RE adjacent to the peptide gene. After disruption of the emulsion 
and recovery of the aqueous phase, the resultant p53/peptide/peptide gene complex is 
captured on anti-p53 antibody coated beads, preserving the genotype-phenotype linkage. 
Conversely, in the event of a negative selection (figure 1 left bubble), translated peptides do 
not reinstate DNA binding to the mutant proteins, resulting in the lack of genotype-
phenotype association. 
Notably, because the field of re-activating mutant p53 is still shrouded in much uncertainty, 
the design of this selection scheme has been developed to be as all-encompassing as 
possible. Firstly, studies on full-length p53 and deletion mutants have implicated possible 
involvement of both the N- and C-terminal domains in sequence-specific DNA binding of the 
core [165,216]. This prompted the use of full-length, instead of core domain, p53 mutants 
seen in previous reports [164,172,187]. Additionally, deriving peptides that may only 
selectively activate core domain proteins, and lose its activity in full-length proteins could 
also be avoided. Secondly, instead of using purified proteins, the use of an IVT expression 




system allowed the concomitant synthesis of peptides and proteins. This provided an added 
advantage of selecting peptides that may have re-activating functions on nascent p53 during 
protein translation. Lastly, unlike other selections conducted using randomized epitopes 
within a protein aptamers [155], the library was designed to encode free peptides that 
varied in length ( 1 – 20 amino acid residues), so as to not place unnecessary limitations on 
the peptide length or the mode of activity. Furthermore, 4 p53 mutants were selected to be 
tested in the IVC selection such that different classes of mutation were adequately 
represented in this study; the 4 mutants were the R175H (globally denatured), R273H 
(contact mutant), G245S, and R248Q (contact mutants with weak local distortions in 
structure) [96]. 
3.2 Materials and Methods 
3.2.1 IVC selection 
 Apart from the additional components added to the selection mixture, the IVC 
selection was performed as previously described [211]. Briefly, 50 μL of the aqueous IVC 
mixture was assembled and comprised of 74% IVT extract (EcoProTM T7 system, Novagen), 2% 
of Ranlib (random peptide cDNA library diluted in poly-dIdC), 500 μM ZnSO4, 0.5 μL T7 
polymerase (NEB), and 100 ng of mutant p53 cDNA. 500 pg of Ranlib, was used for rounds 1 
and 2 (~2.84 x 109  DNA molecules), and was further reduced to 250 pg for round 3 of the 
selection. Additionally, poly-dIdC (Amersham) was added to Ranlib, to a final concentration 
of 10 ng/μL. The aqueous IVC mixture is then added to a 2 mL cryo-vial (Nalgene) containing 
450 μL of pre-chilled mineral oil (Sigma-Aldrich) and a magnetic stir-bar. The reaction 
mixture was then emulsified as before [212]. Once formed, the emulsion was incubated at 
30oC for 2.5 hours to allow in-vitro transcription/translation, and DNA binding to proceed. 
After the IVT incubation, emulsion is transferred into a clean 1.5 mL microtube, and the 
aqueous compartments are concentrated by centrifugation using a tabletop centrifuge  









(8000 rpm for 10 minutes). The oil phase (top layer) is then carefully removed before 50 μL 
of p53 binding buffer 1 (this increases the volume of the aqueous component for easier 
handling downstream) is added to the pellet of aqueous compartments. The aqueous 
compartments are then disrupted through three rounds of hexane extraction (1 mL hexane) 
to remove the organic phase, before being transferred to a fresh tube. 
DO-1 coated protein G beads were prepared by incubating Dynabeads® Protein G (Invitrogen) 
(10 μL) with salmon sperm DNA (1 μg/μL), DO-1 antibody (2 μg), in 3% BSA/PBS solution on 
the rotator at room temperature for 1 hour. Coated beads are then washed once in WB1, 
once in WB2, before being added to the aqueous phase from above (10 μL DO-1 beads per 
selection). The aqueous phase/DO-1 beads mixture is then placed on the rotator at 4oC for 1 
hour. After which, the supernatant is removed and beads are washed three times in WB1 
and three times in WB2. The beads are resuspended in 20 μL nuclease-free water (HyClone® 
molecular grade water, Thermo Scientific) and incubated at 100oC for 5 minutes to elute 
captured DNA, which are subsequently PCR amplified for sequence analysis or library 
reconstruction. 
 3.2.2 p53-DNA binding ELISA 
 The ELISA technique was performed as previously described [76] with minor changes 
described below. Protein was synthesized at 30oC for 2 hours, using the Novagen IVT system, 
following manufacturer’s protocol (500 μM ZnSO4 added for p53 synthesis). Depending on 
the experiment, p53 was either synthesized alone (using plasmid or PCR cDNA) or co-
translated with an equi-molar concentration of peptide PCR cDNA. 5 μL of IVT-p53 (per data 
point) was incubated with 100 nM of biotinylated RE-oligonucleotide for 20 minutes, before 
an additional 5 minutes of incubation with 0.1 μg of DO-1 antibody. The p53/DNA/DO-1 
mixture is then made up to a final volume of 30 μL (p53 binding buffer 1) and transferred to 
a streptavidin coated plate for 45 minutes at 4oC, allowing the biotinylated oligonucleotides 




to be captured on the plate. The remaining procedure is performed as described earlier in 
Section 2.3.1. 
3.3 Results and Discussion 
3.3.1 Design and synthesis of random peptide library 
The random peptide library (Ranlib) was synthesized via standard polymerase chain 
reaction (PCR) using three commercially synthesized oligonucleotides. In the first round of 
PCR (Section 2.2.1, PCR protocol 1), the oligo-nucleotide RANLIB2, which contained a 60 
basepairs (bps) randomized sequence, was used as the template and amplified using 
forward primer RL2-pUMA-2F2 and reverse primer RL2-p21-2R. Forward primer RL2-pUMA-
2F2 added a PUMA-BS2 RE overhang sequence to give the final library product of 
approximately 156 bps (Figure 3.2A). This final construct consists of a randomized 60-bps 
DNA sequence with a T7 promoter sequence, RBS and an ATG start site upstream, and a TAG 
stop codon downstream (Figure 3.2B). Additionally, it was appended with the pUMA-BS2 RE 
on the 5’ end, and a p21 3’ site RE on the 3’ end (Figure 3.2B). A subsequent round of PCR, 
using the same primer pair, was performed to further amplify the library product. To 
visualized the Ranlib PCR product, a DNA agarose gel electrophoresis (AGE) was performed. 
The resulting image showed a single band migrating at an expected size of ~150-bps (figure 
3.2C, lane 2). A positive control of the same PCR reaction with a different enzyme (Acuzyme 
DNA polymerase, Bioline) also yielded a product of identical intensity and size (Figure 3.2C, 
lane 3). There were also no non-specific PCR products detected in the negative control 
reaction, which was conducted in the absence of reverse primer RL2-p21-2R (Figure 3.2C, 
lane 1).  
To ensure that the library sequences are in-frame and contained all the necessary DNA 
elements for in-vitro transcription/translation, we cloned the library fragments into the 2.1- 










TOPO vector (TOPO TA cloning kit, Invitrogen) following manufacturer’s protocol, 
transformed the plasmids into e.coli (BL21, DE3) bacteria, plated the transformants onto 
ampicillin selective LB-agar plates, and performed colony PCR on 20 randomly selected 
bacterial colonies (using primers RF1 and RL2-p21-2R). The colony PCR product was then 
sent for sequencing, and the resultant chromatogram was analysed using the Lasergene 8 
software (DNASTAR) (Figure 3.2D). The DNA sequencing revealed that, apart from the 
randomized peptide reading frame, all other regions of the DNA library were preserved. DNA 
alignment of all 20 sequences showed no obvious similarities in the reading frames. 
Translation of each DNA sequence into its resulting amino acid sequence revealed absolute 
randomness and sequence diversity, with only 25% encoding a full 20-mer polypeptide 
(Table 3.2).  These data confirmed the success in synthesizing the peptide library, as well as 
the sequence diversity it carried. 
Clone DNA sequence Translated amino acid 
sequence 
1 ACATATTCATCACCGCCCTTTGGGCGAGCAGTCGCCTTTGCATTTAGCTAGAAAGGCGT TYSSPPFGRAVAFAFS 
2 TTTACAGTTTCTGTTATAGCTTCCCCATTTTATAATATTTTCCGCCCTTTTCTCGGCGGA FTVSVIASPFYNIFRPFLGG 
3 GGTGGCTCTCGCTTTATAGCGGCACTTCCGGGAACATCGACGGCTTCTTGGATTAGCTCT GGSRFIAALPGTSTASWISS 
4 ATCGTGTAGATGATTCTCGGATTGTCTCTCCTTGGACGGTAATCTGAGAACCTCTTAGAT IV 
5 TAGCCTTAAAAGTATGTGTTGTAGACTGGGCCTAGATCCAAGTTGTTGTGGTGAGATTTT - 
6 GGGAGTGCACACGTCGTATGTAAGGGTCCTATTATATCTTTGTAACACTAAGATGCTTCC GSAHVVCKGPIISL 
7 ACGATGTAGGTCGACGGCGGTCCCCTGAATACGGGCCCTGTACCCATTGCTCACAGACTG TM 
8 TCTACGAGGGGCAGCCATTGAATTAACGGTTTCAGGAAGTTCTAGTGATATTGGAGTGCG STRGSH 
9 AGTAGGCCTATCACATAGAGTACTGTTTAGGTACCACGGGTTCATGGTTGTACCTCACGG SRPIT 
10 GAAACTATAGGCATCCATCTATCCCGTCTGCCTCAGCAACGTAGTATCATGTGGCGGGGT ETIGIHLSRLPQQRSIMWRG 
11 CCCACATGTTGCCTAGGTACACCCATTATGCCGCCTTGAGAGTAGCTTTTCTGTGTGATT PTCCLGTPIMPP 
12 GAGTGAACCTGAGGGCTCTTAACATGGGAGTATCCCCAATGTGATCGATGGTATCAGCCC E 
13 GAACGACGCATCCTTATTTAGCCTTTCTTTGGTGAGAGAACGCCGGGAGGCCAACTCGAA ERRILI 
14 ACTTTATCGTACTACATAATTTGAATACTCCTGATACTACAGTAAGGCCACGAAAAGATA TLSYYII 
15 ATGATTTTTTCAGTGACGATTGGGCGGAGCCGCAGCATACAAAAAGAATGCAATTTTAAA MIFSVTIGRSRSIQKECNFK 
16 TGGCTCAAGCACTCTTGAAGCGTACCACACACTGTAAGAAGCGATGGCGCTTTAAAGGTC WLKHS 
17 GGTCCATATTTGCGGTGTAGGCTCATGCCAGCTGGTGTTAGGCCTCCGAATGAACTATTT GPYLRCRLMPAGVRPPNELF 
18 GCACTTGGGGTGGAAGCACACAGGGTCGTATCTAATGTGACATATCGTCGTCGCGTGGCG ALGVEAHRVVSNVTYRRRVA 
19 AATAGGACGACGTGAGGACATCCTCGGACTGTCTCGTTGTGTGCCCAGTTCCCGATATAC NRTT 
20 GTCCCTATTGATCATTGAATAGTAGGAATCACCAGCGTTGGACAGAGGTCCCATGTGAGC VPIDH 
Table 3.2 – DNA sequence analysis of random peptide library Ranlib. 20-mer peptides are indicated 
by bold sequences.  
 
p53 mutant cDNA fragments for the IVC selection was prepared by first performing site-
directed mutagenesis on a PET22b plasmid vector carrying wild-type p53 (cloned between 
NdeI and NcoI restriction sites within the multiple cloning site, MCS), followed by PCR  










amplification using primers PET-F2 and PET-RC. Whenever appropriate, the DNA was 
sequenced to ensure that only plasmids carrying the respective mutations were selected. 
The primer pair PET-F2 and PET-RC amplified a region of the PET22b plasmid which carried 
the MCS, T7 promoter, RBS, start and stop sites, and hence, resulted in p53 cDNA PCR 
fragments carrying DNA elements needed for in-vitro transcription and translation. After 
column purification, we separated the PCR products using AGE and confirmed an expected 
size of ~1500 bps (Figure 3.2E). Next, proper synthesis of full-length p53 was checked by 
constituting the IVT cocktail (EcoProTM T7 system, Novagen) with each mutant p53 cDNA 
(100 ng/10 μL IVT) following manufacturer’s protocol. Western blotting on each of the 
different IVT samples, using DO-1 antibody, confirmed the translation of full-length p53 
protein and that the relative protein levels were similar (Figure 3.2F). 
3.3.2 Round 1 IVC selection 
In the first round of IVC selection, 5 separate selections were performed (p53 
mutants R175H, G245S, R248Q, R273H and a negative control selection), each using 
approximately 5.68 x 109 molecules of the peptide library, to give <1 gene per compartment 
(~1010 aqueous compartments [217]). Peptide library was also diluted in poly-dIdC to 
decrease non-specific DNA interactions. In the negative control selection, no p53 cDNA was 
added, and any DNA eluted would be due to non-specific interactions between DNA and 
beads. In each of the selection reactions, the aqueous phase (which consisted of the IVT 
mixture, peptide library in poly-dIdC, mutant p53 cDNA, T7 RNA polymerase and ZnCl2) was 
mixed with pre-chilled oil phase, and stirred for 5 minutes to form the appropriately sized 
water-in-oil micro-droplets. The IVT emulsion was then incubated at 30oC for 2 – 3 hours, 
after which the emulsion was cracked open, and the aqueous phase was extracted and 
added to magnetic protein-G beads coated with DO-1 antibodies (Figure 3.1). This allowed 




any p53/peptide/peptide cDNA complex to be captured on the beads, which was 
subsequently washed and eluted in nuclease-free water. 
The first step to obtaining information from the selection was to enrich the presence of any 
DNA that may have been eluted. Using 5 μL of the eluate as template, amplification of any 
DNA present was first attempted using the original primers for the synthesis of Ranlib (RL2-
pUMA2-F2 and RL2-p21-2R). DNA gel electrophoresis of the PCR products revealed that a 
750 bps product was synthesized for certain samples (control and R175H selection), which 
was far from the expected size of 150 bp (Figure 3.3A). Furthermore, an 850 bps product in 
the no-template control (NTC) indicated possible mispriming issues. The PCR was next 
repeated with more DNA template (10 μL eluate) and a different primer pair (RF2 – an 
inward nested forward primer, and rPETr – an outward nested primer that puts on an 
additional sequence) (Figure 3.2A). The PCR product was then column purified and PCR re-
amplified again (using 2 μL of DNA template) using the same primer pair (but at 60oC 
annealing to reduce non-specific priming) (Figure 3.3B). As the DNA could have been just 
below the detection threshold, the DNA load had to be increased, and the fluorescent stain 
switched from Sybr green to ethidium bromide, before the PCR products could be visualized 
at the expected sizes of ~150 bp (Figure 3.3C). This difficulty in recovering positive selectants 
after the first round of selection is not uncommon due to the diversity of the library and 
scarcity of positive events. Notably, after 3 rounds of PCR enrichment, DNA from the eluate 
of R175H selection was still undetectable (Figure 3.3C). In a final attempt to enrich the 
R175H selectants, PCR re-amplification using RL2-pUMA2-F2 and RL2-p21-2R (using previous 
PCR product as DNA template) yielded a <100bp product, unlike the negative control 
selection where a product corresponding to the expected size was enriched (Figure 3.3D). 
Contrary to the mutant p53 selection events (including R175H selection), the negative 
control selection lacked p53 protein products which would otherwise bind protein-G beads 
and decrease the amount of non-specific DNA peptide genes captured. In light of this, a 




failed mutant p53 selection event may conceivably result in less peptide genes available for 
subsequent enrichment. The significantly smaller single fragment PCR product observed for 
R175H selection was hence concluded as a non-specific PCR product (likely from primer self-
complementarity or concatemers in the absence of appropriate DNA templates) , and that 
the selection for p53-R175H has failed. P53-R175H was therefore removed from subsequent 
selections. 
 




For the remaining mutants, the next step was to enrich and purify their respective selectants 
in preparation for the next round of selection. However, when the PCR enriched selectants 
from before were column purified (Figure 3.3C, G245S, R248Q and R273H) and re-amplified 
using PCR (using RF2 and rPETr, via PCR protocol 4), a smear of DNA bands were obtained, 
indicative of multiple non-specific products (Figure 3.3E). It is apparent, from the large 
amount of unutilized dNTPs observed at the foot of the gel, that the PCR reaction proceeded 
inefficiently, possibly due to the overwhelming presence of bigger non-specific products. 
Other reasons for this problem may be due to excessive DNA polymerase, and a lengthy PCR 
extension time that favored bigger products. Using gel purification, PCR products (at an 
approximate size of 150 bps) from the agarose gel was excised, purified, and used for PCR 
amplification with several changes in the protocol. Firstly, the volume of DNA template was 
diluted by 1/10 (from 2 μL to 0.1 μL), and secondly, PCR extension time was halved to 15 
seconds. In addition, a new primer pair of RF2 and PetRevWalt was used; the latter oligo-
nucleotide primes off a sequence appended by the earlier reverse primer, rPETr (Figure 
3.2A), and hence, selects for only correctly amplified products. The changes allowed the 
positive amplification our product of interest (Figure 3.3F), especially in samples that were 
diluted.  
In the attempt to enrich the reading frame of the positively selected peptide cDNAs, priming 
strategies utilized had altered our library constructs (RF2 removes pUMA-BS2 RE from the 5’ 
end, and rPETr puts on 20bp on the 3’ end). Therefore, the current library had to be 
reconstructed with the necessary DNA elements before the next selection round. DNA 
products from the previous PCR (Figure 3.3F) was column purified, and re-amplified with the 
initial primers used in the library construction (RL2-pUMA2-F2 and RL2-p21-2R via PCR 
protocol 4 with a 15s extension time). AGE of the PCR product revealed that the non-specific 
smear from the previous PCR reaction was equally amplified in this reaction (Figure 3.3G). 
After another round of gel purification by excising DNA  










bands of the expected size (Figure 3.3H), followed by the PCR reaction, the DNA product of 
interest could finally be detected as the major PCR product (Figure 3.3I). This major band 
was then gel purified again before being used as the cDNA library for the next round of 
selection. 
3.3.3 Round 2 IVC selection 
The second round of IVC selection was performed using the same protocol as round 
one, with the exceptions that (i) p53-R175H selection sample was omitted, and (ii) peptide 
cDNA library used for the negative control selection was now a combination from all cDNA 
library inputs (G245S, R248Q and R273H) at equal proportions. Unlike the previous round of 
selection, DNA products could be visualized on the agarose gel after just one round of PCR 
enrichment (10 μL of eluate as template, using rPETr and RL2-pUMA2-F2, PCR protocol 4 at 
15s extension). There is a clear enrichment of PCR product for all 3 samples at the expected 
size of ~190bp (due to the added 40 bps by reverse primer rPETr), and additionally, lack of 
PCR products in both the NTC and control selection sample (Figure 3.4A). This was indicative 
of a true enrichment of positive selectants. The PCR reaction was then repeated, using 0.8 μL 
of the PCR product as DNA template (reduced template), a different primer set (RL2-pUMA2-
F2 and RL2-p21-2R), and a further reduction of the extension time to 10 seconds. The result 
was a relatively specific amplification of the desired product (Figure 3.4B).  
Some of the selectants were next sequenced to check the sequence integrity of the library 
constructs. The enriched PCR products were cloned into the TOPO vector, transformed into 
BL21 cells, and grown on selective ampicillin plates before being amplified using colony PCR 
to check for inserts (using TOPO vector specific M13 forward and reverse primers). Colonies 
that were positive for vector inserts (~350bp PCR fragment, Figure 4C) were sequenced. A 
total of 8 clones for each mutant were sequenced, analysed using EditSeq (DNASTAR 
Lasergene 8), and the resulting amino acid sequences tabulated (Table 3.3). The fact that all  










sequences came back with the correct insert displaying in-frame peptide genes indicated 
that the molecular amplification methods used did not adversely affect the library DNA 
sequences, and that the correct peptide library DNA fragments were used in both selection 
rounds. Furthermore, distinct enrichment of selected peptide sequences can be seen for 
each of the p53 mutants (Table 3.3). As the random library has only been enriched through 2 
rounds of selection, the short peptide sequence, LM (G245S selection) could just be 
selection noise, especially considering the typical biologically functional peptide length of 4-
7 residues (linear epitope [218] and single α-helical turn [219]). This said, instances of 
functional dipeptides with physiological relevance have, nevertheless, also been reported 
[220,221].  
Clone G245S R248Q R273H 
1 L M I L N V L P L L A S R K P R L Q Q V  
2 T A L I D I W E H S V L G K G Y P R M S I L N V L P L L A S R K P T A L I D I W E H S V L G K G Y P R M S 
3 T A L I D I W E H S V L G K G Y P R M S VSWSACVLLELCNYFPENPIEEEDWACLG T A L I D I W E H S V L G K G Y P R M S 
4 L M I L N V L P L L A S R K P R A V T D R P V P C P N P R L N L V A N 
5 T A L I D I W E H S V L G K G Y P R M S I L N V L P L L A S R K P T T L I D I W E H S V L G K G Y P R M S 
6 VRHQHVGATILGWKMGWTDH I L N V L P L L A S R K P R L Q Q V  
7 T A L I D I W E H S V L G K G Y P R M S I L N V L P L L A S R K P  R L Q Q V  
8 - I L N V L P L L A S R K P  R L Q Q V  
Table 3.3 – DNA sequence analysis of randomized peptide reading frame from round 2 selection. 
 
Because the final post-selection PCR amplification was done using primers RL2-pUMA2-F2 
and RL2-p21-2R (had all required DNA elements for in vitro transcription/translation), PCR 
products from Figure 4B were directly gel purified and used in the next round of IVC 
selection. 
3.3.4 Round 3 IVC selection 
The final round of IVC selection was repeated as per previous round, with the 
exception that the amount of input library DNA (from 500 pg to 250 pg) for each sample was 
halved, so as to increase the selection stringency. 




Once the selection was complete, 10 μL of the eluate was used in a PCR to enrich for the 
positive selectants (same protocol as in round 2). The resultant products were easily 
detectable after separation using AGE, showing further library enrichment in the third round 
of selection (Figure 3.5A). However, unlike in round 2, a PCR product was observable for the 
control selection sample (Figure 3.5A). Without purification, PCR products were re-amplified 
using primers RL2-pUMA2-F2 and RL2-p21-2R (Figure 3.5B), cloned into the TOPO vector and  
 
  




sequenced analysed as before. For each group of selectants, we sequenced up to 16 clones 
and analyzed the coded peptide sequence using EditSeq (Table 3.4).  
Clone G245S R248Q R273H 
1 S P N T N H  I L N V L P L L A S R K P R L Q Q V 
2 M P H L M A C VSWSACVLLELCNYFPENPIEEEDWACLG A R H Q H V G A T I L G W K 
3 S P T T N H VSWSACVLLELCNYFPENPIEEEDWACLG V R H Q H V G A T I L G W K 
4 S P T T N H I L N V L P L L A S R K P T A L I D I W E H S V L G K G Y P R M S 
5 DELVAIPVRLTYYRGPNIAI I L N V L P L L A S R K P L M 
6 S P T T N H VSWSACVLLELCNYFPENPIEEEDWACLG T A L I D I W E H S V L G K G Y P R M S 
7 M P H L M A C I L N V L P L L A S R K P R L Q Q V 
8 S P T T N H VSWSACVLLELCNYFPENPIEEEDWACLG V R H Q H V G A T I L G W K 
9 M P H L M A C I L N V L P L L A S R K P R L Q Q V 
10 ERRFPIMGVNSPEGKMWPLI VSWSACVLLELCNYFPENPIEEEDWACLG T A L I D I W E H S V L G K G Y P R M S 
11 S P T T N H VSWSACVLLELCNYFPENPIEEEDWACLG T A L I D I W E H S V L G K G Y P R M S 
12 DELVAIPVRLTYYRGPNIAI I L N V L P L L A S R K P V R H Q H V G A T I L G W K 
13 ERRFPIMGVNSPEGKMWPLI I L N V L P L L A S R K P R L Q Q V 
14 S P T T N H I L N V L P L L A S R K P V R H Q H V G A T I L G W K 
15 M P H L M A C I L N V L P L L A S R K P T A L I D I W E H S V L G K G Y P R M S 
16 M P H L M A C I L N V L P L L A S R K P V R H Q H V G A T I L G W K 
Table 3.4 – DNA sequence analysis of randomized peptide reading frame from round 3 selection. 
 
Comparing the peptide sequences selected for each mutant, and across selection rounds, 
several striking observation emerged. The mutants can be grouped into two categories 
based on the pattern of sequences. Only 2 unique peptides were selected for the R248Q p53 
mutant. Contrastingly, selectants of R273H and G245S mutants consists of a few primary 
sequences interspersed with several sporadic ones. The latter two mutants also shared a few 
peptide sequences like TALIDIWEHSVLGKGYPRMS and VRHQHVGATILGWK after round 2. Notably, these 
shared sequences were lost from the G245S selectants in round 3 of the selection. 
Furthermore, none of the peptide sequences carried regions of positively charged residues, 
which has been described to confer a false positive sequence-specific DNA binding 
phenotype to transcription factors through the electrostatic interaction and aggregation of 
DNA [163]. 
Another interesting result is the elongated sequence selected for R248Q which exceeded the 
original library design encoding 20-mer peptides (VSWSACVLLELCNYFPENPIEEEDWACLG , Table 3.4) by 
10 amino acids. This was due to a mutation in the stop codon (possibly due to DNA 
polymerase error) which resulted in the inclusive translation of the p21 DNA response 




element on the 3’ end of the library construct (Figure 3.2B). For this sequence to be enriched 
through 3 rounds of selection, either the preceding sequence is such a strong activator of 
the mutant p53 it can withstand the addition of an innocuous or even detrimental peptide 
sequence, or the serendipitous addition of the ‘p21’ poly-peptide has somehow enchanced 
the activity of the existing sequence. 
No. Peptide 
Reference 
Amino Acid Sequence p53 mutant 
1 Pap-SPT S P T T N H  G245S 
2 Pap-MPH M P H L M A C G245S 
3 Pap-TAL T A L I D I W E H S V L G K G Y P R M S R273H/G245S 
4 Pap-ILN I L N V L P L L A S R K P R248Q 
5 Pap-VSW VSWSACVLLELCNYFPENPIEEEDWACLG R248Q 
6 Pap-RLQ R L Q Q V R273H 
7 Pap-VRH V R H Q H V G A T I L G W K R273H 
Table 3.5 – Amino acid sequences and references of peptides selected for further testing. 
 
We next consolidated and selected 7 peptide sequences to be used for subsequent 
secondary assays. The peptides were named using the acronym Pap (for P53 activating 
peptide), followed by a peptide reference tag corresponding to the first 3 amino acids of the 
randomized sequence (Table 3.5).  
 
  




3.3.5 Preparation of peptide cDNA fragments for secondary assays 
After selecting the peptides, the coding sequences (remove flanking RE regions) 
pertaining to each peptide was cloned and isolated for further experiments. To do this, a 
forward primer, that sits on the T7 promoter sequence (T7-F), was used together with 
peptide specific reverse primer (Section 2.1.3, Table 2.4) and amplified using PCR protocol 4 
(using M13 amplified PCR products as template). cDNA of Pap-VSW was amplified using RL2-
T7-F1 and RL2-p21-2R. A gel-analysis of the PCR products showed multiple non-specific 
bands (Figure 3.6A) possibly due to the presence of an additional T7 promoter within the 
M13 amplicon (from TOPO vector). Due to this problem, the pooled positive selectants from 
round 3 of the selection was then amplified using RL2-pUMA2-F2 and rPETr primers (PCR 
protocol 4) (Figure 3.6B), followed by PCR amplification using peptide specific primer pairs as 
above (Figure 3.6C). The resulting PCR products were then gel purified and individual 
fragments were checked before further experiments (DNA gel-analysis, Figure 3.6D and 
sequencing). 
3.3.6 Optimization of an ELISA-based DNA binding assay 
 An ELISA-based DNA binding assay, previously described for purified p53 [76], was 
used to validate the functionality of the selected peptides. Briefly, biotin-conjugated RE 
oligonucleotides were incubated with IVT-translated p53 on a 96-well plate coated with 
streptavidin. P53-RE complexes formed are then captured on the plate (via biotin-
streptavidin interaction) and detected using anti-p53 antibody and a horseradish peroxidase 
(HRP) conjugated secondary antibody (Figure 3.7C).  
Next, the effects of using plasmid DNA or PCR fragments as p53 coding templates in IVT was 
briefly examined. Although PCR fragments were used as p53 cDNA template in the IVC 
selection, protocol for the Novagen IVT system recommended plasmid DNA (in the range of  










500ng per 50 μL IVT reaction) as they are more stable in the bacterial extract. Full-length p53 
protein translated using different amounts of plasmid DNA (400 ng, 800 ng and 1200 ng) was 
compared. The results showed that levels of protein synthesis were inversely related to the 
amount of plasmid DNA added in the concentrations tested (Figure 3.7A). Next, p53 protein 
synthesis between PCR fragment and plasmid DNA was compared by using either 400 ng of 
PCR fragment, 400 ng of plasmid DNA (equi-mass), or 1600ng of plasmid DNA (equi-molar). 
Western blot analysis using DO-1 antibody revealed that the use of PCR cDNA templates 
gave a significantly higher protein yield (Figure 3.7B) for both wild-type and mutant p53, and 
was used for subsequent assays.  
As IVT-synthesized p53 was used in the experiments instead of affinity purified p53 (as 
described previously), avoidance of possible background issues was attempted (from the use 
of bacterial extract IVT) by performing control binding experiments on full-length proteins 
(wild-type and mutants) under several experimental conditions. Full-length p53 proteins 
(wild-type, G245S, R248Q and R273H) were synthesized by reconstituting the IVT mixture 
with the desired amount of PCR cDNA templates, followed by incubation at 30OC for 2 hours. 
The p53/IVT mix is then incubated on a 96-well plate pre-coated with p53 RE oligo-
nucleotides (equal mix of p21 and PUMA REs), at room temperature, for different durations 
(30, 45 and 75 minutes), before detection and analysis using a plate spectrophotometer. 
Within each set of experiment, the effects of protein level and different buffers (with or 
without binding buffer 1) on positive control binding using p53wt-FL was also examined. 
From the results, it was noted that the increase in RE incubation time resulted in an increase 
in background binding of mutant p53, but not sequence specific binding of wild-type p53 
(Figure 3.7D); possibly due to the instability of mutant p53 at room temperature. Halving the 
amount of streptavidin used to pre-coat the plate also led to increased mutant binding, 
possibly due to non-specific hydrophobic interaction with the polystyrene matrix (Figure 
3.7D). From the results, it was concluded that the optimal condition for the plate binding  
















assay was to use 5 μL of IVT protein in p53 binding buffer 1, with a RE incubation time of 30 
minutes (Figure 3.7D).  
3.3.7  Preliminary validation of peptides using ELISA-based DNA binding assay 
The peptides were next tested by essentially replicating an IVC positive event with or 
without peptide present. The plate binding assay was performed as above and each p53 
mutant protein was co-synthesized with their respective peptides by co-incubating the IVT 
mixture with equal molar amounts of DNA templates (160 ng p53 to 12 ng peptide cDNA). 
We could detect a slight increase in RE binding for combinations of G245S-FL + Pap-MPH, 
and R248Q-FL + Pap-VSW (Figure 3.8A). Pap-ILN elicited an even bigger binding increase of 
~2-fold over mutant only control (Figure 3.8A).  
While it was reassuring to observe activity from some peptides, the current experimental 
set-up made it impossible to control for the amounts of protein and peptide synthesized, 
and hence, reactivation events that were sensitive to protein-peptide molar ratios may not 
be sampled appropriately. To account for this, the assay was repeated for selected peptides 
(one for each mutant), but with the concentration of peptide cDNA varied across a range 
(between 5 ng and 20 ng). Additionally as control, a cDNA template (10 ng) that encoded a 
dummy peptide was included (PelB leader sequence from PET22b vector, ~20 amino acid 
polypeptide) into the sample for wt-FL. The results indicated, with the exception of R248Q-
FL + Pap-VSW which showed similar binding re-activation as before, a decrease in RE-binding 
as peptide cDNA increased (Figure 3.8B). Western blot analysis of the protein samples used 
revealed that the relative synthesis of mutant p53 protein was very much affected by the 
presence of peptide cDNA, causing a significant difference in protein input across samples 
(Figure 3.8C). This phenomenon was, however, not appreciable in wt-FL binding which 
remained unaffected. To circumvent this problem, proteins and peptides were translated 
separately before co-incubation (at increasing volumes of IVT-synthesized peptides: 2 μL, 6  










μL and 10 μL) in the presence of RE oligonucleotides. A slight Pap-MPH induced reactivation 
for the G245S-FL mutant was observed when 2 μL of IVT made peptide was used (Figure 
3.7D), which did not increase with added amounts of IVT-Pap-MPH. The observed inactivity 
from the remaining samples (R248Q-FL + Pap-VSW and R273H-FL + Pap-TAL) may be due to 
an elevated mp53 background binding owing to the absence of a peptide entity in ‘mutant 
protein’ only control samples. The assay was therefore repeated with the inclusion of an IVT-
synthesized dummy peptide in the ‘mutant only’ control. The results show a clear peptide 
induced reactivation for sequence-specific DNA binding for two of the mp53 tested (both the 
R248Q and R273H mutants were reactivated by Pap-VSW and Pap-TAL, respectively, by ~2-
fold increase in RE binding) (Figure 3.8E) . 
3.3.8 Simple bioinformatics approach to peptide analysis and possible biological 
significance   
A simple bioinformatics approach was also taken to screen for possible biological 
relevance of the peptides. Basically, each sequence was (i) compared with previous reports 
of known p53 interacting peptide sequences, (ii) queried against a non-redundant database 
of human proteins using the blastp algorithm to identify obvious known or possible 
interactors of p53 or (iii) queried against non-redundant databases of protein across all taxa 
to identify protein sequence homology of known structures. 
A comparison with published p53 peptide interactors revealed sequence homology between 
Pap-SPT and a peptide sequence derived from a p53 binding selection using filamentous 
phage that displayed a randomized 12-mer peptide library (Figure 3.9A) [222]. The study also 
attempted to characterize interactions between p53 and the phage peptide, designated φ2. 
Accordingly, φ2 seem to have a conformational sensitive binding mechanism and favored 
interacting with properly folded p53; as demonstrated by an increase binding to wildtype 




over mutant p53 (R175H and R248Q) and Pab1620 epitope over Pab240 epitope displaying 
p53 [222]. The authors also noted that φ2 bound p53wt-FL and p53wt-∆30 equally well, and  
  




did not bind to any of the 15-mer peptides mapped from the entire linear protein sequence 
of full-length p53 [222]. Another notable observation is the negatively charged patch on Pap-
VSW (Figure 3.9C), which resembles a similar feature on the previously described re-
activating peptide CDB3 [170], possibly indicating the importance of an acidic region in re-
activating certain mutants. 
When the peptide sequences was blasted in search for known p53 interacting proteins, a 
remarkable hit was the sequence homology between Pap-MPH and p53’s cellular antagonist, 
Mdm2 [223]. Interestingly, the region of homology is mapped to the RING domain of Mdm2 
(Figure 3.9D), far away from the primary region of interaction that lies on the N-terminal end 
of both proteins [53,224]. The RING domain of Mdm2 has not been shown to bind p53, but 
has been described with several associated properties including nucleotide binding [17,225], 
facilitating nuclear export [226] and more importantly, ubiquitin E3-ligase activity [227]. 
Structural and mutagenesis studies of Mdm2 homo- and hetero- dimers have revealed that 
dimerization of the RING domain is essential for the stability and E3-ligase activity of Mdm2 
[137,228,229]. Contacts on the flanking residues of the N- and C-terminus of the RING 
domain brings the monomeric subunits together forming a highly symmetrical structure 
coordinated by 4 Zinc atoms (two per monomer)(PDB:HDN2)(Figure 3.9D1). A compact ββαβ 
fold present in both Mdm2 subunit comes together and forms a β-barrel made up of 6 β-
strands, encasing a mainly hydrophobic core of ~900 Å2[228] (Figure 3.9D1, 3.9D2). Unlike 
the HECT class of E3-ligases (covalent bound ubiquitin molecule), Mdm2 belongs to the 
(RING)/U-box and PHD domain family of E3s, and function by bringing ubiquitin-bound E2 
enzymes to close proximity with substrate p53 molecules before mediating the attachment 
of ubiquitin onto target lysine residues [230], most of which are clustered at the CTD [231]. 
The solvent accessible α-helix and adjacent loop is projected away from the β-barrel and is 
the site of recognition and interaction with ubiquitin-bound E2 enzymes [229]. Mutagenesis 
studies of Mdm2/MdmX hetero-dimers indicate that each RING domain subunit within the  










dimeric structure may play distinct roles in conferring E3-ligase activity, where one interacts 
with E2 enzyme and the other ubiquitinating target substrates [137]. Pap-MPH homology 
maps structurally to a region of the β2-strand and runs into the first residue of the adjacent 
α-helix (Figure 3.9D3). Incidentally, the first and last residues in this homologous sequence 
(His and Cys) also act as zinc coordinating ligands in the Mdm2 RING domain. Taken together, 
this region on Mdm2 may be involved in a process of transient binding, where the β-barrel 
recognizes and holds the CTD of p53 in place while mediating the transfer of ubiquitin from 
E2 enzyme onto p53. Pap-MPH may, in this light, be developed to possibly inhibit Mdm2’s 
E3-ligase activity, similar to a previously reported compound [148]. 
Pap-TAL was found to have a rather significant, extended region of homology to the catalytic 
domain of human lymphoid tyrosine phosphatase (LYP) (Figure 3.9E, PDB: 3H2X). While this 
protein is not known to interact with p53, the solved crystal structure of LYP indicates that 
the region of peptide homology lies within an α-helix (Figure 3.9E), and suggests a possible 
structure for a free peptide Pap-TAL.  
Sequence homology between Pap-VSW and poly (ADP-ribose) polymerase 4 (PARP4 or 
VPARP) was also identified (Figure 3.9B). PARP proteins are responsible for the detection 
and repair of single-stranded DNA breaks, and can also mediate apoptosis through the 
depletion of cellular ATP. Unlike most PARP proteins, PARP4 has a polymerase catalytic 
domain, but lacks the DNA binding domain [232]. With this in mind, it is conceivable that p53 
senses and binds DNA single-stranded breaks, and recruits PARP4 to mediate poly ADP-
ribose polymerization. Furthermore, the region of homology lies in the N-terminal region of 
PARP4; similar to DNA-binding competent PARP proteins, which do so through the N-
terminal zinc finger domains [233]. Additionally, PARP1 protein has been reported to 
interact with p53 and altering its DNA binding properties, establishing a precedence in the 




biological relationship between the p53 and the PARP family of proteins [234]. This is 
however, speculative and will require further assessment. 
 















 A novel IVC selection scheme was designed and use it to identify the sequences of 7 
different peptides which restore sequence-specific binding to several p53 hotspot mutants. 
Looking at the selection data and sequencing results, several factors may imply the success 
of the selection scheme. Initial post-selection PCR enrichment for positive selectants (in 
selection rounds 2 and 3) showed lower levels of PCR amplification for the negative control 
selection, indicating that DNA captured during selection was mainly due to the presence of 
mutant p53.  The failed selection of p53-R175H mutant can also be viewed somewhat as a 
negative control, implying that either a single short peptide is insufficient to restore wild-
type conformation to a globally-unfolded mutant, or a bigger random library is required. The 
maintenance and enrichment of certain sequences (eg. Pap-VSW, Pap-TAL) observed in the 
progression of the selection process indicated a true course of directed evolution. The 
difficulty in recovering selectants after round 1, followed by the relative ease after rounds 2 
and 3 is indicative of a diverse starting library successively enriched for positive selectants. 
The pattern of sequence emergence could suggest that certain p53 mutants have unifying 
structures or defects rendering them susceptible to the same peptides (Pap-TAL for G245S 
and R273H mutants), and other mutants like the R248Q harbor qualities that require distinct 
re-activating molecules. The selection results for R248Q mutant may also imply that mutant 
specificity can be achieved in identifying re-activating compounds. Additionally, each 
peptide may confer RE binding specificity to the p53 mutants, and ideally mediate distinct 
cellular response; a functionality which has yet to be assessed. Strangely, unlike R273H, the 
selection for G245S did not enrich Pap-TAL in round 3, and was replaced by 2 entirely 
different peptides (Pap-MPH and Pap-SPT). This may be due to slight differences in 
experimental conditions (eg. extracting aqueous phase, IVT batch variations) between 
selection rounds, causing a shift in the selective pressure. Another possibility is that of cross 
contamination between the G245S and R273H positive selectants after round 2 selection. 




While it’s noted that this is a plausible caveat, the lack of peptide sequence RLQQV from the 
G245S selection may indicate otherwise. 
The approach in validating peptide activity using the ELISA plate DNA binding assay was a 
preliminary one, and functioned around recapitulating the events that transpired in an IVC 
compartment. As such, only binding activity from wildtype p53 (and not known reactivating 
compounds) was used as positive control. Although there are some evidence of peptide 
activity from all the peptides in the results, the narrow dynamic range of the assay, and 
rigidity of experimental conditions (unknown p53 and peptide concentrations…etc) 
mandates further reassessment with more appropriate and sensitive measurements. The 
results also do not indicate if the peptides are restoring sequence-specific DNA binding to 
the p53 mutants, or increasing DNA binding non-specifically. As such, a more sensitive qPCR 
based p53-DNA binding assay was developed (discussed in Chapter 6) and was subsequently 
used in measuring compound- and peptide-induced mutant p53 reactivation (discussed in 
Chapter 7). 
From the alignment to existing protein databases, a lack of sequence similarity to known p53 
interacting proteins could arise from the fact that only essential contact residues of the p53 
ligands are represented, and given the short length of the peptides, are not representative 
of linear sequences. It was, however, rather remarkable and encouraging to identifying 
sequence homology to known interacting molecules to p53, especially with a natural binding 
partner (Pap-MPH and Mdm2). In addition, it also signifies the applicability of the IVC 
selection schemes and that it can be designed to probe intricate and functional interactions 
that display techniques cannot. This selection also had the added advantage of identifying 
possible novel p53 interacting proteins (PARP4), or revealing previously unknown modes or 
sites of interactions.  




It was apparent from the multiple attempts of PCR amplification after first round of selection 
that the initial amounts of positive selectants were miniscule. The initial heavy reliance on 
PCR to recover selectants can add to bias during selection, whereby certain peptide cDNAs 
may be selectively amplified. Multiple PCR enrichment and subsequent reconstruction 
would have invariably placed some selective pressure on DNA sequence, selectively 
amplifying amplicons that favored PCR reactions (eg. lesser GC content, or less secondary 
structures…etc). The phenomenon of disproportionate PCR amplification is evident in the 
enrichment of our negative control selection samples, where the final PCR products are 
comparatively higher and is not representative of starting amounts of DNA template before 
PCR enrichment. (Figure 3.5A-B, lane C). 




4 Studying p53 using in-vitro transcription/translation systems  
4.1 Introduction 
 Almost all in-vitro assays used to characterize p53 are performed with purified 
recombinant proteins. While many techniques that require high levels of protein purity or 
yield (eg. X-ray crystallography, fluorescence polarization, protein NMR) mandate the 
purification process, the use of in-vitro transcription/translation systems to study p53 allows 
the study of certain aspects not possible with purified proteins. This may be especially true 
when dealing with p53 and its many conformationally diverse and sensitive mutants, a factor 
further confounded by the fact that full-length structure of p53 and its mutants remain 
unsolved. Historically indeed, a large number of studies using a rabbit reticulosyte lysate 
system showed that p53 conformation and interaction could be studied using IVT 
approaches [235]. Furthermore, many new interactions being unraveled currently seem to 
pivot around various conformational states of each p53 variant. For example, a study on 
interaction between mutant p53 and homologs p63 and p73 showed that wild-type p53 
binds to p73, but not when immuno-depleted by Pab240 antibody [114]. It will be 
interesting to revisit this phenomenon using an IVT system so as to investigate possible 
interactions with nascent p53 protein during translation, an element more representative of 
cellular systems. Also, in the case of mutant reactivation using ellipticine, the authors claim 
that ellipticine targets nascent mutant protein as CHX treatment ablated the mutant rescued 
phenotype in cells [193]. However, considering the complexity of the cellular milieu and the 
wide-ranging effects of CHX (global inhibition of protein translation), such a conclusion may 
have been more suitably tested in an IVT system. Additionally the use of IVT systems allows 
a quick and easy way to synthesize different protein constructs without the hassle of dealing 
with technical problems associated with affinity purification (induction, expression and 




purification processes). It also negates the need to tag the protein of interest, which may 
cause further complications during downstream experiments. 
Very critically, the IVT system was used so as to incorporate a critical element into our 
selection scheme; the selection of peptides that may exert their function during the 
translation of p53 mutant proteins. In this light, the IVT system was used for further 
downstream investigation of peptides functionalities. Although the IVT system used for the 
selection process,  EcoPro T7 system (Novagen),  has been previously described in a 
successful selection involving p53 [211], a switch to a minimal IVT system (CosmoBio PURE 
system) was chosen to minimize unwanted, non-specific background interactions from the 
proteins in the IVT system. 
The CosmoBio PURE system is a minimal IVT system constituted mainly from hexa-histidine 
affinity purified protein components (32 in total, including aminoacyl-tRNA synthetases, 
elongation and release factors, polymerases, and ribosomes) [236]. Because this system has 
not been used previously for translating p53, we briefly characterized and evaluated if the 
system is suitable for synthesizing the p53 protein. 
4.2  Materials and methods 
4.2.1  Protein quantification using ELISA 
 To obtain the standard curves, anti-p53 antibodies (DO-1 or Bp53-10.1) were 
immobilized on 96-well polystyrene plates (1 μg/well) as described in Section 2.3.2. Purified 
p53QM-FL proteins (diluted in p53 binding buffer 2 containing equal components of IVT 
mixture), diluted over a concentration range between 0.3 nM to 30 μM, and IVT synthesized 
p53 proteins were then added to the antibody-coated wells. After a 1-hour incubation at 4oC, 
the mixture was discarded, and the plate was washed (3x WB1, 3x WB2). Next, 50 μL of the 
detecting antibody (CM-1 diluted at 1:150 in PBS) was added to each well and incubated at 




room temperature for 20 minutes. The detecting secondary antibody is then discarded, and 
the procedure is completed as described in Section 2.3.1. Data analysis and calculation were 
performed using the SoftMax® Pro software.  
4.2.2  Immunoprecipitation of IVT synthesized p53 
 Antibody-coated beads were prepared by incubating protein G beads (Dynabeads® 
Protein G, Invitrogen) with either Pab240, Pab1620 or DO-1 antibody (1 μg/5 μL beads) in a 3% 
BSA/PBS solution at room temperature for 2 hours on a rotator. Coated beads were then 
washed twice (200 μL wash volume) with WB1, twice with WB2, and stored in 50 μL WB2 at 
4oC until needed. 
P53 proteins were IVT-synthesized and incubated with the respective antibody-coated beads 
(20 μL of IVT to 5 μL beads) for an hour at 4oC on a rotator (5 μL of each post-translation IVT 
extract containing the respective p53 variant was set aside as input control in western 
blotting). Following which, the IVT mixture was removed and the beads were washed three 
times in WB1 and three times in WB2. After removing the wash buffer, the beads were 
heated in 20 μL of LDS buffer at 95oC for 10 minutes to elute bound protein. Eluted samples 
were used for western blotting as described in 2.3.3 and probed with CM-1 primary antibody.  
4.2.3  Coomassie stained protein gel 
 BSA standards (Bio-Rad) and purified p53QM-FL were each diluted in 1X NuPAGE® 
LDS sample buffer (Invitrogen) with 100 mM DTT, boiled for 10 minutes, and separated on a 
NuPAGE® 4 -12% Bis-Tris Gel (Invitrogen) in 1X NuPAGE® MOPS SDS Running Buffer 
(Invitrogen) at 150 volts for 1.5 hours. The gel was then stained with coomasie-blue protein 
stain for 30 minutes, and destained (using coomasie destaining solution) until the bands 
appeared visually distinct. Image of the gel was captured using the Epson Perfection 4490 
scanner.  




4.2.4  Protein quantification using Bradford reagent 
 Bradford protein quantification was performed using the Quick StartTM Bradford Dye 
Reagent (Bio-Rad) following manufacturer’s protocol. Briefly, 200 μL of Bradford dye was 
added to each well in a  96-well plate containing a titration of BSA standards (Bio-Rad), 
unknown protein sample (purified p53QM-FL), p53QM-FL buffer only (blank measurement). 
Samples were incubated for 20 minutes at room temperature before being measured on the 
SpectraMax Plus 384 microplate reader (Molecular Devices, USA) at a wavelength of 595 nm. 
Data analysis and calculation were performed using the SoftMax® Pro software. 
4.3 Results and discussion 
4.3.1 Optimizing p53 synthesis using CosmoBio PURE system 
PCR constructs encoding each p53 variant were generated and used for protein 
synthesis via the PURE system for 2 hours at 30OC, before visualization by western blot. DO-1 
western blot of the IVT protein lysates shows p53 protein made at the expected sizes of ~49 
kDa for full-length, and ~43 kDa for ∆22 C-terminal truncated constructs (Figure 4.1A). While 
the relative amounts of protein synthesis for the different p53 variants appeared similar, a 
smaller truncated product of ~42 kDa was observed (migrated at similar size with p53-∆22 
protein). Using an anti-p53 antibody that targets a C-terminal epitope (Bp53-10.1), it was 
confirmed, using western blot, that the 49 kDa product was indeed a completed p53 product 
(Figure 4.1B). Next, the effects of cDNA template concentration on protein translation were 
determined by comparing levels of synthesized wt-p53∆22 over a concentration range of 
template cDNA (15 ng to 120 ng). Instead of full-length protein, wt-p53∆22 was selected for 
this purpose as it gave a single protein product. Western blot analysis using DO-1 showed no 
significant increase in protein yield when the cDNA template was increased above 30 ng/10 
μL IVT (Figure 4.1C), prompting the adherence to this template concentration for  










downstream experiments. Next, we focused on examining the ~42kDa truncated product 
(IVTp53-trunc), and investigated if its production can be circumvented. Using western blot, 
IVT synthesized P53-wt∆22 was loaded at decreasing concentrations and compared with IVT 
synthesized p53-wtFL. The result indicated that IVTp53-trunc was slightly smaller than the 
wt-∆22 protein (Figure 4.2A). This suggested that the IVTp53-trunc product was not due to a 
premature stop codon, which would otherwise result in a similar truncation in the ∆22 
protein lysate. Next, the effects of temperature and IVT incubation duration was examined 
using a timecourse experiment where the synthesis of p53wt-FL was examined at 30 
minutes intervals over 3 different incubation temperatures (24oC, 30oC and 37oC). The 
results showed a transitional appearance of IVTp53-trunc, which accumulated and 
disappeared with time (after 3 hours) or increased temperature (37oC IVT) (Figure 4.2B). 
Taken together, the results suggest (possibly due to the lack of certain protein factors in this 
minimal system) some form of transient and passive translational pausing due to effects 
pertaining from cDNA or mRNA (possibly due to secondary structures) encoding full-length 
p53. The effects of DMSO was next tested (conventionally used in PCR reactions to reduce 
the formation of secondary DNA structures [237]) on IVTp53-trunc by looking at p53wt-FL 
protein synthesis with increasing amounts of DMSO additive. The results revealed not only 
an absence of IVTp53-trunc after 2 hours of IVT synthesis (when DMSO used between 0.05% 
- 5%), but a DMSO concentration-dependent increase in protein production (Figure 4.2C-D). 
The IVT system, however, could not tolerate an addition of 10% DMSO and was completely 
inactive (Figure 4.2C-D). The observation also supports the hypothesis that the IVTp53-trunc 
product was due to secondary structures formed by the cDNA or mRNA templates. It seems 
obvious, by comparing the effects of temperature on IVT (Figure 4.2B-C), that translation at 
37oC aided the synthesis of a single full-length p53 product, whereas translation at 30oC 
resulted in higher protein yield. The decreased of IVT efficiency at 37oC was attributed to 
possible protein aggregation events that retarded the IVT reaction. Because of p53’s  
















instability at 37oC (rate of unfolding in mutant core domains are 40-130 times lesser at 30oC 
compared to 37oC [105].) and the fact that DMSO can partially address the issues with 
IVTp53-trunc product, we decided to incubated all future IVT reactions at 30oC in the 
presence of 5% (v/v) DMSO. 
The effects of cDNA template quality on the presence of IVTp53-trunc were also investigated 
briefly. A comparison between old p53 cDNA (PCR synthesized and left at 4oC for a week) 
with freshly PCR amplified p53 cDNA was made by profiling a timecourse (30 minute 
intervals) of the respective p53-wtFL synthesis at 30oC. The results, analysed via DO-1 
western blot, showed an apparent inability, in IVT reactions using ‘old’ template, for the 
IVTp53-trunc product to be resolved with time (Figure 4.2E-left). Protein synthesis in IVT 
samples using freshly made PCR templates proceeded as expected, with the IVTp53-trunc 
product almost completely resolved by 3 hours (Figure 4.2E-right).This further strengthens 
the notion that the truncated product was due to cDNA secondary structures and 
demonstrates the sensitivity of DNA template quality when using the CosmoBio PURE 
system. This has also mandated the appropriate aliquoting and storage of cDNA template 
constructs for IVT at -20oC.  
As the IVT reaction using the CosmoBio PURE system is initiated by reconstituting 2 separate 
cocktail mixtures (components A and B, in the ratio of 5:2, respectively), protein synthesis 
and p53-trunc from altering the respective ratios of the cocktail was also examined briefly. 
Unfortunately, any permutation apart from the manufacturer’s prescribed ratio of the 2 
components drastically reduced the protein yield (Figure 4.2F).  
Through the assimilation of the above information, it became possible to translate a 
relatively clean single full-length protein product for all the p53 variants using the CosmoBio 
PURE system; a 2 hours incubation at 30oC using 30 ng of fresh cDNA template with 5% 
DMSO additive (Figure 4.2G).  




4.3.2 Assessing the conformation of IVT-synthesized p53wt-FL 
After successfully synthesizing full-length protein using the current IVT system, the 
conformation of the wildtype full-length protein was next examined by performing an 
immuno-precipitation (IP) using IVT synthesized p53. P53 protein was immuno-captured on 
magnetic protein-G beads coated with either (1) DO-1 antibody which targets p53 Ntd and is 
insensitive to protein conformation, (2) Pab240 antibody which detects a buried linear 
epitope only exposed when the protein core domain is totally unfolded, or (3) Pab1620 
antibody targeted at a native epitope present when the core is properly folded. Additionally, 
samples of IVT synthesized R175H-FL (a globally unfolded mutant bearing the Pab240 
epitope) and the R273H-FL (a contact mutant with similar conformation as wild-type p53) 
mutants were also analyzed as additional controls. Proteins eluted off the beads were 
analysed via western blot using a rabbit polyclonal anti-p53 antibody (CM1). The result 
showed an expected presence of Pab1620 epitopes in both p53wt-FL and R273H-FL mutant, 
at similar levels, but not in the R175H-FL IP (Figure 4.3). As expected, the level of Pab240 
epitope was also high in the IVT-synthesized R175H-FL mutant. Interestingly, IVTp53-trunc 
product, which was present in this IP experiment (detected in the input and DO-1 blot), was 
not detected by either conformation sensitive antibodies (Figure 3). Our results here 
indicate that the CosmoBio PURE IVT system is capable of synthesizing full-length p53 with 
expected conformations. 
4.3.3 Quantifying IVT-synthesized p53 protein concentration 
 As the concentration of p53 protein had to be determined within a cocktail of IVT 
proteins, a sandwich ELISA approach was adopted, whereby IVT-synthesized p53 is 
measured against a standard curve using purified p53 of a known concentration. The 
reference protein used was a purified full-length variant of the p53 wild-type protein 
(obtained from a collaborating lab, Alan Fersht, Cambridge) which contains 4 stabilizing  










mutations within the core domain (termed p53QM-FL), but is otherwise conformationally 
identical to wild-type p53 [185]. The purity and concentration of the purified p53QM-FL 
(determined to be 30 μM in Cambridge) was first confirmed using Bradford reagent and 
coomassie staining. The purified p53QM-FL protein was separated, together with titrated 
BSA standards, using polyacrylamide gel-electrophoresis (PAGE) and visualized using 
coomasie protein staining (Figure 4.4A). The results displayed a clean product that migrated 
at the expected size of ~49kDa with an estimated concentration between 1 – 1.5 mg/mL (by 
visual comparison to BSA standards). The purified protein was then quantified using the 
Bradford reagent by measurement against a standard concentration curve using BSA 
standards (Figure 4.4B). Using this method, the measured protein concentration was ~1.35 
mg/mL which is equivalent to a molar concentration of ~31 μM (p53 MW = 43.6 kDa), hence 
confirming the concentration of 30 μM measured before. 
Purified p53QM-FL protein was next diluted with equal amounts of the IVT mixture (to 
account for IVT-dependent background protein interaction) to cover a concentration range 
of 0.3 nM – 30 μM and used to construct 2 standard curves, each by capturing p53 onto 
plates immobilized with anti-p53 mouse monoclonal antibodies (DO-1 and Bp53-10.1), and 
detecting with rabbit polyclonal CM-1 anti-p53 antibodies (Figure 4.4C). IVT-synthesized p53 
(wild-type FL and ∆22, with or without DMSO) was also concurrently measured and its 
concentration determined by extrapolation using the 2 standard curves (Figure 4.4C-table). 
A western blot (DO-1) of the same IVT-synthesized p53 samples used for ELISA quantification 
was also used as reference for the concentration estimate (Figure 4.4C-right inset). The 
results showed that the concentration estimates for full-length protein (with and without 
DMSO) was similar using both antibodies (86 nM versus 72 nM, and 310 nM versus 273 nM), 
confirming the accuracy of the measurement. Additionally, as expected, measurements on 
the DO-1 plate indicated higher concentrations then on Bp53-10.1 plate as DO-1 targeted 
p53 Ntd and hence, measured both finished and unfinished protein products.  










Also consistent with all other results before, DMSO addition caused a significantly higher 
protein yield and was reflected in the quantification results (Figure 4.4C-table). There was, 
however, a slight discrepancy for wt-∆22 and wt-FL (5% DMSO) protein samples between 
ELISA measurement and western blot protein levels, which was probably due to the 
insensitivity and narrow dynamic range of western blot detection. 
An estimated range of the respective concentrations was made and incorporated plate ELISA 
measurements (including standard deviation) together with the respective p53 western blot 
(Figure 4.4C-table). 
With the concentration estimates in mind, a comparison of protein synthesis between 
p53wt-FL and -∆22 was performed using titrated amounts of each IVT-synthesized protein. 
Both p53wt-FL and p53wt-∆22 were IVT-translated under identical conditions (either 30 ng 
or 60 ng cDNA template, all with 5% DMSO) and analysed using western blot (DO-1). In each 
blot, IVT lysate of either variant was loaded at a fixed volume (5 μL of IVT product), against 
the other which was loaded in serial dilution (4 μL to 1 μL of IVT product) (Figure 4.4D). It 
was apparent from the results that wt-∆22 was always translated more efficiently than wt-FL, 
this could be due to the shorter protein length or related to the DNA secondary structure in 
wt-FL cDNA template (discussed earlier in Section 4.3.1). From the western blot, wt-FL 
protein yield was estimated to be 30% of that of wt-∆22. This estimate is consistent with the 
ELISA quantifications, where wt-FL concentration (200 – 250 nM) was estimated at 1/3 of 
wt-∆22 concentration (700 – 800 nM). Notably, the adverse effect in protein translation by 
slightly increasing the cDNA template (from 30 ng to 60 ng) was more pronounced in wt-FL 
compared to wt-∆22 (figure 4.4D). In both cases, a concentration of 30 ng of cDNA template 
resulted in the highest yield and was adopted for all future IVT reactions. 
 











In this chapter, the CosmoBio PURE IVT system was shown to be capable of 
synthesizing full-length p53 proteins which adopted conformations expected from their 
coding sequence. However, due to the ‘minimalistic’ reconstituted nature of the IVT system 
in use, several conditions that included additives, were essential in translating proper p53. In 
addition, an estimate of IVT-synthesized p53 concentrations was also derived. The presence 
of a transient IVTp53-trunc protein product (which was only noticeable in a specific window 
of time) carrying neither the Pab1620 nor the Pab240 epitope was an extremely interesting 
observation. Whether its transitional presence is a conformational phenomenon intrinsic to 
the translation or folding of the p53 protein or merely a by-product of a minimal bacterial 
IVT system remains to be determined. Its presence, however, suggests the existence of 
conformational states between folded and unfolded forms of wildtype p53, and could 
manifest as multiple forms in nature. Furthermore, it also demonstrates how invaluable IVT 
systems can be to studying such biochemical occurrence.




5  In-vitro characterization of p53-activating peptides 
5.1  Introduction 
 According to the IVC selection scheme, the peptides will need to fulfill two 
conditions to be considered functionally active; (A) they need to interact physically with the 
mutant p53 either during or after protein synthesis and (B) restore sequence-specific DNA 
binding functions to the mutant p53. This chapter will discuss several in-vitro experiments 
used to determine if the peptides bind to mutant and wild-type p53, and if binding results in 
an increase in wild-type conformation. As seen in the preliminary reactivation data (Section 
3.3.7), the use of IVT-synthesized peptides for in-vitro experiments was not ideal for several 
reasons, one of which was the inability to control the peptide concentrations. Therefore, 
commercially synthesized peptides (described in Section 2.1.5) were used for further 
experiments. Because of problems in synthesizing peptide Pap-VSW, it was omitted from 
further studies. 
5.2  Materials and Methods 
5.2.1 Peptide-p53 interacting ELISAs 
ELISA conformation 1 – Commercial streptavidin plates (Reacti-BindTM Streptavidin 
Coated, High Binding capacity, Thermo Scientific) were first blocked (50 μL of 3% BSA/PBS 
for 1 hour at 20oC), before being coated with peptides by incubating 10 μM of biotinylated 
peptides (either N- or C-terminal modifications) in 1% BSA/PBS for 2 hours at 20oC. Peptide-
coated plates were then washed (twice in WB1, and twice in WB2) and over-layed with IVT-
synthesized p53wt-FL (2.5 μL IVT in 27.5 μL PBS) for 45 min at 20oC. IVT-p53wt-FL added to 
un-coated wells acted as blank control (background p53 binding) subtracted from all 
readings. Additionally, blank IVT extract added to peptide coated wells also acted as 
negative control specific for each peptide. The IVT mixture was removed, and the plate was 




washed 4 times in WB1 and 4 times in WB2, before incubation with a primary antibody (DO-
1, CM1, or Bp53-10.1) for 10 minutes (0.5 μg/well in PBS). The remaining procedure is 
performed as described in Section 2.3.1. See Figure 5.2 for a schematic of the ELISA 
conformation. 
ELISA conformation 2 – Full-length mutant p53 were synthesized in the presence of 
biotinylated peptides (100 nM – 200 μM) using IVT, and transferred onto DO-1 coated plates 
(as described in 2.3.2) pre-filled with PBS buffer (2.5 μL IVT in 27.5 μL PBS). The target 
complexes were then detected using streptavidin-HRP conjugate (1:4000 in PBS), and 
developed as described in Section 2.3.1. As a positive control, N-terminal biotinylated 
peptide carrying the DO-1 epitope was used (biotin-TFSDLWKLLP). Negative controls plotted 
include ‘mutant p53 only’ (no peptide), or peptide in IVT-extract (no p53). See Figure 5.2 for 
a schematic of the ELISA conformation. 
ELISA conformation 3 – Full-length mutant p53 were synthesized in the presence of 
biotinylated peptides (1 μM – 200 μM) using IVT, transferred onto commercial streptavidin 
plates (Reacti-BindTM Streptavidin Coated, High Binding capacity, Thermo Scientific) pre-filled 
with 27.5 μL of PBS, and incubated for 45 minutes at 24oC. After which, the solution is 
removed and the plate is washed 4 times in WB1, and 4 times in WB2. Detection of p53-
peptide complex is achieved using anti-p53 antibodies (DO-1 or Bp53-10.1) following 
protocol described in Section 2.3.1. See Figure 5.2 for a schematic of the ELISA conformation. 
5.2.2  Pab240/Pab1620 sensitive ELISA 
 Mutant and wildtype nano-tagged full-length p53 (p53 protein with a N-terminal 9-
mer streptavidin affinity tag, see Section 7.3.3) were IVT-translated in the presence of 200 
μM of peptides, and portioned with the relevant monoclonal antibodies in the following 
manner; 1 μg Pab1620 with 30 μL IVT extract, 0.5 μg DO-1 with 5 μL IVT extract, and 0.5 μg 




Pab240 with 5 μL IVT extract (where necessary, volume is made up with p53 binding buffer 
1). The mixture is then incubated for 40 minutes at 24oC on the rotator, before being 
transferred onto commercial protein G plates (Pierce® Protein-G coated plates, Thermo 
Scientific) for another 20 minutes at 20oC (allowing the antibody-p53 complexes to be 
captured). The solution is then removed, and the wells are washed 3 times in WB1, 3 times 
in WB2, before target complexes were detected using streptavidin-HRP conjugate following 
the procedure described in Section 2.3.1. For reference experiments (Figure 5.5A), data was 
normalized to wildtype p53 values. For all other experiments (Figure 5.5B), data were first 
globally normalized using DO-1 values to each respective ‘DMSO blank’ reading, before each 
data subset is further normalized to its own DO-1 reading. 
5.2.3  Thermal shift assay 
 Purified p53QM-FL protein were mixed with SYPRO® Orange Gel Stain (Molecular 
ProbesTM, Invitrogen), dH2O, and other variable components (synthetic peptides and DNA 
duplex) as follows: 
Components Volume 
p53QM-FL 7.5 μM 
SYPRO dye (50x) 6 μL 
6x p53 binding buffer 2 5 μL 
Peptide (optional) 20 μM 
DNA duplex (optional) 20 μM 
dH2O -as needed- 
Total 30 μL 
Table 5.1 – Components in a thermal shift assay reaction 
Samples are mixed thoroughly and subjected to a thermal program (C1000TM Thermal Cycler, 
Bio-Rad) where temperature was increased from 25oC to 85oC in a stepwise manner 
(increments of 0.5oC with a 20 second interval). The level of fluorescence was measured at 
each interval using the green fluorescence filter (Ex/Em = 488/525) on the CFX96TM Real-
Time System (Bio-Rad). Data was later analyzed using GraphPad Prism Software (Version 
5.03) using a non-linear fit to a simple melt curve algorithm. 




5.3  Results and discussion 
5.3.1  Using ELISA to probe for interaction between peptides and p53 
 By analyzing the level of wild-type full-length p53 protein IVT-synthesized in the 
presence of peptides, the possible non-specific effects of the peptides on the IVT 
transcription/translation process was first addressed.  DO-1 western blot of IVT-synthesized 
wt-FL p53 showed no changes in levels of protein translation when tested with any of the 6 
peptides (Figure 5.1), indicating that none of the peptides interacted non-specifically with 
the IVT components. To ascertain if a physical association exists between peptide and p53, 
an ELISA approach was taken, but consisted of three different experimental designs (Figure 
5.2). For this purpose, two sets of peptides were synthesized, each with a biotin molecule 
attached to either the N-terminus (designated as biotin-peptide), or the C-terminus 
(designated as peptide-biotin). 
Interactions between p53wt-FL protein and any of the 2 sets of biotinylated peptides were 
first examined using ELISA conformation 1 (Figure 5.2A). In this assay, p53wt-FL protein was 
synthesized using IVT in the absence of peptides and incubated on streptavidin coated plates 
pre-coated with the biotinylated peptides. P53-peptide complexes formed are then detected 
with anti-p53 antibody, developed and read using a spectrophotometer. Additionally, three 
different antibodies (anti-p53 Ntd DO-1, anti-p53 Ctd Bp53-10.1 and anti-p53 polyclonal CM-
1) were used to discriminate possible false positive events in which a peptide interacted with 
a particular antibody. The results showed that wells containing peptides Pap-TAL (maximum 
of 4-fold increase), Pap-ILN (maximum of 3.5-fold increase), and Pap-VRH (maximum of 2.5-
fold increase) (Figure 5.3) gave significantly higher p53 binding when compared to control 
wells (same setup except incubated with p53 deficient IVT mixture). The three different set-
ups each using a different antibody also gave similar trend of results, suggesting a real p53-
dependent interaction. Interestingly, the peptides seemed to display different modes of  













interaction; Pap-ILN and Pap-TAL displayed higher levels of binding with C-terminal biotin 
modification (peptide-biotin), whereas Pap-VRH showed no preference for either biotin 
attachments (Figure 5.3). The lower signal from N-terminal biotinylated Pap-ILN and Pap-
VRH could have resulted from a partial disruption between peptide and p53 binding due to 
the presence of N-terminal biotin moiety. In both cases, the data strongly suggest that 
p53wt-FL interacts mainly with the N-terminal end of peptides Pap-ILN and Pap-TAL. For the 
remaining peptides (Pap-SPT, Pap-MPH and Pap-RLQ), the binding, although present, was 
very weak. This may be attributed to several factors; either (i) these peptides bind weakly in 
general, (ii) bind weakly only to wild-type p53, (iii) bind p53 strongly only when present 
during p53 protein translation, or (iv) bound p53 but required a different experimental setup 
to be detected.  
After establishing an interaction between wild-type protein and several of the peptides, the 
focused shifted to detecting an interaction in mutant p53 proteins. ELISA conformation-2 
was used to assess this hypothesis, but proved to be highly inefficient due to the strong non-
specific interaction between the biotinylated peptides and the polystyrene matrix of the 96-
well plates (discussed in Section 10.1). 
Since detection of the complex through probing for the biotin tag (using streptavidin 
conjugated HRP) on the peptides was not ideal. ELISA conformation-3 was performed using 
commercial streptavidin plates by essentially reversing the orientation of conformation-2, 
Figure 5.2C). In this layout, p53 mutants are IVT-translated with increasing concentrations of 
the respective peptide, incubated on the streptavidin plate, and detected using an anti-p53 
primary antibody, followed by an HRP-conjugated secondary antibody (Figure 5.2C). Data 
was interpreted as fold-increase over ‘mutant only’ negative control (which was assigned a 
value of 1). Also included was a ‘no-p53’ control, where background binding was measured 
using 200 μM of peptide in blank IVT extract. Initial results, using DO-1 primary antibody,  

















showed a concentration dependent response in peptide-p53 binding for all the peptides, 
except Pap-TAL (Figure 5.4E-Top) and Pap-VRH (Figure 5.4F-Top), which displayed high levels 
of background peptide binding in the absence of p53 (peptide only control). A true peptide-
p53 interaction for these two peptides only became apparent when a different primary 
detection antibody was used (Bp53-10.1) (Figure 5.4E-Bot and Figure 5.4F-Bot, respectively), 
possibly suggesting that some degree of DO-1 (or antibody subtype) recognition was evolved 
in these peptides (as DO-1 was used in the selection process). The bigger fold-difference 
response from using Bp53-10.1 could also stem from a lower background reading due to the 
inability of Bp53-10.1 to detect truncated p53 products (unlike DO-1). Additionally, IVT-p53 
protein was analyzed using western blot (DO-1), and showed comparable levels of p53 when 
each of the mutants were IVT-synthesized with either DMSO blank, or 200 μM of the 
respective biotin-peptides (Figure 5.4A-F, western blot insets). 
Both peptides selected for p53-G245S-FL mutant interacted comparatively weakly in this 
assay; Pap-SPT pulled-downed a 2-fold increase, and Pap-MPH a 3.5-fold increase of mutant 
p53 protein (Figure 5.4A-B). The interaction between Pap-ILN and R248Q-FL was more 
appreciable (over 8-fold increase at 50 μM, Figure 5.4C), even though some degree of 
peptide-antibody interaction was detected (~2-fold increase at 200 μM peptide, Figure 5.4C). 
Pap-RLQ also interacted with p53-R273H-FL, displaying a ~4.5-fold increase in binding at 25 
μM which increases to ~8-fold at 200 μM (Figure 5.4D). As Pap-TAL interacted strongly with 
the DO-1 antibody and was masking the detection of any real interaction (over 5-fold 
increase at 200 μM, Figure 5.4E-Top), the experiment was repeated with Bp53-10.1 antibody 
(which did not interact with Pap-TAL) and displayed a strong interaction, of ~13-fold increase 
at 10 μM peptide, between Pap-TAL and p53-R273H-FL proteins (Figure 5.4E-Bottom). 
Background issues arising from peptide-antibody interaction was also apparent between 
Pap-VRH and DO-1 (Figure 5.4F-Top), and could only be partially eliminated by using 
Bp5310.1 (Figure 5.4F-Bottom). The background was, however, decreased substantially to  




























discern a decent level of interaction between p53-R273H-FL and Pap-VRH (~18-fold over ‘no-
p53’ control and 10-fold over ‘200 μM ‘peptide-only’ control, at 25 μM) (Figure 5F-Bot). A 
























Pap-SPT G245S 25 2 No - 
Pap-MPH G245S 25-50 4 No - 
Pap-TAL R273H/G245S 10 14 Yes (strong) Ntd 
Pap-ILN R248Q 25 9 Yes, (strong)  Ntd 
Pap-VSW R248Q - Not assessed - 
Pap-RLQ R273H 1 7 Yes (moderate) Ntd 
Pap-VRH R273H 25 18 No - 
Table 5.2 – Summary of peptide-p53 interaction via ELISA 
 
Notably, a similar trend (to earlier ELISA results, Figures 5.3 and Figure 10.1) of distinct 
binding preference for C-terminal biotin modification, as opposed to N-terminal modification, 
for peptides Pap-ILN and Pap-TAL was observed. This could suggest that the region of 
peptide-p53 interaction lay predominantly in the N-terminal of these peptides. However, 
this same trend was also evident in the non-specific interaction between biotin-peptides and 
polystyrene plate matrix (Figure 10.2A). A plausible explanation for this could be the N-
terminal hydrophobicity in both sequences (ILNVLPLLASRKP and TALIDIWEHSVLGKGYPRMS, where 
hydrophobic residues are colored red) resulting in the increased binding affinity for both 
polystyrene and the exposed hydrophobic residues of unfolded p53 proteins.  
5.3.2 Peptide induced Pab240/ Pab1620 epitope sensitive conformational changes 
 Since physical interactions between the full-length mutants and their corresponding 
peptides have been detected, the focus was next shifted to assessing if this interaction led to 
an increase in conformational stability (determined by an increase in Pab1620 epitope). 
Relative Pab240/Pab1620 epitopes of each p53 variant translated in the absence of peptides 
were first assessed. IVT-translated full-length p53 proteins (conjugated with a 9-mer N-




terminal streptavidin affinity tag) was first incubated with either Pab240 or Pab1620 
antibody, and captured on commercial protein-G plates before detection using streptavidin-
HRP. Data for all samples were normalized to p53wt-FL which was assigned with an arbitrary 
100%. The C-terminal truncated p53-∆22 variants were used in the following assays as (i) 
changes in the levels of Pab240 and Pab1620 epitopes will likely involve structural changes 
specific only to the core domain, and (ii) Pab1620 epitope was more readily detectable in 
p53-∆22 proteins. 
As expected, results from the Pab1620 control experiment placed the R175H and R273H at 
opposite ends of the spectrum in terms of Pab1620 epitope presence (40% and 100% of 
wild-type, respectively, Figure 5.5A-Top), with the G245S mutant in the middle with 55% 
compared to wild-type protein. Data from Pab240 pull-down, however, showed similar 
levels for all samples and was less informative (Figure 5.5A-Bottom). This could be due to 
comparatively higher levels of Pab240 epitopes in IVT-synthesized p53 (present also in 
nascent protein products), or indicative of higher epitope affinity from the Pab240 antibody.  
To further discern the levels of Pab240 epitope present, the amount of antibody used was 
doubled (0.5 μg to 1 μg) and incubated with less p53 protein (5 μL to 2 μL IVT extract). 
The experiment was then repeated, but with each p53-∆22 variant translated in the 
presence of either DMSO (as peptide blank control), or 100 μM of a specific p53-activating 
peptide. DO-1 values are first normalized across each data set (for each p53 variant) to 
‘DMSO blank’ control. After which, each data subset (comprising DO-1, Pab240 or Pab1620 
values) was individually normalized to their respective DO-1 controls. Data from DO-1 pull-
down in each sample acted as a benchmark and control for protein levels, as well as possible 
peptide-induced perturbations in p53-antibody interactions. Comparing all data sets, a 
striking trend emerged in which peptides Pap-SPT and Pap-MPH had little to no effect on the 
presence of both epitopes. Pap-RLQ and Pap-VRH resulted in a drastic reduction in Pb1620  
















epitopes accompanied by a slight reduction in Pab240 epitopes (Figure 5.5B), suggesting a 
mechanism whereby peptides Pap-RLQ and Pap-VRH target core domain and cause a 
conformational change. Similarly, the seemingly innocuous effects from Pap-SPT and Pap-
MPH may be indicative of non-core interactions, or the requirement of p53 C-terminal 
presence for peptide-induced activity or interactions. Notably, the panel of peptides induced 
a very similar Pab240/Pab1620 response in both wt-∆22 and R273H-∆22 p53 proteins, 
suggesting consistency in the interaction mechanism arising from similar conformation 
between the R273H and wild-type proteins. The effect of this concurrent decrease in Pab240 
and Pab1620 epitopes is also induced by Pap-ILN for all p53 variants except, interestingly, 
the mutant (R248Q) it was selected for (Figure 5.5B). This may imply mechanistic differences 
in the function exerted by a specific peptide depending on the conformation, or 
predominant conformation, of the target p53. One anomaly, however, was the decrease in 
total protein signal for mutant p53 samples translated with Pap-VRH (Figure 5.5B), which 
was not observed for wild-type protein. This may partly be due to IVT-translational toxicity 
when Pap-VRH is used at high concentrations (which can be slightly detected in earlier 
results Figure 5.4D), or a phenomenon specific to mutant p53 proteins. 
5.3.3 Determination of peptide-induced thermal stability using thermal shift assay 
  Thermal shift assay is a fluorescence-based technique, employed to determine the 
apparent melting temperature (Tm) of a target protein. Purified target proteins are mixed 
with a protein binding dye (SYPRO), and exposed to thermal denaturation through gradual 
and small increments in temperature (typically 0.5oC – 1oC). As protein unfolds in response 
to the rising temperature, the SYPRO dye binds non-covalently to the exposed hydrophobic 
regions, and fluoresces, allowing a real-time measurement of protein thermal stability, and 
the determination of the apparent melting temperature Tm (defined by the mid-point of the  
  










linear phase on a RFU versus temperature graph, or the lowest point on a –d(RFU)/dT versus 
temperature graph) [238,239].  
As seen earlier, several peptides had rather strong effects on the presence of 
Pab240/Pab1620 epitopes in p53wt-∆22 (Figure 5.5B). Peptides were therefore tested for 
induction of thermal stability in purified p53QM-FL proteins. Using thermal shift assay, the 
Tm of purified p53QM-FL protein alone was determined to be 52.90 ± 0.5
oC. This figure is in 
good correlation with several published Tm of p53 determined using differential scanning 
calorimetry (wt-FL = 49.7 ± 0.7 [240], wt-core domain = 42oC and QM-core domain = 46.2 oC 
[185]). Further assay validation was achieved by pre-incubating the purified p53QM-FL with 
either 5 μM of p21 3’ site RE DNA duplex, or 5 μM of scrambled DNA sequence. The results 
showed that, while the presence of scrambled DNA duplex can stabilize p53 slightly (possibly 
due to non-specific C-terminal interactions)(55.68 ± 0.3, Figure 5.6A), the presence of a DNA 
response element sequence increased the Tm by 10
oC (62.95 ± 0.7, Figure 5.6A). Next, we 
went on to test if pre-incubating p53QM-FL with 20 μM of each peptide can induce a shift in 
the Tm. Thermal shift results indicated no apparent shift in any of the Tm compared to DMSO 
blank control (Figure 5.6B). We then repeated the experiment, but included 5μM of p21 
DNA-duplex in the peptide pre-incubation step. The result showed a slight destabilization 
shift (reduced Tm) in some samples containing, interestingly, the same peptides which was 
previously shown to cause a reduction in Pab1620 epitopes (Figure 6B). Both Pap-VRH and 
Pap-ILN induced a reduction in Tm (1.5
oC and 0.9oC, respectively) in the presence of 5 μM of 
p21 DNA-duplex (Figure 5.6C), but not in the presence of scrambled DNA-duplex lacking a 
consensus RE (Figure 5.6C). 
 
  

















 In this chapter, several in-vitro techniques were used to investigate the presence 
and nature of physical interactions between the selected peptides and both IVT-translated 
and purified p53. Using an ELISA approach, a physical association between every peptide 
and the mutant/s they were selected for was established (in certain cases, interaction with 
wild-type p53 was also observed). The results also indicated that p53 interacted 
preferentially with specific termini in certain peptides (ILN, TAL, and RLQ), and not others 
(SPT, MPH and VRH). At this point, it is unclear if peptides have specificity in targeting p53 
variants and exerting reactivation functions. It is possible, from both the Pab240/Pab1620 
and peptide-p53 interaction ELISA data, that some degree of non-specific interaction may 
exists amidst specific and functional interaction between peptide and p53. This non-specific 
protein-peptide interaction could arise from hydrophobic interactions, considering how 
several peptides contained regions of strong hydrophobicity (ILN, TAL, VRH). More 
interestingly, several peptides seemed to result in the structural destabilization of p53 
(observed in the Pab240/Pab1620 and thermal shift assay data), the very quality deemed, 
conventionally, to be detrimental to wild-type conformation, and consequently sequence-
specific DNA binding and function. In fact, several reports on developing reactivating 
compounds were based on increased Pab1620 epitope and thermal stability [170,172,187]. 
Pap-VRH induced a thermal destabilization of 1.5oC on p53QM-FL, which may be significant 
considering how the G245S mutation (distorts the local structural milieu of the DNA binding 
interface within the core domain) destabilizes the full-length protein by 1.5oC [240]. Also, 
compound Phikan 083, which reportedly binds to a mutation induced crevice in the Y220C 
p53 mutant, stabilized the protein by < 2oC[187]. However, most of the peptides did not 
invoke much change in the melting temperature of p53 in the thermal shift assay, and could 
possibly stem from the use of purified p53QM-FL, which may not be ideal as peptides may 
only interact optimally during p53 translation, or require structural defects present only in 




mutant proteins. Furthermore, the stabilizing mutations in p53QM may cause the protein to 
be excessively stable, preventing the discernment of induced stabilizing effects. The 
apparent activity of Pap-VRH in this case could be due to the fact that it was selected for the 
R273H mutant, which has a similar structure to wild-type and QM p53 protein.  
The collective analysis of in-vitro data presented in this chapter suggests that all the 
peptides interacted with p53, and can be further categorized, preliminarily, based on the 
basis of interaction. Peptides Pap-SPT, Pap-MPH and Pap-ILN may be targeting either N-, or 
C-terminal domains, and hence, did not actuate any observable conformational changes (in 
Pab240/Pab1620 and protein Tm). Conversely, Pap-RLQ, Pap-VRH and Pap-TAL could be 
interacting with the core domain region of the protein causing a change in the presence  of 
Pab240/Pab1620 eptiopes, and in the case of Pap-VRH, a change in the thermal dynamics of 
the protein fold. In many of these experiments, data pertaining to non-specific peptide-
mutant pairs were included as negative controls (for example G245S and Pap-ILN) as the 
peptide interaction/activity were initially believed to be mutant specific. However, results 
here (and in Chapter 7) show each peptide may exert activity on different mutants, 
prompting a model of peptide-induced reactivation in which compounds act on similar 
elements present in different p53 mutants (discussed in Chapter 9).




6  Development of qPCR p53-DNA binding assay 
6.1 Introduction 
As a transcription factor, one crucial determinant of p53’s binding affinity to distinct 
response elements is the DNA sequence of each recognition site itself [41]. This is seen in 
the significant degeneracy across p53’s recognition sites in the human genome, and is 
evidence of intricacy and regulation of the p53 response at the level of DNA binding [241]. 
The most commonly used in-vitro methods for determining p53-DNA binding include the 
electrophoretic mobility shift assay (EMSA)[242] and DNA footprinting [243]. The complex 
nature of these assays, coupled with the use of radioisotopes for optimal results has led to 
the development of safer, more facile alternatives. Jagelska and co-workers reported an 
ELISA-based technique (which involves the use of biotinylated REs to capture p53-DNA 
complexes on streptavidin plates [76]) which we have implemented in our preliminary 
assessment of peptide activity (Chapter 3). However, the limited detection threshold 
inherent to the technique, confounded by the use of bacterial IVT extracts calls for a more 
suitable and sensitive assay. A more quantitative variation of the plate-ELISA technique has 
also been described using microspheres and flow analysis [244]. Other techniques include 
surface plasmon resonance (SPR) [245],  and fluorescence anisotropy [21,41]. Whilst 
powerful and insightful, these methods require expensive instrumentation, are laborious, 
and often harbor inherent technical restrictions that preclude characterizations involving 
both endogenous or bacterially expressed/purified full length p53 protein. 
The method developed here essentially inverts the configuration of the ELISA assay, to allow 
for accurate quantification of the bound RE via real-time PCR. The outline of the binding 
assay is shown in Figure 6.1. Specifically, DNA carrying a RE sequence is added to IVT-
expressed p53 and allowed to equilibrate. Protein-DNA complexes are then captured on 




beads coated with an antibody targeting p53 that does not disrupt DNA-binding, and bound 
DNA is eluted off the beads after a series of washes to remove weak and non-specific 
binding. The DNA eluates are then quantified via real-time PCR. The results show a method 
that allows sensitive detection of p53-DNA binding within half a day, without recourse to any 
protein purification. Much of the work described in this chapter has been recently published 
[246]. 
6.2  Materials and Methods 
6.2.1  Synthesizing response element PCR fragments 
Response elements were appended onto the 5’ end of a 110 bps DNA fragment 
(corresponding to region 5010 to 5120 on  pET-22b(+)) by PCR using either one of primers 
p21-PET-F2, PUMA2-PET-F2, RGC-PET-F2, P2XM-PET-F2 (Table 2.5, Section 2.1.3) along with 
primer WPet-R1 and pET-22b as template. The resultant constructs harbor a unique RE 
tagged to a conserved sequence that is amplified during the real-time quantification phase 
of the assay (Figure 6.2). The control DNA fragment used is the exact same PCR fragment but 
lacking a 5’ response element sequence, synthesized using primers WPET-R1 and PET-F2. 
6.2.2  p53-DNA binding beads assay (Ab-beads) 
Protein G coated magnetic beads (Dynabeads® Protein G, Invitrogen) were 
incubated with DO-1 antibody (1 ug per 10 μl of beads) in a 1% BSA-PBS solution at room 
temperature for 2 hours on the rotator, washed twice with 200 μl PBST (PBS with 0.1% 
Tween 20), and aliquoted out accordingly for use in the binding assay.  
After protein synthesis was carried out using an IVT system (as described in Section 2.3.4), 2 
μl of 6x p53 binding buffer 2 (150 mM sodium phosphate, pH 7.2, 600 mM KCl, 24 mM DTT) 
was added along with required amount of response element (or control) construct, and 
reactions were incubated at room temperature for a further 30 minutes.  










For each set of experiments we used the control construct as a measurement of non-specific 
binding by p53 and non-specific binding of DNA to the beads. The total molar concentration 
of all DNA elements (RE or control DNA) was fixed at 36 nM. Data points involving REs 
consist of the respective concentration of RE construct added to the required amount of 
control DNA such that the molar concentration always add up to 36 nM (eg. 4.5 nM of RE 
added to 31.5 nM of control DNA to give a total DNA concentration of 36 nM). In this 
manner, the total molar concentration of DNA exposed to the protein is held constant across 
all experiments. Additionally, this significantly reduces the number of background control 
DNA reactions required. 
5 μl anti-p53 antibody (DO-1) coated beads were then added and the bead-reaction mixture 
incubated for 1 hour at 4oC with constant rotation. The beads are then washed to remove 
non-specifically bound response element/DNA control constructs. We have explored 
different ways of washing the beads and found that vortexing gave the most consistent wash 
across samples. For these sets of experiments, washing was done in 200 μL PBST with 
vortexing at 1600 rpm for 6 seconds on the MS2 Minishaker (IKA) followed by one further 
wash in 200 μl PBS (1600 rpm, 5 seconds). After washing, the beads are resuspended in 20 μl 
nuclease-free water, and the DNA eluted by heating the beads at 95oC for 5 minutes. After 
heating, the tubes were removed from the heat block and quickly chilled on ice for 20 
seconds before removal of the supernatant. 5 μL of this eluate is used for subsequent real-
time PCR analysis (Figure 6.3). 
 6.2.3  p53-DNA binding multiplex assay 
For the multiplex assay, the protocol remained unchanged apart from the binding, 
and elution steps. p53wt-Δ22 protein was synthesized and added into a total binding volume 
of 65 μl (equivalent to 5 binding reactions, with all components scaled up proportionately), 
containing 9 nM of each of the 4 REs (PUMA-BS2, p21 3’ site, RGC, and P2XM). Due to the 




increased volume of the binding reaction, we eluted the DNA into 50 μl of nuclease-free 
water. 
6.2.4  p53-DNA binding plate assay (Ab coated plate)   
 In reconfiguring the p53-DNA binding assay from the antibody-bead format to the 
antibody-plate format, the protocol remains largely unchanged apart from the binding and 
elution steps. The procedure for coating antibodies by adsorption onto polystyrene 96-well 
plate is described in Section 2.3.2. After the 30 minutes incubation step where p53-DNA 
complexes are allowed to form, the mixture is transferred directly onto DO-1 coated 96-well 
plate containing 30 μL (per well) of pre-chilled plate layering buffer, and incubated for an 
hour at 4oC on a shaker. The binding mixture is then removed and the wells are washed 
three times in WB1, three times in WB2 (200 μL wash volume) and dried. The captured DNA 
is eluted by adding 20 μL of 150 mM NaOH (10 minutes incubation at room temperature), 
followed by the sequential addition of 23 μL of 150 mM HCl, and 20 μL of 50 mM Tris-Cl (pH 
7.4) to neutralize the pH. 5 μL of this eluate is used for subsequent real-time PCR analysis. 
6.2.5  Real-time PCR and data analysis 
All real-time PCR quantification of the eluates, except those pertaining to the 
multiplex assay, were performed using 50 nM each of primers PET-F3 (5’-ATA GGC GCC AGC 
AAC CGC ACC TG-3’) and WPET-R1 using the the iQTM SYBR® Green Supermix (Bio-Rad 
Laboratories). The PCR samples were cycled on a C1000 Thermal Cycler (1 cycle of 95 oC, (7 
minutes) followed by 50 cycles of 95oC (5 seconds), 55 oC (30seconds)) and signals quantified 
via a CFX96 Real-Time System CCD camera (Bio-Rad Laboratories). Data were collected from 
3-4 separate binding experiments, and were interpreted as fold differences (calculated 
based on cycle threshold differences) over non-specific DNA binding control included in each 
experiment (control DNA fragment only). For the multiplex assay, 100 nM of each forward 




primer, PumaBS2_short_F (5’- CGC GCC TGC AAG TCC TGA CTT G-3’), P21_short_F (5’- TAG 
AGG AAG AAG ACT GGG CAT GTC TG-3’), RGC_short_F (5’- CAC ATG CCT TGC CTG GAC TTG 
CC-3’), and P2XM_short_F (5’- CTT GGG AAC AAG GGC ATG AGC TTG T-3’), were used, with 
100 nM of reverse primer Wpet-R1, to detect for the amount of respective RE present in the 
eluate. Results for the multiplex assay were normalized to the weakest binding RE by 
assigning an arbitrary value to the C(t)(cycle threshold) value. C(t) values for the remaining 
REs were calculated, and interpreted as fold-difference over binding to the weakest RE, 
accordingly.  
6.3 Results and discussion 
6.3.1 Constructing DNA response element and qPCR tag for real-time PCR quantification 
 The DNA recognition element used in this assay was constructed by PCR amplifying a 
non-coding region of the PET22b plasmid (several hundred bps upstream of the T7 promoter, 
(Figure 6.2A) and consisted of a qPCR tag (for subsequent real-time quantification) with a 20 
– 30 bps p53 RE appended onto the 5’ end using a suitable forward primer with the 
respective 5’ overhanging sequence (Figure 6.2A). Two sets of oligo-nucleotide primers are 
critical in this assay; one for the synthesis of the DNA construct, and a second for priming the 
qPCR tag (Figure 6.2A). After a brief optimization to identify primer pairs suitable for real-
time PCR amplification (Section 10.2), primers PET-F3 and Wpet-R1 were selected. The RE 
appended DNA fragment was constructed by PCR amplifying a portion of the PET vector 
using the PET-F2 forward primer with a 5’ RE overhang (either p21 3’ site, PUMA-BS2, or 
P2XM[21]) and WPET-R1 reverse primer (Section 2.1.3, Table 2.5). This gave a PCR fragment 
of approximately 150 bps (Figure 6.2B). A control DNA fragment (con-DNA) was also 
synthesized using the Pet-F2 primer without attached RE sequence (~120 bps, Figure 6.2B). 
The final DNA constructs were then column purified and quantified using a 
spectrophotometer before being used in further experiments. 











6.3.2 Development and optimization of assay protocols 
 In a real-time PCR measurement, the fluorescence signal (from Sybr green binding to 
DNA) is quantified at the end of every thermal cycle as the dsDNA doubles in quantity. As 
the amount of fluorescence signal increases, it crosses a detection threshold into an 
exponential linear phase. The C(t) (cycle threshold) value measures the amount of cycling 
required before a given DNA sample enters this exponential phase and is directly 
proportional to the amount of starting DNA template available (Figure 6.3A). This DNA 
binding assay quantitates, essentially, the amount of DNA (with or without appended RE) 
bound to p53. As the qPCR tag within each of the RE construct does not discern between 
con- and RE-DNA, sequence-specific DNA binding is measured by comparing cycle-threshold, 
C(t), differences when p53 is incubated with equi-molar concentrations of either con- or RE-
DNA. The data is represented as an increase in fold-difference binding over con-DNA control. 
Figure 6.3A is an example of real-time PCR data showing duplicate measurements in which 
interaction between p53 and RE1 (C(t)∆1 = 8 -fold difference) gave a stronger sequence-
specific DNA binding then with RE2 (C(t)∆2 = 4-fold difference). 
After a successful proof-of-concept measurement using IVT-translated p53wt-∆22 following 
several refinements in the wash procedure and p53 binding buffer used (Section 10.3), p53 
sequence-specific DNA binding was characterized using different concentration of REs. The 
difference in concentration of RE-DNA was always balanced using control-DNA, such that the 
DNA molar concentration was always kept at 36 nM (i.e. 0 nM RE + 36 nM con-DNA, or 18 
nM RE + 18 nM con-DNA). Due to the sensitivity of this assay, a real-time PCR measurement 
was performed to ensure that the relative concentrations of the DNA-mixture inputs are 
kept constant (using ~18 pg of DNA template) (Figure 6.3B). Additionally, melt curve analysis 
was conducted and showed that the all the real-time PCR signal came from a single PCR 
product with a Tm of 88.50
oC (Figure 6.3C). 










6.3.3 Measurement of full length wild-type p53 binding to physiological REs 
The binding of bacterially expressed full-length p53 (p53 wt-FL) to a consensus RE is 
not observed using conventional in-vitro DNA binding assays [76,161]. This form of p53 
represents the inactive, latent state which intrinsically displays low affinity to REs [75,159]. 
Therefore, the sensitivity of the assay was first ascertained using variable amounts of p53 
wt-FL and two physiologically relevant REs; the 3’ recognition site of cyclin dependent kinase 
inhibitor, p21, which regulates cell-cycle arrest [247], and PUMA-BS2, a high affinity binding 
site of the pro-apoptotic effector protein PUMA (PUMA-BS2) [248]. At the lower 
concentration of p53 wt-FL (approximately 40 nM), weak binding to PUMA-BS2 was 
observed at all concentrations of RE used (~ 2.5 -fold increase over control) (Figure 6.4). 
Contrastingly, p53wt-FL bound with similar affinity to the p21 RE at 4.5nM (2.5-fold increase 
over control), which increased to ~8 -fold when the concentration of the RE was highest at 
36 nM. When the amount of p53 was doubled, a dose-responsive increase in binding to both 
RE’s was observed at all concentrations tested. Binding to the PUMA-BS2 RE increased 
significantly, ranging from 5 -fold over control at 4.5 nM to 17 -fold at 36nM. At the higher 
dosage of p53wt-FL, there was only a slight difference in binding to the two RE’s, most likely 
due to an excess of p53 masking true differences in affinity. We therefore used the lower 
amount of p53 in all subsequent assays.  
To ensure that the differences in C(t) values are a true reflection of DNA eluted in a p53-
dependent manner, binding experiments were repeated as before (20 nM of p53wt-FL 
protein and 36 nM of DNA), but using either un-coated beads, or beads coated with a p53 
non-specific monoclonal antibody (2A9, anti-Hdm2 antibody). The results show almost 
identical C(t) values between p21 RE-DNA and con-DNA samples (Figure 6.5A), suggesting a 
p53-dependent sequence-specific binding in earlier results. Structural coordination of the 
zinc atom and proper folding of the p53 core domain requires a strong reducing  










environment, and is typically reflected in the high levels of DTT additive in p53 buffers (3 – 8 
mM) [103]. We therefore investigated if the levels of DTT might destabilize the antibody 
structure and cause a decrease in DNA binding signal from p53wt-FL. The DNA-binding assay 
was repeated using p53 binding buffer 2 containing different molar concentrations of DTT (1, 
2, or 4 mM). A positive correlation between sequence-specific DNA binding and DTT 
concentration was observed (Figure 6.5B), suggesting that the importance of the DTT 
presence strongly outweighs any possible detriments from antibody destabilization in the 
context of this assay.  
6.3.4 Increase binding observed with ‘activated’ p53 
The results above indicated the extreme sensitivity of the assay and we next tested 
if it could discern the putative increase in binding to target REs of an “activated” form of p53 
compared to latent p53. The unstructured carboxyl terminal domain (Ctd) of p53 (residues 
356 – 394[249]) has been postulated to play an auto-inhibitory role by sterically interfering 
with the core domain’s ability to interact with DNA recognition elements [75,159]. A well 
established method to ‘activate’ the otherwise latent state of bacterial expressed full length 
p53 protein, for use in in-vitro assays, is to either delete the C-terminal domain, or activate it 
with monoclonal antibodies (Pab 421, Bp53-10.1) [75,76,159,250]. A C-terminal deletion 
variant was chosen (p53wt-Δ22, lacking residues 372 – 393) to represent ‘activated’ p53. 
When equal amounts (~20 nM, Figure 6.6A-inset) of full-length and C-terminally deleted p53 
proteins were used in the binding assay, an increase in binding to p21 3’ site and PUMA-BS2 
REs was observed for the latter (Figure 6.6A). A 19 -fold increase in binding to p21 3’ site RE 
(36 nM concentration) over control was observed for p53wt-Δ22 compared to ~8 -fold for 
p53wt-FL. Binding to the same concentration of PUMA-BS2 increased from 2.8 -fold (p53wt-
FL) to ~29 -fold (p53wt-Δ22). The results are consistent with previous data indicating 
increased binding affinity of p53 core-domain to PUMA BS2 over P21 3’ site (KD = 7.1±1.8  
















and 12.0±7.0, respectively) [21]. Additionally, comparison of the binding ratios of p53wt-FL 
over p53wt-Δ22 for each RE indicate the pronounced effects of p53 activation on binding to 
PUMA-BS2 (10.4 -fold relative increase) compared to p21 3’ site ( 2.4-fold relative increase) 
(Figure 6.6A).  
As the carboxyl domain of p53 has also been described to play a part in binding DNA non-
specifically [35,64,166], we investigated if the phenomenon was detectable in this assay and 
how it may affect the relative binding differences between full-length and c-terminal 
truncated p53. The binding reaction was repeated as before, but with 36 nM of control DNA 
only, and compared the amount of non-specific DNA bound between p53wt-FL and p53wt-
Δ22 when subjected to either the normal washing conditions used throughout this study, or 
a reduced stringency wash (halved vortex duration). The results showed that p53wt-FL did 
bind more strongly to non-specific DNA then p53wt-Δ22 (~21 –fold increase), but this 
interaction was weak and was completely removed under the wash conditions used in this 
study (Figure 6.6B).This indicated that the effects of non-specific binding via p53’s carboxyl 
terminal was unlikely to manifest in our results, and that the DNA binding measured was 
primarily sequence-specific. 
6.3.5 p53wt-Δ22 binds different physiological response elements over a dynamic range 
The assay was further validated by investigating the binding of p53wt-Δ22 to other 
physiological REs, representing different affinities in the p53 binding spectrum. Specifically, a 
moderate (ribosomal gene cluster recognition site, KD = 18.0[34])  and a weak binding RE 
(P2XM recognition site,[251] KD = 221±41[21]) were chosen. P53wt-Δ22 gave a very modest 
response to the P2XM response element, giving an ~2.5 -fold increase at the lowest 
concentration of RE (4.5 nM) and only reaching an ~3 -fold increase at the highest dose of RE 
(36 nM) (Figure 6.7), a stark contrast to the 29-fold increase seen with the PUMA-BS2 RE. 
The low affinity of the P2XM RE to p53 has been previously reported by Weinberg and 




colleagues (apparent KD estimated to be 221±41 nM for binding to p53 core domain)[21] 
(Table 6.1), and is consistent with the findings here. Likewise, the RGC response element 
showed a dose responsive binding to p53wt-Δ22 at a moderate strength, starting off with a 2 
-fold binding increase at 4.5 nM, which rose to ~9 -fold increase at 36 nM of RE (Figure 6.7). 
This is also consistent with another previous study on p53 core domain binding affinity 
(reporting an estimated KD of 18.0 nM for the RGC RE[34]), placing the RGC RE as a moderate 
affinity response element, hierarchically below the p21 3’ site and PUMA-BS2 RE, but above 
the P2XM RE (Table 6.1). Notably, both studies have reported a similar KD for the p21 5’ site 




























GAACA TGTCC CAACA TGTTG 4.9 ± 0.6[21] 
7.0[34] 
Not assessed in 
this study 




CGCGC CTGCA AGTCC TGACT TGTCC GCGGC 7.1 ± 1.8[21] 28.7 ± 4.3 91.7 ± 5.4 
p21 3’ 
site 
TAGAG GAAGA AGACT GGGCA TGTCT GGGCA 12.0 ± 7.0[21] 19.1 ± 1.0 101.6 ± 7.8 
RGC TGCCT TGCCT GGACT TGCCT 18.0[34] 8.8 ± 1.9 14.3 ± 0.7 
P2XM CTTGG GAACA AGGGC AT GAGCT TGTCT GGGCT 221 ± 41[21] 2.9 ± 1.1 1.0 ± 0.2 
Table 6.1 – Hierarchical comparison between p53 fold-increase binding (individual and multiplexed binding 
assays) and previous published apparent equilibrium dissociation constant (KD) of REs used in this study. 
Shaded boxes show nucleotide sequence of decamer half site. 
 
6.3.6 Measurement of RE binding by full length mutant p53 proteins 
Some 95% of p53 somatic tumorigenic mutations lie in the DNA binding core domain. 
Of these, 75% are the result of single nucleotide missense mutations, leading to a single 
amino-acid substitution. When a missense mutation causes the substitution of a functionally 
critical amino acid it can completely abrogate p53’s ability to recognize and transactivate 
target genes [62,96,97,252]. 4 of the most commonly occurring p53 mutants were selected  










to represent the different functional classes of p53 core binding domain mutation: a DNA 
contact mutant retaining native structure (R273H), a DNA contact mutant with a distorted 
structure (R248Q), a weakly destabilized mutant (G245S), and a globally denatured mutant 
(R175H)] [96,97]. All have been shown to be non-functional both in vivo and in vitro 
[88,97,113,170,252,253]. At the same maximum concentration of RE used for previous 
experiments (36 nM), none of the full length p53 mutants bound significantly to either the 
p21 3’ site or PUMA-BS2 response element (Figure 6.8). Mutants R175H, R248Q, and R273H 
showed extremely low binding signals (< 1-fold over non-specific control DNA binding) for 
both p21 3’ site, and PUMA-BS2 REs. The G245S mutant showed some residual binding to 
the REs (1.8 ± 1.1 -fold increase for p21 3’ site RE, and a 1.4 ± 0.8 -fold increase for PUMA-
BS2 RE) (Figure 6.8). A similar phenomenon has been previously observed by Bullock and 
colleagues who reported a 67% retainment of binding between p53 core domain harboring 
the G245S mutation with the gadd45 RE, which was not seen with the other mutants tested 
(R248Q, R273H, and R175H showed no traces of binding) [97].  
6.3.7 Multiplex assay of p53 binding to 4 REs with different affinities 
After having ascertained the assay’s reliability in accurately discerning binding of p53 
to 4 different response elements individually, the utility and sensitivity of the system was 
further demonstrate by reconfiguring to a multiplex assay. P53wt-Δ22 was incubated with 
9nM each of 4 REs (PUMA-BS2, p21 3’ site, RGC, and P2XM). To detect for the relative 
amounts of RE bound, forward primers that only complement the respective REs (Figure 
6.2A) were used along with a common reverse primer (Wpet-R1). To ensure that each 
primer pair worked properly, two control real-time PCR analyses were conducted to address 
issues of priming efficacy and possible cross reactivity. Similar C(t) values (threshold cycle) 
were obtained when real-time PCR was conducted on each primer pair with equal 
concentrations (50 pM) of the respective RE template (Figure 6.9A-left), indicating  










comparable amplification efficiency of each primer pair. Additionally, melt curve analysis of 
the resulting PCR product indicated the presence of only one PCR product (Figure 6.9A-right). 
To ensure that each primer pair will only amplify its respective RE from a pool of REs 
(possible cross reactivity of forward primer), a series of control real-time PCRs were 
conducted, where each reaction contained a specific RE template with a mixture of all 
forward primers, except the one specific for the template. The results indicated no cross-
reactivity (data not shown). The multiplex binding assay results indicated significant binding 
for both the PUMA-BS2, and the p21 3’ site REs when normalized to the weakest binder, 
P2XM (91.7±5.4 -, and 101.6±7.8 –fold binding increase over P2XM, respectively). RGC gave 
an intermediate response with ~14.3±0.7 –fold binding increase over P2XM. The multiplex 
assay results yielded a trend in agreement to the individual RE binding assays (Figure 6.9B), 
and previous reports of the apparent equilibrium dissociation constant, KD (Table 6.1).  
6.3.8 Increased target DNA binding of full length p53 using an activating peptide 
Reactivation of mutant p53 present in around 50% of all human cancers [9,241] 
represents an attractive means of therapy [136,156,177]. Conversely, potentiation of the 
activity of the wild type protein present in the remaining cancers is also being investigated 
[136]. To this end, several small molecules and peptides have been described that can either 
structurally stabilize or (re)activate p53 mutants both in-vitro and ex-vivo 
[161,170,177,187,188]. The effect of peptide 46, which has previously been shown to 
‘activate’ the otherwise latent binding activity of wildtype full length p53 towards a non-
physiological consensus DNA recognition sequence, was therefore tested [161]. The results 
showed a dose-responsive increase in sequence specific DNA binding of p53wt-FL when 
peptide 46 was co-incubated with 36 nM of RGC RE. At the highest dose of peptide 46 (10 
uM), a 7 -fold increase in binding to the RE was observed over the DMSO only control (Figure 
6.10).  
















6.3.9 Adaptation of p53-DNA binding assay into high-throughput plate configuration 
 As the current configuration using beads in the p53-DNA binding assay (1 microtube 
per data point) presents a technical bottleneck that prevents the sampling of multiple 
binding reactions at once, the platform was extended into a higher throughput 96-well plate 
format. The assay is the same as before, except antibodies are now immobilized on a 96-well 
plate instead of beads. The system was tested initially by measuring IVT-p53wt-∆22 binding 
to REs (p21 3’ site and PUMA-BS2) and comparing the suitability of either (i) immobilizing 
DO-1 antibodies overnight by adsorption on normal polystyrene plates, or (ii) repeating the 
assay as before but captured on pre-coated commercial protein-G plates. As high levels of 
binding was detected for both REs on the adsorption plate (similar to the beads format), but 
not on the protein-G plate (Figure 6.11A), we chose the adsorption method for future 
experiments. The weak signals from the protein-G plate could be due to the drastic 
reduction in surface area switching from beads to plate configuration (beads = ~10 cm2, 
plate = 0.32 cm2). To optimize the wash steps, DNA binding between IVT-p53wt-∆22 and 
both con-DNA and p21 RE-DNA was compared under different wash conditions (either 1 or 3 
washes of 200 μL wash buffer during each step). The results showed no difference in C(t) 
value between wash conditions (Figure 6.11B), suggesting that background signals are 
significantly lower than before, and that formed DO-1-p53-DNA complexes are associating 
tightly, and are resilient to increased washing. Next we measured DNA binding between IVT-
p53wt-∆22 to p21 3’ site and PUMA-BS2 over a range of p53 protein concentrations (15 nM 
– 180 nM). The results showed a p53 protein concentration-dependent increase in binding 
to both REs that peaked between 180 – 240 nM of protein (Figure 6.12). Like before, the 
results show that IVT-p53wt-∆22 bound with higher affinity to PUMA-BS2 (37-fold increase 
at 180 nM of p53) compared to p21 3’ site (14-fold increase). Above 180 nM of p53 (or 6 μL 
of IVT), signals from sequence-specific binding to both REs seem to plateau, possibly 
indicative of an upper detection limit due to the limited surface area in each well.   

















Many p53-DNA binding studies have focused solely on characterization of the DNA 
binding core domain, and have often neglected the mainly unstructured N and C termini, as 
the presence of these domains significantly destabilizes the protein [61] (possibly by causing 
protein aggregation), and also retain p53 in a latent, low-affinity DNA binding state [61,75] 
which may be below the detection threshold. The assay we describe is sensitive enough to 
detect dose responsive binding between the latent wildtype full length protein (synthesized 
in a prokaryotic expression system) and several biologically relevant response elements. We 
have demonstrated that the strong binding between wildtype p53 and two of the high 
affinity REs (p21 3’ site and PUMA-BS2) is not observed in mutants with known 
compromised sequence-specific DNA recognition functions, and can also be further 
enhanced by deleting the carboxyl terminal end of the protein, hence ‘activating’ the protein. 
Notably, consistent with a separate binding study conducted using G245S-core domain on 
the gadd45 response element [97], our binding data for the mutants indicated residual 
binding only with the weakly destabilized structural mutant G245S. The trend for binding 
affinity seen in the 4 REs that we have chosen also agrees with previous reports detailing 
their equilibrium dissociation constants, thus further validating our method. 
The use of freshly synthesized p53 (made in an expression system containing only the 
minimum essentials of the transcription/translation machinery) that has not been post-
translationally modified can provide valuable insights into the unadulterated dynamics of 
p53’s ability to recognize and bind target DNA. Our study using p53wt-Δ22 on the p21 3’ site 
and the PUMA-BS2 recognition site indicates a possible inherent mechanism of regulating 
cell fate. Latent p53’s ability to bind the PUMA-BS2 RE remained low at all RE concentrations, 
contrary to the p21 3’ site binding, which showed a dose-responsive increase. However, 
when ‘activated’ p53 was used, a marked  10.4 -fold increased binding over latent p53 was 




observed for the PUMA-BS2 RE compared to only 2.4 -fold for the p21 3’ site RE (Figure 
6.6A). This significantly increased “induction-potential” highlights the role of subtle changes 
in RE sequence that regulates p53 binding. Our data also show the importance of comparing 
the binding activities of both latent and ‘activated’ p53 when characterizing REs as use of 
only the latter may not discern physiologically relevant variation in binding properties (the 
reported KDs for PUMA-BS2 and P21 3’ site binding to ‘activated’ p53 core domain are very 
similar-Table 6.1) 
Furthermore, the binding data seem to further reiterate an “all or nothing” scenario wherein 
p53 directs cell death through transactivation of pro-apoptotic genes (such as PUMA), only 
in the most dire of situations (irreparable cell damage) upon post-translational activation. 
On the other hand, the process of recognizing and binding to the p21 RE which directs the 
comparatively less drastic fate of cycle arrest in-vivo, is not as variant between latent and 
‘active’ p53, and proceeds in a simple concentration dependent manner.  
As a technique, the method of studying protein-DNA interactions described here presents 
several beneficial alternatives to other various different methods presently available. One 
immediate advantage is its ease to perform compared to others, specifically techniques that 
require work with radio isotopes like gel shift assays. As it is a quantitative PCR-based 
method, it can amplify and generate readouts from exceedingly small copy numbers of RE 
DNA template. This tremendous sensitivity allows the system to tolerate the presence of 
other proteins, hence allowing the use of IVT systems (and possibly nuclear extracts to study 
in vivo transactivation of p53 in the future), and obviates the need to purify the protein of 
interest. Additionally, our success in adapting the p53-DNA binding assay into a 96-well plate 
configuration has resulted in a technique that significantly champions others in areas of 
sensitivity, throughput efficiency and cost-effectiveness. There is much potential for this 




assay to be developed into screening platforms for drug development, protein selection, or 
profiling of protein-DNA interactions.  
The data from the multiplex assay demonstrates its capacity to accurately discern varying 
extents of p53-DNA interaction in the face of rigorous competition, and highlights some 
promising attributes of this system. The dynamic range attainable by this assay immensely 
exceeds those of traditional techniques like EMSA, and ELISA-based protein-DNA binding 
assays (>100-fold difference between 2 physiologically functional response elements, i.e. 
p21 3’ site and P2XM) (Figure 5). In order to adequately represent the different degrees of 
interaction, a key criterion in assays involving large screens, and numerous interacting 
partners (especially the case for p53 and its response elements) is a large dynamic range. 
Based on the data here, there is potential for the multiplex assay to be extended to 
incorporate larger numbers of REs involved in the p53 pathway. A possible obstacle will be 
the method of detection, as it won’t be technically feasible to prime similar RE sequence 
separately for PCR detection. A solution would be to design target DNA probes comprising 
unique tag sequence flanking an RE site. An alternative approach would be to use array-
based methods for detection and quantification of bound REs. Many methods, particularly 
those involving massive screens, utilizes direct immobilization of either protein or DNA on a 
solid matrix (SPR, ELISA-based protein-DNA binding assay, and microsphere assay for 
protein-DNA binding) which invariably causes steric obstructions during protein-DNA 
interaction, and does not accurately depict true interactions in solution. One major 
consideration in our assay design was to allow the step involving protein-DNA complex 
formation to occur in solution, thus being more representative of a cellular milieu. 
The use of an IVT component in this system does not stem entirely from convenience and 
presents several strong advantages of its own. Users can potentially introduce additional 
protein components to a system of interest by simply obtaining a cDNA gene and using that 




in the IVT, avoiding time spent on optimization and purification. However it should be noted 
that not all eukaryotic proteins (especially those requiring extensive post-translational 
modifications) are active when expressed in vitro. The use of IVT also allows the study of 
proteins that are unstable or have short half-lives as the window between protein synthesis 
and experimental usage is negligible. Furthermore, using an IVT system offers the option of 
assaying during translation of p53, an attribute potentially invaluable in the area of 
screening for reactivating compounds, and which cannot be realized by using purified 
proteins.  
In a bona fide cellular system, p53’s decision between the selection and transactivation of 
different target genes leading to specific cellular phenotypes would involve a host of 
complexities, including cell type, the type and extent of stress stimuli, extent of protein level 
stabilization, the site and nature of post-translational modifications, protein co-factors[254] 
and chromatin remodeling events (for a review see refs. 5-6.). The use of this assay to study 
p53, or any transcription factor for that matter, and the possibility of expanding its utility 
into an all encompassing multiplex system, provides an insightful, albeit incomplete, 
rudimentary perspective into the mechanism of protein-DNA association, and should be 
interpreted holistically with other in vitro, and cell based data to provide an authentic 
depiction of p53’s modus operandi. 




7   Characterizing compound reactivation potential using qPCR p53-
DNA binding assay 
7.1 Introduction 
 The Y220C mutation in p53 results in the loss of wild-type structure due to the 
formation of a solvent accessible crevice that lies on the opposite side from the DNA binding 
surface. This mutation-induced structural lesion is hence, an ideal target for virtual modeling 
of small molecules that can bind to and stabilize the Y220C mutant [188]. Phikan 083 (PK083, 
Figure 7.1A) is a water soluble, carbazole compound that was identified through an in-silico 
virtual screen of approximately 24.8 million low molecular weight structures, based on 
crystal structure data of the Y220C mutant, and the propensity of the molecules to bind and 
stabilize the mutant [187]. Subsequent biophysical characterization revealed co-crystal 
structure of PK083 plugging the mutation-induced crevice of the Y220C protein (Figure 7.1B), 
associating with a KD of 140±73 μM and inducing a thermal stability of ~2
oC [187]. However, 
there are currently no other published data for PK083 induced reactivation of Y220C mutant.  
As part of an ongoing collaboration with the group that developed the Phikan compounds 
(Alan Fersht, Cambridge, UK), the qPCR p53-DNA binding assay was used to determine the 
activity of PK083. Additionally, several other more potent carbazole derivatives were also 
provided to us for comparison. PK209 (acyclic aliphatic sidechain substitution) and PK214 
(amine containing aromatic sidechain substitution) were identified through rational design 
by substitution of the amide sidechain on PK083, for larger and more rigid structures (Figure 
7.1A). Both PK209 and PK214 were shown by our collaborators to associate at the expected 
site on Y220C-core domain using x-ray crystallography (data not shown), with increased KD of 
107±34 and 80±13, respectively. Lastly, two more compounds were also provided, PK784 
and PK5176, which were reportedly more active than the other Phikan molecules described 
before. However, due to certain legal issues (patent pending), further information could not 
be provided. The use of the above Phikan compounds to measure p53 reactivation (in terms  










of sequence-specific DNA binding) has the added benefits of providing a comparative 
benchmark against which the activity of the selected peptides  can be assessed, as well as to 
further demonstrate the utility of the qPCR p53-DNA binding assay. 
7.2  Material and methods 
7.2.1  Nanop53-DNA binding plate assay (Strept-plate) 
 This procedure is identical to the p53-DNA binding assay (Ab-plate) configuration 
apart from two steps. The expression constructs used for IVT protein synthesis should have a 
nano-tag sequence appended on the 5’ end of p53’s cDNA (expression constructs used are 
PCR amplified from the pET-22b(+)-NTp53wt-FL/pET-22(+)-NTp53wt-∆22, or mutant p53 
vector derivatives). Additionally, commercial streptavidin plates (Reacti-BindTM Streptavidin 
Coated, High Binding capacity, Thermo Scientific) were used instead of antibody coated 96-
well plates. The reasons and procedure behind reconfiguration of the DNA binding assay are 
described in Section 7.3.3. 
7.2.2  Nanop53 pulldown using streptavidin beads 
 This procedure was similar to the IP assay described in Section 4.2.2 apart from 
several changes. P53 IVT expression constructs used were PCR amplified from the vector 
pET-22b(+)-NTp53wt-FL, and carried a gene encoding nano-tagged p53 protein. Additionally, 
instead of antibody-coated protein G beads, streptavidin beads were used (beads were 
washed once in 200 μL WB1, and blocked for 2 hours in 3% BSA/PBS before usage). After 
protein elution, samples were western blotted and probed with the DO-1 antibody as 
described in Section 2.3.3.  
  




7.3 Results and discussion 
7.3.1 Control sequence-specific DNA binding of IVT synthesized p53wt- and p53Y220C-∆22 
 Before investigating the effects of the Phikan compounds on p53 Y220C mutant, 
levels of residual sequence-specific DNA binding from IVT-p53Y22C-∆22 were first 
established. Because the Phikan compounds were selected, and have been shown, to 
interact specifically with the core domain of p53, the c-terminal truncated p53-∆22 was used 
instead of full-length protein for the binding measurements. In vitro expressed p53-∆22 was 
used at a final concentration of ~150 nM in a control DNA binding assay, and showed an 
increase of ~21-fold binding over control DNA for the p21 3’ site response element, and a 
~37-fold increase for the PUMA-BS2 response element. In contrast, residual sequence-
specific DNA binding from the structurally compromised Y220C mutant was marginal, giving 
only a 1.7-fold increase for the p21 site, and a 0.9-fold increase for PUMA-BS2 site (Figure 
7.2A). To further validate the DNA binding assay and profile the functionality of IVT 
expressed p53, the same binding assay was performed but titrated across 30 – 300 nM of 
p53wt-Δ22 protein. The results showed a clear p53 concentration-dependent increase in RE 
binding for both the p21 3’ site and PUMA-BS2 response elements, which respectively 
showed between ~4 to 20-fold, and ~8 to 42-fold increases over the range sampled (Figure 
7.2A). A previous in-vitro study of mutant p53 DNA binding using SPR reported the Y220C 
mutant core domain retaining considerable levels of wild-type sequence-specific DNA 
binding (17% of wild-type at 37oC, and 45% of wild-type at 20oC to Gadd45 RE) [97]. The 
possibility of increasing sequence-specific DNA binding by increasing the amount of Y220C-
Δ22 mutant protein was hence tested. The assay was conducted using 60 nM, 120 nM, 180 
nM, or 300 nM of IVT-Y220C-∆22 protein. The results show that up to the maximum 
concentration of Y220C-Δ22 tested, there was no significant increase in binding (1-fold 
increase for both REs at 300 nM) (Figure 7.2B). The apparent disparity of sequence-specific  










DNA binding from the Y220C mutant could be attributed to a variety of factors; including (i) 
the temperature and method of synthesizing p53 protein, (ii) the technique and RE used for 
determining sequence-specific DNA binding, and (iii) the difference in binding response 
between core domain and C-terminally truncated p53 variants. 
7.3.2 Measuring Phikan compounds dependent reactivation of Y220C p53 mutant using 
qPCR p53-DNA binding assay (Cosmo IVT) 
To investigate the reactivation effects of the Phikan compounds, each compound 
was added at varying concentrations to ~70 nM of IVT expressed Y220C-Δ22 in the presence 
of 36 nM of either p21 3’ site or PUMA-BS2 DNA response element. Reactivation fold 
increase was a function of sequence specific DNA-RE captured over non-specific binding of 
control DNA in DMSO blank by p53Y220C-Δ22. All 4 compounds reactivated Y220C mutant 
and reinstated sequence-specific DNA binding function to varying degrees (Figure 7.3). 
Interestingly, some compounds showed preferential activation of one RE over the other, 
mimicking to some extent the effects of mutations in p53 that alter its RE binding specificity 
[211,255] . PK083 yielded the weakest overall response, showing very weak reactivation for 
p21 binding (~1-fold increase), but a comparatively higher PUMA-BS2 binding, which gave an 
~6-fold increase over residual Y220C-Δ22 binding at the maximum drug concentration of 100 
uM (Figure 7.3A). Compound PK209 elicited moderate reactivation, increasing the binding 
for both p21 and PUMA response element to ~10-fold increase over control DNA between 
the compound concentrations of 1 uM and 10 uM (Figure 7.3B). This translated to a ~ 5-fold 
increase and a ~ 12-fold increase over residual binding of the p21 and PUMA-BS2 RE 
respectively (Figure 7.3B). PK214 and PK784 elicited the greatest reactivation of Y220C-Δ22. 
For the p21 3’ site RE, binding reactivation peaked at a drug concentration of 100 uM for 
PK214, and between 100 nM and 1 uM for PK784, showing an almost complete restoration 
in sequence-specific binding compared to p53wt-Δ22 (Figure 7.3C-D). The level of  
















reactivation in response to the PUMA-BS2 RE is similar, reaching a peak of ~22-25-fold 
increase over control DNA, translating to a 25-29-fold increase over basal PUMA-BS2 binding, 
at the concentration of 1 uM of drug (Figure 7.3D). Furthermore, the comparative extent of 
reactivation from all 4 Phikan compounds correlates well with their respective binding 
affinity (Table 1A, data contributed by Rainer Wilcken), in order of 
PK083>PK209>PK214>PK784 in terms of apparent KD. 
 
Interestingly, the DNA-binding assay seemed to be measuring Y220C reactivation at very low 
compound concentrations (around 1 – 10 μM), especially considering their much higher 
measured KDs (Figure 7.1A). A possibility of how the apparent KD of the compound can seem 
reduced may be attributed to the phenomenon of macromolecular overcrowding. This 
occurs when there are high concentrations of large background molecules (eg. Dextran 
polymers), and has been shown to artificially increase the effective concentration of reacting 
solutes by excluding solvent volumes, and hence reducing the apparent KD of solutes and 
increasing the rate of enzymatic reactions [256]. This phenomenon seems plausible 
considering the high amounts of protein present in this expression system (>2 ug/DNA 
binding reaction) [236], and how they complex into macromolecules with DNA, nascent 
protein, and mRNA chains. The effect can become more pronounced if the test molecules 
are also large (i.e. a p53 tetramer bound to a 120 bp DNA) [256], and if it homopolymerizes 
[257]. Another possibility to be considered is that a component of the expression system 
(comprising 32 proteins and ribosomes) may act as an indirect accessory factor to improve 
the kinetics of p53-RE binding.  
 
The observation that ‘reactivation’ of sequence-specific DNA binding of the Y220C mutant 
can be adversely effected by increasing the concentration of the activating compounds past 
a threshold point seems strikingly peculiar (Figure 7.3C-D; reactivation by compounds PK214  










and PK784 dropped after 1 uM). High concentrations of these compounds may be 
destabilizing the process of p53-DNA association, perhaps through altering the pH level or 
electrostatically associating with DNA through an overall dipole charge, and hence 
sequestering its interaction from p53. This may also explain the cyto-toxicity when the 
compounds are applied in tissue culture (Alan Fersht, personal communication). Another 
possibility is that a mutant p53 tetramer is activated by less than 4 drug molecules, with 
saturation giving rise to reduced RE binding. 
 
As a control, it was also investigated if Phikan compounds could interact with, and cause 
DNA to be pulled-down non-specifically, either by itself or through interacting with proteins 
present in the IVT extract. During the p53-DNA binding step; we co-incubated blank extract 
(no p53 protein present) with each of the compounds, in the presence of 36 nM of control 
DNA. Our results indicated that all the compounds had little to no effect in causing DNA to 
be captured on the plate non-specifically (Figure 7.3E), and that the responses above arose 
from reactivation of p53Y220C-Δ22. 
7.3.3 Reconfiguring p53-DNA binding plate assay 
When the binding assay, in its current configuration, was used to assess mutant p53 
reactivation using the peptides selected, the signal was extreamly weak (Section 10.4). It 
became apparent that the format of the current DNA binding assay may have adverse 
effects, or a decreased detection threshold for measuring peptide activity, due to (i) the 
presence of antibodies, or (ii) the use of conventional polystyrene plates, both of which was 
shown to interact non-specifically to many of the selected peptides (Chapter 5). The DNA 
binding assay was therefore reconfigured by introducing a streptavidin binding tag to our 
p53 constructs and the capturing matrix was replaced with commercial streptavidin plates 
(used earlier in Chapter 5). This obviated the use of both monoclonal antibodies and  




conventional polystyrene plates. To minimize any non-specific effects from introducing an 
affinity tag to our recombinant protein, we selected a 9-mer tag (termed nano-tag [258]) 
that had similar binding affinity to monoclonal antibodies (published KD = 17 nM [258]).  
 
By performing a pulldown using IVT-translated nano-tagged p53wt-FL (Nanop53wt-FL), the 
suitability of IVT expression and streptavidin interaction of the recombinant protein was first 
tested. The results (DO-1 western blot) indicated that addition of the tag did not affect IVT 
translation (similar p53 protein levels in input), and that streptavidin-beads captured only 
nano-tagged p53 and not wild-type p53 (Figure 7.4A). Using the newly configured assay, the 
sequence-specific DNA binding of IVT-Np53wt-∆22 to p21 and PUMA-BS2 response elements 
was evaluated over a range of protein concentration. The results showed increased binding 
to both REs in a p53 concentration dependent fashion with a similar trend (p21 binding 
reached >20-fold, and PUMA binding reached >40-fold) to the antibody capture format 
(Figure 7.4B and 7.2B). Additionally, binding to PUMA-BS2 reached ~50-fold over non-
specific DNA binding at 150 nM of p53 protein (compared to ~38-fold increase at 180 nM 
p53), suggesting that this configuration is more sensitive. 
 
The advantages of using Nano-tagged p53 and streptavidin coated plates were three-fold; (i) 
cost-effectiveness from precluding the use of antibodies, (ii) increased technical flexibility 
and efficiency as plates no longer need to be coated the night before, and (iii) increased 
sensitivity (seen in the results above) due possibly to increased p53 captured in the wells 
(antibodies are sterically cumbersome, and often not oriented optimally for binding when 
coated using plate adsorption technique). 
  










7.3.4 Using the Novagen EcoPro IVT system in the qPCR DNA binding assay. 
 As the quality of subsequent batches of the CosmoBio IVT extracts became 
inconsistent and increasingly inferior (~7-fold decrease in protein expression yield), we 
discontinued the supply and switched back to using the Novagen EcoPro IVT system (a whole 
bacterial lysate IVT system used in the IVC selection). The use of the more complex Novagen 
system, may provide an added advantage of better representing the cellular milieu, allowing 
us to sample p53 sequence-specific DNA binding in a more comlex setting. , and was made 
possible by the large dynamic detection range of the qPCR p53-DNA binding assay.  
 
First, p53 concentration dependent RE binding response seen before was recapitulated by 
repeating the exact binding experiment using Novagen IVT synthesized Np53wt-∆22 (Nano-
tagged p53 on streptavidin plates). Because the protein expression levels between both 
systems were relatively similar (Figure 10.7-inset), levels of p53 containing IVT extract used 
remain unchanged. After some optimization (Section 10.5), appreciable levels of RE binding 
was observed when Nanop53 was translated using 50 μM of ZnSO4 using the Novagen 
system. However, as expected, the levels of RE binding were significantly lower than before 
(due to a more complex extract), with binding to both REs reaching ~18-fold over non-
specific DNA binding at 150 nM of protein used (Figure 7.5A). We were also able to detect a 
similar, albeit attenuated, p53 concentration dependent sequence-specific DNA binding 
response for full-length p53 (Np53wt-FL), which peaked at 10-fold increase and 12-fold 
increase, for p21 and PUMA REs, respectively (150 nM of p53 protein) (Figure 7.5B). 
  










7.3.5 Measuring Phikan compounds dependent reactivation of Y220C p53 mutant using 
qPCR Nano tagged p53-DNA binding assay (Novagen IVT) 
 The reactivating potential of each of the Phikan compounds on the p53 Y220C 
mutant was revisited again, but this time using nano-tagged recombinant p53 proteins 
translated from the Novagen IVT extracts. PK5176 was the latest Phikan compound 
developed and had the highest binding affinity (data undisclosed), and we next investigated 
if the presence of PK5176 could restore sequence-specific DNA binding to IVT synthesized 
Np53Y220C-∆22. As the compound-targeted cavity was exposed and accessible even on fully 
translated p53Y220C protein, we compared the effects of the compound added either 
during, or post IVT-translation. PK5176 asserted restorative effects to IVT-Np53Y220C-∆22 
even when added post IVT-translation, giving a drug concentration dependent effect on 
reinstating RE binding. Binding for p21 RE reached 5-fold over DMSO control at 10 μM of 
drug, and ~6-fold for the PUMA RE at 100 μM of drug (Figure 7.6A). Like the PhiKan 
compounds before, variation in response to each RE is observed with PK5176, and suggests a 
drug-induced preference in binding mechanics that is possibly conformation dependent. 
Contrastingly, co-translating Y220C mutant proteins in the presence of PK5176 yielded a 
lower reactivation phenotype, with both the p21 and PUMA reaching only 2-fold over DMSO 
control at the highest dose of compound used (Figure 7.6B). Western blot analysis revealed 
that PK5176 conferred a level of toxicity to the transcription/translation system as protein 
translation was significantly reduced at 100 μM of drug (Figure 7.6B-inset). However, this 
may only partially account for the decreased efficacy of PK5176 activity, as the protein level 
is largely unaffected at 10 μM of drug (Figure 7.6B-inset), possibly indicating other factors 
involved. 
 
Next, the relative activity of the Phikan compounds was examined using the current p53-
DNA binding format. However, we decided to omit PK083 from the experiment due to its  










low activity. Additionally, an inactive analog of the compounds was also included as a 
negative control in the DNA binding measurements (PKX001). Compounds were all added 
post IVT-translation to Np53Y220C-∆22 proteins. All three compounds sampled reactivated 
Y220C p53 mutant in a concentration-dependent manner (Figure 7.7A). Control drug PKX001 
had no apparent effects on the DNA-binding capacity of Y220C across all concentrations 
sampled. As before, the diminishing effects of PK784 activity was apparent at high 
concentrations (binding dropped from ~5-fold to ~2-fold, and ~4-fold to ~2-fold when drug 
concentration was increased from 10 μM to 100 μM, for p21 and PUMA REs, respectively) 
(Figure 7.7A). Generally, the results showed a trend of activity that coincides with their 
respective binding affinities. While the results did show an element of drug concentration 
dependent response, the level of activity was drastically lower then before (Cosmo Bio IVT 
system, Figure 7.3B-D), with the maximum reactivation reaching only ~5-fold over control-
DNA binding (compared to ~25-fold from before). This attenuation in signal was expected, 
considering the increased concentration of molecules in the Novagen IVT system.  
 
The binding experiments were then repeated, but on Np53Y220C-FL instead. Compounds 
PKX001, PK784 and PK5176 were added across a concentration range (1 μM, 10 μM, and 100 
μM), to IVT-translated full-length Y220C mutant p53 and binding to RE was measured as 
before. A concentration dependent sequence-specific DNA binding response was detected 
for PK5176, which peaked at ~4-fold increase binding (over DMSO blank control) at 100 μM 
of drug used, for both REs measured (Figure 7.7B). Contrastingly, the activity of the next 
strongest drug binder, PK784, was weak, reaching a high of only 2-fold binding increase at 10 
μM drug concentration (Figure 7.7C). 
 
Notably, an interesting observation appeared upon closer observation of the relative binding 
of Y220C p53 to non-specific DNA (binding to control DNA), when in the presence of either  
















PK5176 or PKX001. The data showed, a drug concentration dependent increase in C(t) values 
(decreasing binding) in the presence of compound PK5176, but not PKX001 for both Y220C-
FL and Y220C-∆22 (Figure 7.8). This suggests that the PK5176-induced increase in sequence-
specific DNA binding seen here comes from both, an increase in RE binding, as well as a 
decrease in non-specific DNA binding (probably due to an increase in properly folded p53). 
7.3.6 Measuring p53 activating peptides reactivation of ’activated’ C-terminal truncated 
p53 mutant, using qPCR Nano tagged p53-DNA binding assay (Novagen IVT) 
Having established a benchmark for mutant reactivation using known interacting 
compounds, the activity of the selected peptides was assessed using their respective mutant 
p53. Unlike the Phikan compounds, the site of peptide-p53 interaction was not known, and 
hence, mutant p53 were IVT-translated in the presence of the peptides (over a range of 
peptide concentration; 2 μM, 20 μM, and 200 μM), thus adhering to one of the conditions 
they were selected for. Furthermore, it was shown (Chapter 5) earlier that the peptides do 
not increase protein translation (potential false positive). The panel of peptides was first 
tested on C-terminal truncated p53 mutants (~120 nM of Np53-∆22), thinking the ‘activated’ 
state might predispose the mutants to any restorative effects from the peptides. The results, 
however, indicated otherwise. Most of the peptides had little or no effects on their 
respective p53-∆22 mutants, showing basal sequence-specific binding, across all 
concentrations of peptides, comparable to DMSO blank. These include Pap-SPT (G245S-∆22), 
Pap-MPH (G245S-∆22), Pap-ILN (R273H-∆22), and Pap-TAL (G245S-∆22 and R273H-∆22) 
(Figures 7.9A-D). These results suggest that either the mutant reactivation was undetectable 
by the technique used, or was not present due either to the absence of the interacting 
region (p53 Ctd), or the required the presence of the C-terminal domain. Only peptides Pap-
RLQ, and Pap-VRH elicited an increase in sequence-specific binding to response elements for 
R273H-∆22 mutant. 20 μM of Pap-RLQ cause RE-binding to increase by 21-fold, and 5-fold,  










for p21 3’ site and PUMA-BS2 REs, respectively (Figure 7.9E). For Pap-VRH, an appreciable 
increase in RE-binding was only observed at 200 μM of peptide, and for PUMA-BS2 RE only 
(Figure 7.9F). Notably, presence of peptide-VRH and -ILN caused a significant decrease in 
protein translation at the highest concentration of 200 μM (Figures 7.9D- and F-inset). 
7.3.7 Measuring p53 activating peptides dependent reactivation of ’latent’ full-length p53 
mutant, using qPCR Nano tagged p53-DNA binding assay (Novagen IVT) 
 Peptides which appeared inactive in the previous set of experiments were selected 
and tested on their respective full-length mutants under the same experimental protocols. 
Additionally, because Pap-TAL was selected for both the G245S and R273H mutants, it was 
also tested on the R248Q mutant. The binding data showed significant levels of reactivation 
for all the mutant p53 (p53 protein used at ~120 nM) tested. Sequence-specific DNA binding 
for G245S-FL mutant increased from under 1-fold (DMSO control) to ~5-fold, and ~6-fold 
over control DNA, in the presence of 20 μM of Pap-SPT and Pap-MPH, respectively (Figure 
7.10A). Interestingly, only peptide-SPT and -MPH reactivated p53 mutant without actuating 
any preference in RE binding, possibly suggesting an interaction with p53 away from the 
core domain. The activity of Pap-TAL was very significant in restoring sequence-specific DNA 
binding, and notably, to all three mutants. Furthermore, a strong preference for binding to 
the p21 RE over the PUMA RE was seen in all the reactivated mutants. The effects of Pap-
TAL was most prolific in activating G245S-FL mutant, with a significant increase in p21 RE-
binding observed (~14-fold over control DNA) at a peptide concentration of only 2 μM 
(Figure 7.10B). At 20 μM peptide, the RE binding reached 37-fold increase and 14-fold 
increase over control-DNA, for p21 and PUMA REs, respectively (Figure 7.10B). Pap-TAL’s 
induced reactivation was relatively weaker on the other two mutants; binding to p21 RE 
peaked at 11-fold over control-DNA for R248Q-FL mutant (at 20 μM peptide) (Figure 7.10C), 
and 10-fold over control-DNA for R273H-FL mutant (at 200 μM peptide) (Figure 7.10D). Pap- 




























ILN also elicited a significant increase in sequence-specific DNA binding for R248Q-FL, which 
was not seen before when using R248Q-∆22. At 2 μM peptide, RE-binding increased to 15-
fold and 4-fold (for p21 and PUMA REs, respectively) over control-DNA (Figure 7.10E). This 
peptide-dependent reactivation was greater at 20 μM peptide concentration, eliciting a p21 
RE binding of 22-fold over control-DNA (Figure 7.10E). In most cases (all except Pap-ILN), 200 
μM peptide caused a decrease in protein levels, which translated to an attenuation in DNA 
binding signal. This may be an effect specific to the Novagen IVT extract, or suggest some 
degree of toxicity from these peptides at higher concentrations. Also notably, all the 
reactivation phenotype reported here seem to be specific to mutant p53, as repeating the 
binding assay using p53wt-FL protein resulted in no significant increase in sequence-specific 
DNA binding, for any of the activating peptides (Figure 7.11). 
Instead of co-translating p53 in peptide presence as before, the ability of activating peptides 
asserting their functions post protein translation was also examined. For this experiment, 
levels of peptide-induced reactivation were compared in full-length mutant p53 against full-
length wild-type p53 (DMSO control). The results showed some degree of reactivation for all 
the combinations sampled (Figure 7.12). Peptide-induced sequence specific DNA binding 
reached wild-type levels for the PUMA-BS2 RE (~5-fold increase), and close to wild-type 
levels for the p21 RE (~2-3-fold increase), for all the mutants tested. Strangely, however, 
almost identical binding results were seen for all the combinations of peptide and mutant 
p53. The RE specific induction from certain peptides was also undetectable in this instance. 
Collectively, the data might suggest two mutant reactivation mechanisms at play. The first is 
peptide and mutant specific, and actuates a particular rescue phenotype (giving rise to RE 
preference), but requires peptide presence during p53 translation. The second elicits a more 
generic and weaker response, arising probably from a less specific form of interaction, and 
takes place when peptides interacts with full-length mutant proteins. 



































 The binding assay used measured the ability of p53 protein to bind target REs within 
a set of specific experimental confines involving molar ratio and dynamics of the interacting 
molecules (compounds, p53 protein, specific/non-specific DNA, and antibody). Hence the 
derived values (expressed as fold difference) may not be an accurate depiction of binding 
kinetics between compound and p53. In the case of Phikan compounds and p53 Y220C 
mutant, the effects each compound had in the apparent reactivation of Y220C mutant in 
sequence specific DNA binding may not be representative of rudimentary biophysical 
characterizations. However, the trend in binding kinetics between drug and protein should 
nonetheless be reflected in the mutant protein’s ability to bind DNA in a sequence specific 
manner. Eventual configuration of the qPCR p53-DNA  binding assay (using nano-tag 
streptavidin interaction) allowed us to sensitively measure sequence-specific DNA binding, 
and critically afforded the utility of the Novagen IVT extract (whole-cell bacterial lysate), 
providing a more rigorous and possibly physiologically relevant technique.  
 
While pure biophysical analyses often provides quantitative characterization that are 
elementary in nature and important in conceptualization phases of drug discovery, results 
may be different or even detrimental when translated to more complex ex-vivo or in-vivo 
systems. This is often evident in high affinity compounds that also incidentally exert strong 
non-specific cytotoxicity. The assay described here could function as an early indication of 
the suitability in developing mutant p53 reactivating compounds. For example, although 
PK784 could bind and reactivate Y220C mutant, the recurrent diminishing activity (Figure 
7.3D, 7.7A and 7.7C) at higher concentrations of compound meant its usability was limited. 
In contrast, PK5176 showed a drug dependent increase in Y220C reactivation even at the 
highest concentration used (7.6A and 7.7B), suggesting a stronger potential as a drug 
candidate in this aspect.  




Detection of decreased non-specific DNA binding as the Y220C mutant takes a more 
wildtype-like form (from PK5176 activity) (Figure 7.8), suggest an additional avenue for this 
assay to be exploited. Relative changes in both sequence-specific, or sequence non-specific 
DNA binding (either in the presence of protein cofactors like p63/p73, or environmental 
changes like thermal denaturation) can be interrogated simultaneously, especially for p53 
mutants predisposed to GOF activities (R175H and R273H). 
There was also strong evidence that the p53 activating peptides are interacting with p53 
mutants specifically, and restoring sequence-specific DNA binding function to the mutants 
they are selected for. The variation in RE binding manifested through different combinations 
of mutant protein and peptides further validates the accuracy of the assay and the 
authenticity of the peptide induced phenotype. A striking element of the result was the 
apparent ability for some of the peptides to reactivate full-length mutant beyond wildtype 
activity, suggesting both restorative and inductive function from the peptides. A similar 
phenomenon was seen in the study of CP31398, where a secondary screen showed some 
compounds stabilizing mutant p53 beyond wild-type levels [172]. 




8   Characterizing Pap-SPT and Pap-MPH in cell culture 
model 
8.1  Introduction 
 Earlier in-vitro data showed that the interaction between Pap-MPH and the G245S 
p53 mutant resulted in the restoration of sequence-specific DNA binding. Whilst this induced 
activity was comparatively weak (Figure 7.10A), the sequence homology with p53’s most 
well characterized and intricate interacting partner Mdm2, made it an interesting candidate 
for further characterization. Furthermore, the region of homology maps to the E3 ligase 
RING domain of Mdm2 and is a region not known to interact directly with p53. We next 
investigated the effects of Pap-MPH in ex-vivo cell culture models. 
8.2  Material and methods 
8.2.1  Cell-line and culture conditions 
 H1299 (p53-null human lung carcinoma) cells were obtained from ATCCTM and grown 
in RPMI medium 1640 (GIBCO®) supplemented with 10% fetal calf serum (GIBCO®) and 1% 
penicillin/streptomycin (Invitrogen). The cells were cultured in T75 flasks (Greiner Bio-One), 
in a 5% CO2 incubator at 37
oC. Cells were passaged at 80-90% confluence by first removing 
the media, and incubating the cells in 2.5 mL of 0.125% Trypsin/Versene (BSF, Astar, 
Singapore) for 3-4 minutes before inactivating the trypsin with 10 mL of culture medium. 
Trypsinized cells are then pelleted at 1100 rpm for 3 minutes, and the supernatant is 
removed before cells are resuspended in fresh medium.  
ARN8 cells were obtained from Dr May Ann Lee (ETC, Astar, Singapore) and grown in DMEM 
medium (GIBCO®) supplemented with 10% fetal calf serum (GIBCO®) and 1% 
penicillin/streptomycin (Invitrogen). This cell line, derived from the A375 malignant 
melanoma cell line which carries endogenous wild-type p53 protein, is stably transfected 
with the pRGC-∆fos-LacZ reporter cassette as described previously [259]. 




8.2.2  Transient transfection of mammalian expression constructs 
 The FuGENETM 6 Transfection Reagent was used to transiently transfect protein 
expression plasmids into H1299 cells following manufacturer’s protocol. Briefly, cells were 
seeded at the appropriate amount such that the culture reached 50 – 70% confluence at the 
time of transfection. Plasmid DNA to be transfected were then mixed and the empty vector 
pBlueScript SK(-) was added to bring the total mass of plasmid DNA to an optimal level for 
transfection. Plasmid DNA were then constituted with FuGENE 6 transfection reagent and 
added directly to the cell medium. 
8.2.3  β-galactosidase reporter assay 
  β-galactosidase activity were quantified using the Dual-Light® System (Applied 
Biosystems) following manufacturer’s protocol. Briefly, cells were seeded on a 24-well plate, 
and transfected with the relevant expression constructs following the procedure described 
in Section 8.2.2. The transfected vectors are detailed in Section 2.1.4, and includes p53 
expressing vectors, a β-galactosidase expressing reporter construct (pRGC-∆fos-lacZ), 
luciferase expressing control vector (pCMV-Luc), as well as a dummy vector for transfection 
control (pBlueScript SK(-)). Transfected cells are then treated with the desired 
compounds/peptides and grown until the desired timepoint. Following which, cells are 
rinsed in PBS, harvested in Lysis Solution, and pelleted before the supernatant is transferred 
onto a fresh opaque walled 96-well plate. The substrate solution is then reconstituted, 
added into the wells and the levels of luciferase activity are measured using the Tecan Safire 
II microplate reader. After an additional 1 hour incubation at room temperature, the 
Accelerator solution is added into the wells and the levels of β-galactosidase activity is 
measured. The relative levels of β-galactosidase activity are then calculated by dividing β-
galactosidase values by the respective luciferase values. 




8.2.4  Delivery of drugs into cells 
 Cells were typically treated with peptides or compounds 12 hours after DNA 
transfection. Treatment of Nutlin was performed by directly adding the compound into cell 
culture media. Pap-peptides were either delivered using the ChariotTM transfection reagent 
(Active Motif, USA), or through the HIV-Tat transduction domain, which is synthesized fused 
to the peptides of interest. In transfection cases using the latter method, Tat-fused peptides 
are added directly into the cell culture medium 12 hours following DNA transfection. Peptide 
delivery using the ChariotTM reagent was performed following manufacturer’s instructions. 
Briefly, the Chariot reagent is resuspended and mixed with Pap peptides at recommended 
proportions. Formed peptide-chariot complexes are then overlayed on cells with the culture 
media first removed, before fresh serum-free media was added.  
8.2.5  ARN8 cells β-galactosidase reporter assay 
 Cells were seeded in a 96-well culture dish as described previously [260], grown to 
approximately 70% confluence before treatment with Nutlin-3 (2 μM, 4 μM, or 6 μM), Tat-
SPT (2 μM, 10 μM, or 20 μM), or Tat-MPH (2 μM, 10 μM, or 20 μM) for another 36 hours. 
After which, cellular β-galactosidase activity was developed using the Dual-Light® System 
(described in Section 8.2.3, but implementing only the β-galactosidase related procedure) 
and quantified on the Tecan SafireII microplate reader. 
8.3  Results and discussion 
8.3.1 Optimizing RGC-∆Fos-LacZ reporter assay in H1299 cells 
We wanted to investigate if Pap-MPH could reactivate the G245S mutant, and 
increase sequence-specific DNA binding in mammalian cells. Full-length p53 cDNA carrying a 
G245S DNA mutation cloned into the pcDNA3(+) expression vector was used in p53-null 
human lung carcinoma cell line (H1299). We investigated mutant p53 activity by co-




transfecting the mutant p53 plasmid (pcDNA3(+)-p53G245S-FL), across a titrated 
concentration range, with reporter plasmid (pRGC-∆Fos-LacZ). Transfected cells were then 
allowed to grow for 36 hours before being harvested and assayed for levels of β-
galactosidase (β-gal) activity. Levels of luciferase (from co-transfecting the luciferase 
expression vector, pCMV-Luc) were also measured simultaneously, and acted as an internal 
control for transfection efficiency and cell number.  
Western blot analysis indicated that p53 levels were undetectable in un-transfected H1299 
cells, but were readily detectable when pcDNA3(+)-p53G245S-FL was transfected at the 
lowest dose of 10 ng (Figure 8.1-inset). P53 levels also increased in a plasmid concentration 
dependent fashion indicating efficient transfection of cells. Levels of β-gal activity also 
indicated that the overexpression of the G245S p53 mutant proteins did not result in an 
detectable increase in transactivity of the RGC reporter gene up to ~100 ng of plasmid vector 
used, establishing an upper transfection limit for the reporter assay (Figure 8.1).  
8.3.2 Peptide transfection using Chariot peptide delivery reagent 
The ChariotTM reagent is a commercial polypeptide mixture capable of forming non-
covalent interactions with, and aiding in the internalization and delivery of, target peptides 
across the plasma membranes. Using the chariot reagent, we transfected different 
concentrations of Pap-MPH peptides into H1299 cells pre-transfected with 100 ng of either 
wild-type p53, or G245S mutant p53 (along with identical amounts of pCMV-Luc and pRGC-
∆Fos-LacZ plasmid DNA), and measured the β-gal activity. Although some peptide-induced 
transactivity was observed (~3.5-fold over DMSO control using 10 μg/μL of peptide) from the 
mutant p53, p53wt-FL dependent β-gal levels were significantly higher than the maximum 
mutant reactivated levels (Figure 8.2A). A closer look at the reporter assay data revealed 
that the figures for wild-type p53 dependent β-gal activation was artificially inflated due to 
significantly decreased luciferase readings compared to mutant p53 transfected cells. This  










phenomenon was possibly due to the presence of extreme levels of wild-type p53 protein, 
causing cells to growth arrest, and hence, affecting the ectopic translation of luciferase. The 
peptide-induced reactivation of G245S mp53 was not observed in either the DMSO control, 
or the no-p53 control (transfected with empty pcDNA3(+) plasmids in the presence of all 
peptide concentrations sampled) (Figure 8.2B), suggesting a bona-fide reactivation event. 
8.3.3 Peptide transfection using HIV-Tat cell penetrating peptide 
 Next we examined the delivery of peptides into cells by means of attaching the HIV 
TAT protein transduction domain (PTD) onto our Pap peptides. The exact mechanism behind 
TAT-mediated cellular uptake of polypeptides is not fully understood, but is believed to 
involve charge-dependent interaction between the very positively charged TAT sequence 
(RKKRRQRRR), and the highly acidic polysaccharides present on cell surfaces [261]. 
Successful peptide delivery via the TAT PTD has been reported extensively in the past, and 
was also shown to work regardless of which amino acid terminus the TAT sequence was 
attached to [262]. Four peptides sequences were each synthesized with the TAT domain 
attached at the N-terminus (Figure 8.3A-table); peptide corresponding to Pap-SPT (Tat-SPT), 
peptide corresponding to Pap-MPH but either with (Tat-MPHo – original), or without (Tat-
MPHs – short) the first methionine before the randomized region, and a scrambled Pap-MPH 
sequence (Tat-Scram) (Figure 8.3A-table). The reason for synthesizing MPHs peptide 
sequence was to test the possible redundancy of the first methionine residue (provided by 
the ATG start codon immediately preceding the randomized region). In a preliminary 
comparison of peptide-induced G245S transactivity, Tat-SPT displayed a comparatively 
weaker response (maximum induction of ~2-fold over mutant only control) and was 
consequently removed from subsequent experiments (Figure 8.3A). 
As the peptide-induced transactivity may only be noticeable during a transient temporal 
window (due largely to the short cellular half-life of peptides), we next charted peptide  
















induced β-gal activity at three different time points after peptide treatment (12, 24 and 36 
hours), and across a peptide concentration range (1 – 24 μg/mL). The results indicated 
comparatively higher levels of signal at higher dosages of peptide treatment with a 
treatment period of 36 hours (Figure 8.3B). We also examined if varying the levels of plasmid 
pcDNA3(+)-p53G245S-FL transfected could increase the apparent activity from the peptides. 
Additionally, both Tat-MPHo and Tat-MPHs were sampled and the peptide concentration 
was also increased to 4 – 48 μg/mL. The result indicated that activity from Tat-MPHo was 
highest at 100 ng of plasmid (~2-fold over mutant only), but dropped to undetectable levels 
when transfection was increased to 125 ng plasmid (Figure 8.3C). In contrast, Tat-MPHs 
elicited a sustained ~2-fold activity even with 125 ng of pcDNA3(+)-p53G245S-FL (Figure 
8.3D). The difference in results could be due a longer half-life, or higher activity from Tat-
MPHs compared to Tat-MPHo. In light of these observations, we repeated the reporter assay 
using Tat-MPHs, but in cells transfected with 150 ng of mutant p53 plasmid. Tat-MPHs 
elicited a close to 2-fold increase in activity at 24 hours (at 36 μg/μL), which increased 
sharply to 4-fold over control at 36 hours post treatment (Figure 8.3E).  
As a control, we repeated the reporter assay using Tat-scram peptide, across the same 
concentration range, and saw no indication of G245S mp53 reactivation across all peptide 
concentration sampled (Figure 8.4), suggesting a peptide-induced mutant reactivation that is 
reliant on an intact Pap-MPH sequence. Furthermore, β-gal activity levels resulting from the 
treatment of only either Tat-MPHs, or Tat-SPT, in p53 null H1299 cells were well below 
G245S mutant only control (Figure 8.4B), suggesting that the observed peptide-induced 
transactivity of β-gal reporter gene was p53-dependent. 
8.3.4 Using thioredoxin-A aptamers as a protein scaffold for Pap-MPH 
 We next studied the feasibility of constricting the Pap-MPH peptide sequence within 
an aptamer scaffold as a method of presenting the Pap-MPH peptide epitope for p53  




























interaction. Thioredoxin-A (TrxA) is a cytosolic bacterial protein, well suited for the purpose 
of epitope presentation. This function is afforded by its solubility, structural rigidity and the 
conformation of its epitope presenting active site (constrained tightly within a disulphide 
bond within a solvent accessible loop)[263]. Previous studies involving using TrxA as an 
aptamer scaffold for peptide library screens have lead to successful identification of binders 
to Cdk2[264], E2F[265]. More importantly, a phage-display identified Mdm2 binding peptide 
has been successfully inserted into TrxA and shown to stabilize p53 in vivo[147], 
demonstrating practicality in using TrxA as an aptamer for presentation to p53 protein.   
Conventionally, peptide epitopes are cloned into the Trx-A cDNA through restriction and 
ligation. In order to avoid the insertion of an additional two amino acids (N and G) adjacent 
to the peptide epitope through conventional cloning, we inserted the peptide sequences via 
PCR (Figure 8.5). Three of the previous sequences were inserted into the Trx-A scaffold, and 
designated Trx-MPHo, Trx-MPHs and Trx-MPHScram (scrambled Pap-MPH amino acid 
residues) (Figure 8.5). Both plasmids pcDNA3(+)-Trx-MPHo and pcDNA3(+)-Trx-MPHs were 
transfected at increasing amounts into H1299 cells, together with the reporter-, luciferase-
vector and 100 ng of pcG245S-FL. The total amount of CMV carrying plasmids transfected 
was kept constant using parental pcDNA3(+) empty vector. Results from β-gal levels showed 
increasing transactivity with increasing levels of peptide aptamers (PAs) transfected, 
suggesting a PA concentration dependent mp53 reactivation (Figure 8.6A). As before, Trx-
MPHs (>6-fold over mut-only control) elicited a stronger response than Trx-MPHo (5-fold 
over mut-only control). To make the assay even more robust, the experiment was repeated, 
but used pTrx-MPHScram (instead of empty pcDNA) as balance plasmid. This ensures an 
equal transcription/translation load in the cells across all the samples, and activity measured 
will not be an effect of differences in Trx-A protein levels. Transactivity levels appeared 
lower than before, but show the same trend where Trx-MPHs displayed stronger activity 
then Trx-MPHo (3-fold and >4-fold, respectively) (Figure 8.6B). 






















8.3.5 Disruption of Mdm2 interaction and p53 protein stabilization using Pap-MPH 
 Lastly, we investigated briefly if Pap-MPH could possibly confer ‘nutlin’ like effects 
and induce a p53 protein stabilization effect in cells. ARN8 cells (wild-type p53 expressing 
A375 malignant melanoma stably integrated with a RGC-∆fos-LacZ reporter cassette) were 
treated with either Tat-MPHo, Tat-SPT (at concentrations of 2 μM, 10 μM or 20 μM), or 
Nutlin-3 (2μM, 4 μM or 6 μM) and assayed for levels of β-galactosidase from transactivation 
of the reporter cassette. Results show no detectable peptide-induced activity, whereas 
Nutlin induced p53 stabilization was apparent from the Nutlin concentration dependent 
increase in β-gal activity (Figure 8.7A). 
Using an overexpression system, peptide induced effects on the levels of cellular p53 protein 
was examined. Fixed levels of p53wt-FL expressing vector (100 ng of pcP53wt-FL) was co-
transfected with increasing amounts of human Mdm2 expression plasmid (ranging from 50 
ng to 200 ng of pCMV-hmdm2) into H1299 cells, and the levels of p53 protein was analyzed 
via western blot. As expected, a steady decrease in p53 protein levels was observed which 
correlated with increasing Mdm2 levels (Figure 8.7B). We next treated the cells for 24 hours, 
with 2 μM, 10 μM or 20 μM of each peptide (Tat-MPHo, Tat-MPHs, or Tat-scram) 12 hours 
after transfection of p53 and Mdm2 (50 ng of pcDNA3(+)-p53wt-FL with 200 ng of pCMV-
hmdm2), and analyzed the levels of p53. Interestingly, the western blot results revealed a 
p53 stabilizing effect exerted from the presence of both Tat-MPHo, and Tat-MPHs, which 
was not detected in peptide Tat-scram (Figure 8.7C-D). The results also displayed a stronger 
response from Tat-MPHs, consistent with earlier results. 
 
  
















8.4  Conclusion 
 In this preliminary ex-vivo characterization of Pap-MPH, a peptide-dependent 
reactivation of G245S mutant is clearly observable in the cell culture model used. Although 
the levels of reactivation are not very high (up to 6-fold above mutant-only activity), the 
reactivity is consistently observed throughout and is distinctly p53, and Pap-MPH sequence, 
dependent. Additionally, some of the Pap peptides selected had clear preferences for 
specific REs (Chapter 7), and the only p53 response element tested in this chapter was the 
RGC site (not a RE used in selection), which may not carry the optimal DNA sequence for 
reactivation binding. The apparent increase in peptide-dependent activity when presented 
as peptide aptamers in TrxA indicates that restricting this peptide is inconsequential to its 
functionality, which may further suggest that it acts as a linear epitope, and does not adopt 
secondary motifs. This notion is somewhat supported by (i) in-vitro data where no binding 
preference to mutant p53 was seen between N- or C-terminal biotin modifications of the 
peptide (Chapter 5), and (ii) real-time PCR p53-DNA binding assay where peptide-dependent 
reactivation of G245S-FL mutant protein bound with similar affinity to both the p21 3’ site, 
and PUMA-BS2, REs (Chapter 7). A notable observation is the extent of activity increased just 
by removing the first methionine residue from the peptide sequence. This could suggest the 
importance of the methionine positioned before the proline residue (Pap-MPH: 
MMPHLMAC), which may be affected by the amino acid preceding it.  
More interestingly, the MPH peptide could harbor potential in disrupting Mdm2 mediated 
degradation of p53 protein in cells, and may unlock novel p53-Mdm2 biology and new 
cancer treatment targets. The discrepant results between the ARN8 reporter assay (where 
peptides appeared inactive compared to Nutlin) and the overexpression study in H1299 
could either be due to differences in assay detection threshold (especially since the ARN8 
experiment measures p53 activity and not protein levels), or stem from the mechanism of 




peptide function. In the overexpression study, p53 levels were stabilized in a peptide-
dependent manner, and correlated with concentration of peptide treatment. This p53 
stabilization phenotype may be more pronounced in an overexpression model as the 
mechanism is centered around cellular/molecular processes that are at their limits (eg. 
ubiquitin loading onto p53, availability of E1 or E2 ligase, the proteasome complex…etc). 
More specifically, Pap-MPH may stabilize p53 protein levels by disrupting the process of E2 
enzyme-dependent ubiquitin modification of lysine residues. This notion is also supported by 
earlier observations that Pap-MPH likely interacted with the C-terminal domain of p53; (i) 
reactivation of sequence-specific DNA binding to G245S mutant required the C-terminal 
domain (Chapter 7), (ii) binding of Pap-MPH did not result in any changes to both Pab240 
and Pab1620 epitopes, and (iii) Pap-MPH sequence homology in Mdm2 RING domain at C-
terminal end, which was described to interact primarily with C-terminus of p53 protein [231].  
However, the level of characterization performed here is very preliminary, and a lot more 
work will be required to elucidate the precise biological relevance, if any. It will also be 
interesting to test the biological function/activity of the peptide by extending the peptide 
sequence, from either the N-, or C-terminal, using residues homologous to the human 
Mdm2 sequence. As the C-terminal RING domain of Hdm2 has also been reported to bind 
RNA and possibly modulate p53 structurally [17], it may also be important to test if Pap-MPH 
induced mutant p53 activities are related to RNA binding.  




9   Final conclusion 
 In this thesis, the IVC selection platform was utilized to successfully identify several 
peptide compounds that interacted with, and restored sequence-specific DNA binding to 
several p53 hotspot mutants.  
Unlike other more established display techniques (ribosome, baceriophage), in-vitro 
compartmentalization allowed the sampling of unhindered protein-protein interaction in 
solution, through the concomittant translation of tagless proteins/peptides of choice. And 
while our principal goal was to discover mutant p53 reactivating compounds, the selection 
technique proved to also possess the potential as a platform to characterize the p53 
interactome, possibly uncovering novel interactors, or interaction sites. 
9.1 P53 activating peptides mode of activity 
  Experimental results (ELISA, DNA binding and thermal shift data) pertaining to each 
peptide collectively agree in a way that paints an interesting peptide-p53 interaction and 
reactivation portrait. The variations in results observed in the different techniques used to 
characterize the peptides served to validate the assays, as well as the authenticity of the 
results. For instance, the variations in DNA binding responses detected in different REs and 
p53 variant (Chapter 7) were consistent across combinations of p53 and peptide. 
Preferential interactions between mutant p53 and different forms of biotinylated peptides 
were also consistent. 
As observed in Chapter 5, the presence of peptides during mutant p53 protein synthesis, 
which varied with different combinations of peptide and p53 variant, either had no effects, 
or largely resulted in the concomitant decrease in both the Pab240 and Pab1620 epitopes. If 
we next make a tempting, and conceivable, assumption that changes in the Pab240/1620 
ratio must involve the core domain, we can then classify each peptide based on the 




assumption that it either (a) targets the core domain due to the apparent changes in 
conformation of the core or, (b) interacts with either the N- or C-terminal domain, and does 
not affect the structure of the core significantly.  
In view of this, Pap-MPH and Pap-SPT seemed to interact with terminal domains, as neither 
caused significant changes in Pab240/1620 epitopes in any of the p53 mutants. Critically, 
DNA binding data (Chapter 7) also revealed that both peptides reactivated the G245S 
mutant only in the full-length form, and not in C-terminal truncated ∆22 mutants. The 
results also showed no preference in RE binding (similar binding affinity to p21 and PUMA), 
which is somewhat expected if the peptide activity does not cause structural changes in the 
core domain. Additionally, the region of homology between human Mdm2 protein and Pap-
MPH suggests the possibility of transient interactions between p53 and Mdm2 during E3-
ligase activity, which lies predominantly in the C-terminal domain [231]. 
In contrast, the three peptides selected for by the R273H mutant (Pap-TAL, -RLQ and -VRH) 
all resulted in a change in core conformation (reduced Pab240 and Pab1620), which, if one 
accepts the earlier assumption, suggests interaction with the DNA binding core domain. 
Furthermore, it is also fitting that a reactivating compound for the R273H contact mutant 
(which has a wild-type structure [97]) exerts its activity through interaction with the core, 
and not merely the terminal domains. Notably, the same three peptides elicited a similar 
trend in Pab240/Pab1620 profile for both R273H and wildtype p53, but not the other two 
mutants, G245S and R248Q. This further reinforces the possibility that these peptides are 
targeting the core through a structural ‘native-like’ element present in both R273H and wt-
p53 (owing to their conformation). The thermal shift data also supports this hypothesis as 
only Pap-VRH caused a shift in the Tm (decrease in 1.5
oC) of purified full-length p53 quad-
mutant in the presence of p21 RE. The apparent innocuity of the peptides displayed in the 
thermal shift assay could stem from several possibilities, including unsuitability of the p53 




quad-mutant as an interaction candidate, or the exertion of peptide function only on newly 
synthesized p53 protein. Of note, the observation that Tm shift only occurred in the presence 
of p21 RE oligonucleotide (and not control DNA), may also suggest that all 3 elements 
(mutant, peptide, RE) may need to be present simultaneously for the desired reactivation 
phenotype to occur. Furthermore, DNA binding data also showed that only two peptides 
could restore sequence-specific DNA binding to C-terminally truncated mutant p53 (Pap-RLQ 
and Pap-VRH), and further verifies specific targeting of p53 DNA binding core domain from 
this group of peptides. 
Pap-TAL was categorized under the ‘core-targeting’ group of peptides due to its effects on 
Pab240/Pab1620 (similar to RLQ and VRH, which was also selected for R273H), but displayed 
some conflicting results in other characterization experiments. Pap-TAL showed evidence of 
interacting with the p53 core domain, but did not restore sequence-specific DNA binding to 
the C-terminally truncated mutants tested (R273H-∆22 and G245S-∆22). On the contrary, 
Pap-TAL strongly reactivated all three full-length p53 mutants tested (G245S, R248Q and 
R273H), with sequence-specific DNA binding reaching 37-fold over non-specific control DNA 
(Chapter 7). This strongly suggested that Pap-TAL must either be also interacting with the C-
terminal domain of p53, or requires the presence of the Ctd to exert a reactivation function. 
Also notably, Pap-TAL was the only peptide to induce a slight increase in Pab1620 epitope, 
which was observed in both the G245S-∆22 and R248Q-∆22 mutants (Chapter 5). In addition, 
Pap-TAL induced a consistent binding preference for the p21 RE for all three mutants, and 
across all concentrations of peptide tested (2 – 200 μM). It is both intriguing and perplexing 
how a single peptide can affect three conformationally distinct p53 mutants, conceivably 
through different interactions, and yet evoke a reactivation phenotype with recurrently 
similar elements. Interestingly, ELISA data (chapter 5) indicated that Pap-TAL bound directly 
with the G245S mutant, and to a weaker extent, with wild-type p53, through its N-terminal 
region. This is consistent with the possible α-helical structure (suggested by high amino acid 




sequence homology to the structure of human lymphoid tyrosine phosphatase catalytic 
domain, Chapter 3) on the N-terminal of Pap-TAL which may be acting at the primary site of 
interaction. 
9.2 Structural ‘destabilization’ could be integral to sequence-specific DNA 
binding 
 One striking and unprecedented notion that emerged from this study was that the 
loss of Pab1620 epitope may not be detrimental, or even possibly advantageous to 
sequence-specific DNA binding (and possibly to p53-dependent transactivity). As observed in 
the ELISA results (Chapter 5), 4 of the 6 peptides tested elicited a simultaneous decrease in 
Pab240 and Pab1620 epitopes. Additionally, Pap-VRH (and to a lesser extent, Pap-ILN) also 
induced a lowered apparent Tm in p53QM-FL proteins, suggesting a peptide-induced loss in 
structural order. These observations, coupled with the peptide-induced reactivation of 
mutant p53 (seen via qPCR p53-DNA binding assay) could suggest a mechanism in which the 
peptides drive p53 into a semi-folded and ‘open’ conformation (recognized by neither 
conformation sensitive antibodies) favorable for sequence-specific DNA binding. Indeed, 
evidence of this elusive, possibly transient form of p53 was also observed earlier in the IP 
results using IVT-synthesized p53 (in Chapter 4), and was also recently reported by other 
groups [171,266,267]. If held true, this concept can have profound ramifications in the field 
of developing p53 activating compounds, especially if we consider the possibility that a 
Pab1620 folded conformation is not conducive for sequence-specific DNA binding. Firstly, 
strategies of identifying activating compounds that revolve around preserving the Pab1620 
epitopes or increasing Tm (elements of which are often seen in past attempts at developing 
reactivating compounds, including CP31398[172], CDB3[169], PRIMA-1 [177], and Phikan 
083[187]) may be less than ideal. Secondly, more focus should be paid to the 
pharmacodynamics of Pab1620 inducing/retaining drugs as it may be unfavorable to ‘lock’ 




p53 in this DNA binding unreceptive state either excessively, or before it can interface with 
DNA. A good example of the latter point could be the interaction between Y220C mutant 
and Phikan compounds. Even with a relatively low KD, the Phikan compounds failed to 
induce strong sequence-specific DNA binding to the Y220C mutants (compared to the p53-
activating peptides in chapter 7). Furthermore, the Phikan compounds listed here have also 
not been shown to reactivate the Y220C mutant and restore p53-dependent activity in cell 
culture models (data not shown).  
9.3 Further experiments 
 The preliminary results of these peptides show potential for development into a 
mutant p53 reactivating agent, and warrants further characterization and validation. 
Understanding and elucidating the precise mode of interaction between mutant p53 and 
peptide would be an important step towards creating more potent derivatives of the initial 
peptide sequences. It will be interesting to derive co-structural data, through X-ray 
crystallography or NMR using purified mutant proteins, to visualize 3D interaction, or 
possible peptide-induced structures in p53. The technical constraints surrounding 
crystallizing full-length p53 may also be partially alleviated from peptide binding (binding to 
terminal domains or attenuation of Pab240 epitope from core domain interaction may 
increase protein stability and decrease aggregation). An alanine scan can also be performed 
to identify key residues within each peptide sequence critical to binding and function, 
allowing us to curtail or modify the peptides to increase activity (eg. stapling has been 
shown to increase the stability and activity of peptides[146]). Alternatively, cDNA libraries 
based on the coding sequence for each peptide can be generated (carrying infrequent amino 
acid substitutions) and used in further rounds of IVC selection to isolate even stronger 
mutant p53 binding or reactivating peptides. Also by using techniques like surface plasmon 




resonance (SPR) or isothermal calorimetry (ITC), biophysical questions regarding peptide-
p53 interaction kinetics, and stoichiometry, can also be addressed. 
Another critical set of experiments would be to detect bona fide mutant p53-dependent 
reactivation and p53 activity under physiological conditions using cell culture models, 
especially cancer cell lines with endogenous p53 carrying mutations for which the peptides 
were selected for. It will be crucial to ascertain if peptide treatment (either conjugated to a 
PTD, as a peptide aptamer, or a stapled peptide) can up-regulate p53 transactivation targets 
(eg. p21, Mdm2, pUMA, Bax, Noxa), or biomarkers of cellular events (PARP[268], β-
galactosidase[269], caspase-3[270]) at the message, as well as protein levels. Determining 
the temporal window of peptide activity, and cellular responses to drug removal can also 
further illustrate peptide specific mechanisms. For example, a recent study showed p53 
protein stabilization just 15 minutes following Nutlin treatment, and highlights fundamental 
differences and strategies for targeting different aspects of the p53 pathway [271]. 
Additionally, techniques optimized for detecting cell fate (including TUNEL staining, FACS-
based cell cycle analysis, colony survival assay [138], caspase activity assay [272]) can also be 
employed to determine peptide activity in cells.  
It will be interesting to investigate peptide-dependent effects when used in different 
combinations with each other, with non-genotoxic (eg. Nutlin-3, roscovitine[273], tenovin-
6[271]), or DNA damaging (eg. Fluorouracil, actinomycin-D, ellipticine) p53 activating 
compounds, in either wild-type, or mutant p53 backgrounds. Furthermore, because each of 
the peptides interacted physically with mutant p53, it may be worthwhile to examine if the 
peptides can abolish mutant GOF in cells, or block p63/p73-mutant p53 interaction in vitro. 
  




9.4 The multi-conformational states adopted by each p53 variant can affect 
apparent phenotype 
 The quest to reactivate mutant p53 has been an arduous task. The frequent method 
of drug identification (often forward genetic screen using fragment libraries), coupled with 
p53’s unsolved full-length structure and its lability, have resulted in much ambiguity in the 
specificity and action of compound induced reactivation. Reports describing mutant p53 
reactivation showed elements of discrepancy in specificity, which, when coupled with the 
fact that p53 mutants are structurally distinct, lead to puzzling observations often not 
addressed by the authors.  
For example, WR1065 was identified to activate wild-type p53, and was also reported to 
reactivate a sizable panel of mutants [197], but was only shown to reactivate the V272M 
mutant in cells [198]. Similarly, authors describing CP-31398 (also identified via wild-type 
p53 activation) showed in-vitro stabilization of purified V173A and R273H mutants, but 
demonstrated in-vivo activity on R249 and S241F mutants. This incongruity in experimental 
approach is often not explained, and hinders the understanding of compound activity. Of 
note, the sentiment that mutant p53s are functionally and structurally distinct was not really 
present until late 1990s (when biophysical characterization of several hotspot mutants 
showing different stability and residual binding to DNA response elements was available 
[97,274]), and prior reactivation studies classified all mutants generically under one category. 
This can partly account for the above-mentioned inconsistencies as different mutants were 
interchanged freely during early studies. There are also inconsistencies in reports of the 
same compound across different groups. Initial reports for CDB3 described a reactivation 
phenotype which was detected in cells carrying either the R273H and R175H mutants [170]. 
However, subsequent NMR characterization by a different group revealed that CDB3 
induced structural changes, which purportedly mediated the reactivation response, was only  












observed in the R249S, and not the R273H mutant [171]. Contradictory data surrounding CP-
31398-induced reactivation of sequence-specific DNA binding to p53 mutants were also 
reported separately [164,173]. Furthermore, it is also baffling how some compounds can 
single-handedly reactivate different classes of p53 mutants, each carrying structural defects 
effecting vastly different regions of the protein [177,193,198]. 
So how do we explain these ‘inconsistencies’? Contrary to the classic generalization that p53 
exist either in a denatured (Pab240) or native state (Pab1620) [169], we are starting to see 
evidence of elusive intermediate states [266,275](discussed above and in chapter 4). 
Additionally, NMR study on the G249S mutant core domain revealed that the mutant 
protein does not adopt a single conformation, but is in dynamic equilibrium with several 
closely related, alternative conformations [171], suggesting that each mutant could be in 
equilibrium with many subtly distinct forms (and may be more labile then wildtype protein). 
Also, observed experimental phenotypes can be affected by the presence, or lack, of protein 
conformers within a population sample (eg. Interaction between p73 and purified R273H can 
be abrogated by immuno-depleting Pab240-positive proteins [114]). Collectively, these 
observations could suggest a theoretical model which explains the apparent inconsistencies 
in mutant p53 reactivation.  
In this model, p53 can exist in a multitude of different conformations (owing to post-
translational modifications, amino-acid mutations, drug induced allosteric structural changes, 
and environmental conditions like pH or salt concentrations), unlike the classic 2-conformer 
model (Figure 9.1), and is represented on a scale based on the extent of structural folding 
(Figure 9.1). Moving from one end of the structural spectrum, we have Pab240(+) p53 
protein (red zone representing various extents of unfolded protein), followed by Pab240(-
)/Pab1620(-) conformation intermediaries (grey zone), and finally Pab1620(+), native protein 
at the end of the scale (blue zone) (Figure 9.1). Conformations optimal for sequence-specific 




DNA binding belong to the region bordering, and extends into half the intermediate and 
Pab1620 zones (Figure 9.1). Also included in this model is the notion that intermediate 
states, and not Pab1620(+) folded p53, are structurally primed for sequence-specific DNA 
binding. Accordingly, wt-p53 in cells (Figure 9.1 – A (cells)) exist in numerous forms, but is not 
represented adequately in bacterial purified p53 (Figure 9.1 – B(purified)), which artificially 
elevates the faction of native-like p53 due to the purification process removing unfolded 
proteins (eg. only soluble faction purified, heparin columns excludes denatured proteins). 
Even though both forms of p53 display sequence-specific DNA binding properties (owing to 
high percentage of grey and blue zone conformers), they respond differently to compounds 
due to conformer-specific targeting. Additionally, certain modifications (stabilizing mutations 
in the core domain) or compound treatment (Phikan compounds), may shift the equilibrium 
towards Pab1620(+) blue zone (beyond the levels optimal for DNA binding), resulting in an 
overall decrease in sequence-specific DNA binding capacity (Figure 9.1 – C(others)) .  
Similarly, each p53 mutant is represented by different combinations of conformers in 
equilibrium, in which the relative amounts and states are a manifestation of that particular 
mutation. Globally denatured mutants like R175H, V143A and R282W [96] are populated by 
mostly red-zone conformers with little to no Pab1620(+) blue-zone conformers (Figure 9.1 – 
D(global denatured)). Contact mutants like R273H have similar constituent conformers to wild-type 
protein (Figure 9.1 – E(contact)), and local structural mutants like the G245S, R248Q and Y220C 
are mostly in the intermediate grey-zone states. According to this model, the goal to mutant 
reactivation is to increase the equilibrium of the 2 conformers most ideal for sequence 
specific DNA binding (represented within yellow box in Figure 9.1) by targeting conformers 
and shifting the equilibrium towards the sequence-specific DNA binding optimal zone (Figure 
9.1). Compounds target conformers based on similar structural elements (similar to how 
Phikan compounds target a specific mutation-induced cavity), resulting in an observed 
reactivation phenotype across different classes of mutants (albeit to differing extents).  




For example, a compound targeting a subset of Pab240(+) conformers will actuate a huge 
response in the R175H mutants (due to the high levels of denatured proteins), but may still 
act on the small percentage of similar conformers present in R273H, triggering a much 
weaker response. This could explain how Pap-TAL can induce sequence-specific restoration 
to distinct classes of mutant p53 (Chapter 7, Figure 7.10B-D). Indeed, it is often difficult to 
compare the absolute level of mutant reactivation due to technical reasons (eg. semi-
quantitative techniques like western blotting and EMSA, low reproducibility, complexity of 
cell models, different protocols across groups…etc), and may understandably distort and 
misrepresent reactivation data. Also, discrepancies in results across different groups could 
be due to different protein purification or cell culturing techniques, resulting in the same 
mutant having different distribution and incidences of conformation subtypes.   
Additionally, reports on (i) transactivation activity belonging to heterogeneous populations 
of mutant p53 [113], (ii) second site suppressor mutations [276,277] and (iii) effects of DNA 
binding motifs on p53’s selection between transactivation and transrepression [27] suggest a 
strong element of monomer/dimer cross-talks during sequence-specific DNA binding. 
Consequently, development of reactivating molecules capable of shifting the 
monomer/dimer/tetramer equilibrium favorably can also be used in conjunction with 
reactivating compounds that targets specific mutant monomer subtypes. 
Proving this theoretical model will not only allow us to reconcile results across model 
systems or experimental platforms, but pave the way to new approaches in development of 
therapy based on mutant p53 reactivation. This is especially important in the areas of 
reactivating p53 using drug combination (different sub-conformations of each mutant can be 
synergistically targeted to actuate a holistic rescue approach), or a form of cyclo-therapy 
(sequential treatment of reactivating compounds), both of which has not been reported 
before. 




As each p53 mutant is breaking out of its generic mould and acquiring specific characteristics, 
it is also becoming evident that there is probably no silver bullet in treating cancer as a result 
of mutated p53. A successful therapeutic approach would most likely involve mutant p53 
reactivation, with the concomitant abrogation of mutant p53 GOF and oncogene addiction 
often required for cancer maintenance [132]. 





10.1  Probing peptide-p53 interaction using ELISA conformation-2 
In Chapter 5, ELISA conformation-2 was used to detect an interaction between 
commercially synthesized biotinylated peptides and IVT-translated mutant p53. Specifically, 
full-length p53 mutant proteins were in-vitro translated in the presence of increasing 
concentration of their respective biotinylated peptides, and incubated on DO-1 coated 
plates to allow the capture of p53-peptide complexes, which was subsequently detected 
using streptavidin conjugated horse-radish peroxidase (Streptavidin-HRP) (Chapter 5, Figure 
5.2B). In each set of experiments, a biotinylated polypeptide carrying the DO-1 epitope 
(SDLWKL) was used as positive control and, both ‘mutant only’ (no peptide) and ‘peptide 
only’ (200 μM of peptide in IVT mixture) samples acted as negative control. Both p53-FL and 
p53-∆22 (data not shown) mutants samples displayed a similar trend of results in which the 
‘peptide only’ negative control gave background binding high enough to render most data 
meaningless (Figure 10.1). The only peptides that showed apparent binding were Pap-RLQ 
(to p53-R273H-FL) and Pap-ILN (to p53-R248Q-FL) (Figures 10.1C and E). A high ‘peptide only’ 
background in this particular ELISA conformation can arise if peptides are binding to the 
antibody (DO-1) or non-specifically to the polystyrene matrix of the plate. It was soon 
discovered that a high HRP signal was detectable even when biotinylated peptides were 
incubated on an unmodified 96-well plate and washed stringently, confirming that the 
peptides were binding strongly and non-specifically to the polystyrene plate (Figure 10.2A). 
In an attempt to discover possible experimental conditions suitable for this particular ELISA 
set-up (conformation-2), harsher buffering conditions were used in an attempt to decrease 
the peptide-polystyrene background signal, specifically by increasing concentrations of BSA, 
salt and Tween-20. The results show a general decline in background as the concentrations 
of the additives were increased, however, background remained high even at the strongest 
buffer conditions (2% BSA, 300 mM KCl and 0.2% Tween-20) (Figure 10.2B).  










10.2 Optimizing primer pair for real-time PCR tag 
 To find a suitable amplicon for the qPCR tag in Chapter 6, three forward and reverse 
primers were designed and tested to produce PCR fragments of different sizes (~100 – 350 
bps) when used in different combinations. Analysis of the PCR products showed that all 
primer pairs gave a single clean product (Figure 10.3A). Primer pair Wpet-R1 and Test3-F 
(later renamed PET-F3) was then selected for qPCR quantification as it amplified the smallest 
amplicon, and will consequently be more efficient. Next, PCR RE constructs were synthesized 
with a 5’ p53 RE (either p21 3’ site, PUMA-BS2, or P2XM[21]) appended using the same 
reverse primer (Wpet-R1), but with a forward primer that sits ~30 bps upstream of Pet-F3 
(Figure 6.1A). A control DNA fragment was also synthesized using Pet-F2 primer with no RE 
attached (con-DNA). Because of possible mispriming due to the long RE-Pet-F2 forward 
primers (40 – 50 nucleotides), PCR reactions were also performed at different annealing 
temperatures (58oC and 60oC). Analysis of the products showed non-specific priming and 
amplification, evident in the NTC samples and smeary PCR products at 58oC annealing 
(Figure 10.3B). However, PCR at 60oC annealing gave single products corresponding to the 
correct sizes (control-DNA – ~120 bps, RE-DNA – ~150 bps) (Figure 10.3B).  
10.3 Real-time PCR p53-DNA binding assay optimization 
As C-terminal truncated wild-type p53 proteins are markedly more responsive to in-
vitro sequence-specific DNA binding, we first tested single measurements of IVT-synthesized 
p53wt-∆22 (10 μL of IVT-protein with 36 nM of p21 RE-DNA) under varying pipetting wash 
conditions (resuspended either 3, 5, or 8 times during each wash step). Real-time PCR results 
showed sequence-specific DNA binding (lower C(t) values for p21-RE samples), and that it 
was unaffected by the different wash conditions (Figure 10.4). Contrary to that, non-specific 
DNA binding (con-DNA) decreased with increasing washes (Figure 10.4). We then repeated 
the experiment in duplicates, and tested the sensitivity and accuracy of the system by mixing  










varying concentrations of con-DNA and p21 RE-DNA (but always to a total of 36 nM to keep 
total DNA concentration constant).  
Initial data from real-time PCR measurements revealed a huge error margin between 
replicates (Figure 10.5A-left), which was greatly attenuated when we increased consistency 
in the wash steps by vortexing the beads in wash buffer instead of manual pipetting (Figure 
10.5A-right). Switching from binding buffer 1 used earlier (in Chapter 3) to a binding buffer 2 
[21] further reduced the error, and resulted in sequence-specific DNA binding from p53wt-
∆22 that responds accordingly to the increasing RE concentrations (Figure 10.5B-left and -
right, respectively).  
10.4 Measuring Pap peptide dependent reactivation of G245S p53 mutant using qPCR 
p53-DNA binding assay (Cosmo IVT) 
 In Chapter 7, real-time PCR p53-DNA plate binding assay was used to detect 
reactivation of the G245S mutant using two of our peptides. P53G245S-FL or -∆22 protein 
were IVT-translated (using COSMO Bio IVT system) in the presence of either Pap-SPT or Pap-
MPH (1, 10 or 100 μM), and binding to the p21 3’ site and PUMA-BS2 REs were measured as 
before. The results showed that both peptides induced little to no sequence-specific DNA 
binding to either REs for both FL, or ∆22 mutant protein (Figure 10.6).  
  
















10.5 Optimization of ZnSO4 concentration used in Novagen-translated IVT system 
 In Chapter 7, real-time PCR Nanop53-DNA plate assay was performed using p53 
protein translated by the Novagen EcoPro IVT system. Initial binding between Np53wt-∆22 
to response elements were barely detectable across all 4 points of p53 concentration 
sampled (Figure 10.7-Top), when p53 protein was made using 1.5 μM of ZnSO4 
(concentration used for COSMOBio IVT system). The measurement was repeated again using 
500 μM of ZnSO4 (in light of the high concentration of metal chelators present in the extract 
as described by manufacturers), and a slight increase in RE binding was observed that 
correlated to p53’s concentration (Figure 10.7-Bot). The final concentration ZnSO4 used for 
further protein expression was 50 μM, which gave the best protein concentration-
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